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Abstract
This thesis is focused on an investigation of the mechanisms of three enzymatically
mediated carbon skeleton isomerisation reactions.
Chapter 1 provides an overview of some representative examples of the carbon
skeleton rearrangement reactions in enzymology.
Chapter 2 describes the preparation and use of fluorolittorines to explore the
mechanism of the rearrangement of the tropane alkaloid littorine to hyoscyamine
which is a reaction mediated by the cytochrome P450 enzyme.
Chapter 3 describes the synthesis of D-ribose-1-phosphonates and the cyclic
phosphonates (phostone) that are candidate inhibitors of the enzymatic isomerisation
of 5-fluoro-5-deoxy-ribose-1-phosphate (5-FDRP) to 5-fluoro-5-deoxy-ribulose-1-
phosphate (5-FDRulP), an important step in fluorometabolite biosynthesis pathway in
Steptomyces cattleya.
Chapter 4 describes the synthesis of 5-hydroxy-3,4-dioxohexylphosphonate and [5-
13C]-5-hydroxy-3,4-dioxohexylphosphonate. These compounds are proposed as
candidates for the transition state of the retro-aldol/aldol mechanism of the enzymatic
isomerisation of 1-deoxy-D-xylulose-5-phosphate (DXP) to 2-C-methylerythitol-
phophate-2-phosphate (MEP) in the biosynthesis of isopentenyl pyrophosphate (IPP)
and dimethylallyl pyrophosphate (DMAPP). The influence of pH on tautomerisation
of [5-13C]-5-hydroxy-3,4-dioxohexylphosphonate is also described.
Chapter 5 describes the general chemical and biochemical methodologies utilised in
this research project.
Chapter 1
Introduction
Chapter 1
2
1.1 Carbon skeleton rearrangements in enzymology
This thesis explores the mechanisms of three enzymatically mediated carbon skeleton
isomerisation reactions. These are: the littorine rearrangement to hyoscyamine; the
isomerisation of 5-fluoro-5-deoxy-ribose-1-phosphate to 5-fluoro-5-deoxy-ribulose-1-
phosphate; and the isomerisation of 1-deoxy-D-xylulose-5-phophate (DXP) to 2-C-
methylerythitol-4-phosphate (MEP). These three reactions are representative of many
unique isomerisation reactions in enzymology particularly in secondary metabolism.
By way of introduction to this research some representative examples of enzymatic
carbon skeleton isomerisations are discussed in this chapter. Each individual chapter,
2-4 will then introduce details of the enzymatic mechanism under investigation.
1.2 Isomerisations mediated by co-enzyme B121-3
Co-enzyme B12 (1) or adenosylcobalamine is essential to almost all living organisms
but is apparently absent from plants. Co-enzyme B12 has a complex structure which
was solved using X-ray crystallography by D. C. Hodgkin in 1961. The structure
comprises a modified porphyrin ring and a central cobalt ion (Co3+). The metal ion is
covalently bonded with two axial ligands, the benzimidazole and adenosyl groups.
The key feature of co-enzyme B12 is that the Co-adenosine bond is susceptible to
homolytic cleavage to generate an adenosyl radical (2, Figure 1.1), the initiator of co-
enzyme B12 dependents reactions. This adenosyl radical participates in enzymatic
reactions such as a carbon skeleton rearrangements, 1,2-amino group shifts, and
elimination of water or ammonia from substrates (Scheme 1.1).
Chapter 1
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Figure 1.1 Co-enzyme B12 structure and the 5'-adenosyl radical.1
Scheme 1.1 Examples of co-enzyme B12 mediated reactions.
There are four families of co-enzyme B12 dependent enzymes. These are
methyltransferases, dehalogenases, eliminases, and mutases.1 Only the mutase
(isomerase) family is described here. Around five mutase enzymes utilise co-enzyme
B12 to mediate carbon skeleton rearrangements. The general mechanism involves 5'-
Chapter 1
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adenosyl radical abstraction of a hydrogen atom from the substrate to form 5'-deoxy-
adenosine and a substrate-derived radical. Rearrangement of the substrate-derived
radical is followed by recovery of a hydrogen atom from the 5'-methyl group of 5'-
deoxy-adenosine to generate the product and regenerate the initiator. For example,
methylmalonyl-CoA mutase mediates the rearrangement of (R)-methylmalonyl-CoA
(3) to succinyl-CoA (4) a reaction which proceeds via radical intermediates, is shown
in Scheme 1.2. This is the only mammalian B12 enzyme. The intramolecular
rearrangement process had been established by using [2-14C]-methylmalonyl-CoA.
Chemical degradation of the resultant radioactive succinyl-CoA resulted in 80% of
the radioisotope located at C-3 of succinyl-CoA, indicating that the isomerisation
involved the migration of the thioester group (Scheme 1.2).4
Scheme 1.2 Mechanism of co-enzyme B12 mediated rearrangement of
methylmalonyl-CoA (3) to succinyl-CoA (4).2, 5
Chapter 1
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Isomerisation of the non-essential amino acid (S)-glutamate (5) to (2S,3S)-3-
methylaspartate (6) offers a unique example of a carbon skeleton isomerisation which
is mediated by the co-enzyme B12-dependent glutamate mutase. The mechanism has
been proposed to proceed via radical intermediates and is summarised in Scheme 1.3.6
In a similar manner to the methylmalonyl-CoA rearrangement, the C-4 hydrogen atom
of glutamate is abstracted by the 5'-adenosylradical to generate the 4-glutamyl radical
(7) intermediate. Fragmentation of the glutamyl radical generates an intermediate
glycinyl radical (8) and acrylate (9), followed by a recombination of the glycinyl
radical to the other end of acrylate double bond to generate methyl aspartyl radical
(10). Unlike the isomerisation of methylmalonyl-CoA, the migrating carbon of
glutamate rearrangement is an sp3 and this prohibits formation of a cyclopropyl
radical intermediate.7, 8 This radical fragmentation-recombination mechanism was
supported by EPR studies. Incubations of 2H and 13C labelled glutamate substrates led
to the identification of the 4-glutamyl radical intermediate as a radical pair with
cob(II)alamin.9 In addition, the glycinyl radical fragment was trapped as glycine when
14C-glutamate was incubated with glutamate mutase.10
Chapter 1
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Scheme 1.3 Proposed radical fragmentation-recombination mechanism for the
isomerisation of glutamate (5) to methylaspartate (6) using glutamate mutase.6, 9
Crystal structures of glutamate mutase bound co-enzyme B12 and glutamate from
Clostridium cochlearium have been reported.11 This revealed a radical shuttling
process from cobalt to the substrate by changing the conformation of the ribose
moiety of adenosine. The ribose was found to be present in two conformers, C-2'-
endo and C-3'-endo. The C-5' carbon of adenosine is above and points towards
co(II)balamin in the C-2'-endo conformer whereas the C-5' of adenosine is directed
towards the substrate hydrogen in the C-3'-endo conformer (Figure 1.2). Thus, the C-
3'-endo is assumed to be the reactive conformer.
Chapter 1
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polyketide synthase-nonribosomal peptide synthase (PKS-NRPS) and it is involved in
the biosynthesis of pretenellin-A (15).
Scheme 1.4 Tenellin 11 is biosynthesised from tyrosine 12 (or phenylalanine 13)
by condensation with a polyketide intermediate, e.g. 14.
Three mechanisms have been proposed for this oxidative ring expansion reaction and
these are summarised in Scheme 1.5. The first mechanism (route A) involves
oxidation of 16 to a quinomethide intermediate 18, followed by a ring expansion and
tautomerisation to generate 2-pyridone 17. The second mechanism (route B) involves
formation of a benzylic alcohol (21) via a benzylic radical (20), followed by ring
expansion to form an imine 19. The third proposed mechanism (route C) proceeds via
the generation of a benzylic radical (20), followed by the formation of cyclopropyloxy
radical 22, which then undergoes ring expansion to generate radical 23 and then loss
of a hydrogen atom to give 2-pyridone 17.
At present, the most likely mechanism is route C. Route A cannot account for the
biosynthesis of 2-pyridones which lack a para-hydroxyl group. Also it has been
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demonstrated that prototenillin-D (21, route B) did not convert to 2-pyridones when
incubated with cell-free extracts of B. bassiana.
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Scheme 1.5 Proposed mechanisms A-C for the rearrangement of tetramic acid 16 to
2-pyridone 17.13
1.4 Isomerisation of liquiritigenin (24) to daidzein (25).14, 15
Isoflavone biosynthesis.
Isoflavones are a subclass of the flavone natural products. They have a general C6-C3-
C6 structure with a phenyl ring at C3 of a pyrone ring. The isoflavones originate from
the shikimate biosynthetic pathway. These secondary metabolites are distributed in
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higher plants, and particularly the Legumeminosae/Fabaceae. These plants produce
isoflavones as defence substances against phytopathogenic microorganisms.
The isoflavone skeleton arises via the direct rearrangement of flavones. A cytochrome
P450 dependent enzyme catalyses this rearrangement, an enzyme which requires
NADPH and molecular oxygen. The plant Pueraria lobata, expresses a cytochrome
P450 dependant isoflavone synthase which catalyses the conversion of the flavone,
liquiritigenin (24) to the isoflavone daidzein (25). The process is thought to proceed
via a radical intermediate. Abstraction of C-3 hydrogen atom, is followed by a 1,2-
aryl migration to generate 2,7,4'-trihydroxyisoflavanone (26) as shown in Scheme 1.6.
A key feature of this transformation is an “oxygen rebound” process, in which the
rearranged radical intermediate is quenched by an hydroxyl radical from Fe(IV)-OH to
generate 2,7,4'-trihydroxyflavone. The mechanism was deduced after an oxygen-18
investigation on the origin of the oxygen atoms at 2-OH of 26 and the C-4 carbonyl of
25. Incubation of liquiritigenin (24) with cytochrome P450 under 18O2 resulted in the
detection of 2,7,4'-trihydroxyisoflavanone (26) carrying 2-18OH. Oxygen-18 was not
incorporated into the C4 carbonyl of 26. Also an incubation of the cytochrome P450
enzyme with [4-18O]-liquiritigenin showed a retention of the ratio of 16O:18O in the
product, [4-18O]-daidzein, relative to starting material. Thus the C4 carbonyl is not
involved in the rearrangement process.
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Scheme 1.6 Isomerisation of the flavonoid liquiritigenin 24 to the isoflavone
daidzein 25.14, 15
1.5 Biosynthesis of cephalosporin C(27)3
Another example of an enzymatically mediated isomerisation by means of ring
enlargement following from tenellin, can be found in the biosynthesis of
cephalosporin C (27) from penicillin N (35). Penicillins (28) and cepharosporins (29)
are important antibiotics produced by fungi such as the Penicillium and
Cephalosporium spp, respectively. These cyclic tripeptides are derived from the
amino acid precursors L-valine (30), L-cysteine (31), and L-α-aminoadipate (32). It is
noteworthy that the configuration of L-valine is inverted to D-valine during the
biosynthesis and that the configuration of L-α-aminoadipate is inverted to D-α-
aminoadipic acid in the cepharosporins. It has been demonstrated that the L-α-
aminoadipyl-L-cysteinyl-D-valine (LLD-ACV, 33) is the only stereoisomer that is
converted to the β-lactam antibiotics.16 A summary of the biosynthesis of
cephalosporin C is shown in Scheme 1.7. The intermediate LLD-ACV tripeptide is
converted to isopenicillin N (34) and then an epimerase converts the L-α-aminoadipic 
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acid moiety to D-α-aminoadipic acid, to form penicillin N (35). In order to convert
penicillin N to cephalosporin C, the five-membered thiazolidine ring is rearranged to
generate the six-membered dihydrothiazine ring of the cephalosporins. This ring
enlargement also proceeds via a radical rearrangement and is mediated by an iron-oxo
species (L4FeIV-O•) as illustrated in Scheme 1.7.
Scheme 1.7 Ring enlargement reaction of penicillin N 35 to cephalosporin C 27.
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1.6 Cholesterol biosynthesis 17
Steroid biosynthesis offers one of the most elaborate examples of a molecular
rearrangement in enzymology. Although diverse in structure, all steroids are derived
from the straight chain triterpene precursor, squalene. cholesterol is the principal
animal steroid, a constituent of cell membranes, and it has been found in all animal
tissues. Cholesterol is derived from a metabolite of lanosterol which itself originates
from squalene. The cyclisation of squalene starts with an oxidation of the terminal
double bond initiated by an epoxidase to generate squalene oxide (36, Scheme 1.8).
This epoxidation reaction requires NADH and molecular oxygen. In the event,
squalene adopts a chair-boat-chair-boat conformation on the enzyme surface. The
cascade cyclisation is then catalysed by the terpene cyclases to generate the
protosteryl cabocation (37). The rearrangement starts by an elimination of H+ at C-9
followed by a series of Wagner-Meerwein 1,2-shifts to generate lanosterol (38). This
steroid is then modified by a series of subsequent transformations to generate
cholesterol (39).
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Scheme 1.8 Steroid cholesterol 39 derived from rearrangement of lanosterol 38.17
1.7 Biosynthesis of L-myo-inositol18, 19
An example of a carbohydrate ring isomerisation is demonstrated during the
biosynthesis of myo-inositol (40). This naturally occurring cyclitol carbohydrate is the
most important stereoisomer of all nine possible inositol stereoisomers. It is a
precursor of all inositol containing compounds such as inositol phosphates and cell
wall polysaccharides. Inositol metabolism plays an important role in growth
regulation, signal transduction, and membrane biogenesis. Myo-inositol is
biosynthesised from D-glucose-6-phosphate (41). The transformation is catalysed by a
NAD-dependent glucose-6-phosphate-1-L-myo-inositol-1-phosphate cyclase. The C-5
carbon of an open form of 42 is oxidised to the corresponding carbonyl and this then
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initiates an aldol condensation of C-6 to C-1 to generate cyclic ketone 44. NADH
reduction of the C-5 carbonyl generates myo-inositol-3-phosphate (43).
Dephosphorylation of 43 then generates myo-inositol.19
Scheme 1.9 Conversion of D-glucose-6-phosphate (43) to myo-inositol (40).18
In summary, these carbon skeleton isomerisation reactions in enzymology are unusual
in mechanisms. Particularly, unusual are the carbon skeleton rearrangements via
radicals involving co-enzyme B12 and cytochrome P450 enzymes. This thesis is
focused on investigations of the mechanism of three remarkable isomerisation
reactions in secondary metabolism. The isomerisation of the alkaloid littorine (45) to
hyoscyamine (46) which is catalysed by a plant cytochrome P450 enzyme is discussed
in Chapter 2. The isomerisation of 5-fluoro-5-deoxy-ribose-1-phosphate (47) to 5-
fluoro-5-deoxy-ribulose-1-phosphate (48) in Steptomyces cattleya is discussed in
Chapter 1
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Chapter 3. The isomerisation 1-deoxy-D-xylulose-5-phophate (DXP, 49) to 2-C-
methylerythitol-phophate-4-phosphate (MEP, 50) an enzyme reaction of the new
biosynthetic pathway to isoprenoid precursors is discussed in Chapter 4.
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Scheme 1.10 Three isomerisation reactions of secondary metabolism which
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2.1 Introduction
Alkaloids are one of the most diverse groups of secondary metabolites which are not
only widely distributed in plants but also to a lesser extent in microorganisms and
animals. Within the plant kingdom, 21,120 alkaloids have been identified so far.1 As
the name implies, alkali-like, the alkaloids are basic in solution, and contain at least
one nitrogen atom in their structure (mostly heterocyclic). However, amino acids,
peptides, nucleotides, nucleic acids, and amino acids are excluded.2 Due to their
pharmacological properties alkaloids have found extensive use as medicinal agents
such as local anaesthetics and stimulants; e.g. cocaine 51, caffeine 52, the analgesic
morphine 53, and the anti-malaria agent, quinine 54.
Figure 2.1 Selected medicinal alkaloids: cocaine 51, caffeine 52, morphine 53 and
quinine 54.
2.2 The tropane alkaloids
Structurally, the tropane alkaloids possess an 8-azabicyclo[3.2.1]octane (nortropane,
55) skeleton which forms an ester bond with the tropic acid (56) moiety.
Hyoscyamine 46, atropine 58, and scopolamine (or hyoscine 59) have emerged as the
most widely used tropane alkaloids in medicine.
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Figure 2.2 The core structure of the tropane alkaloids; nortropane 55, tropic acid
56 and some medically important tropane alkaloids; hyoscyamine 46, atropine 58, and
scopolamine (or hyoscine 59).3
When (-)-hyoscyamine is extracted from plants into solvents it racemises to (±)-
hyoscyamine, or atropine. The name atropine derives from Greek mythology, the god
Atropos, one of the three Fates, who cut the thread of life. Pharmacologically, atropine
and hyoscyamine act competitively as antagonists of acetylcholine (60) at the
muscarinic receptors. Interestingly, the superimposition of atropine and acetylcholine
reveals a structural similarity. Atropine comprises an ester and amine, which is
protonated at physiological pH.4
Figure 2.3 The superimposition of atropine 57 (ionised at physiological pH) and
acetylcholine 60.4
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In low doses, atropine is used in ophthalmology to dilate the pupil (mydriatis) of the
eyes prior to examination of the retina. It is also used pre-operatively to reduce mucus
secretions during anesthesia and to treat bradyarrhythmias.5 The tropane alkaloids are
also used to reduce sweating, bronchial secretions, and to dilate the bronchi. Atropine
sulfate combined with obidoxime is used in combination as an injection to counteract
organophosphate insecticide poisoning and nerve gases. At higher doses, the tropanes
produce hallucinogenic/aphrodisiac side effects. To minimize the hallucinogenic side
effects, the quaternary salt of atropine, ipratopium 61, and the atropine analogue,
atropine methonitrate 62 and amprotropine 63 are currently used clinically.
Scopolamine presents a similar therapeutic profile to atropine and hyoscyamine. Its
hydrobromide salt is used for its anti-depressant activity, although it causes delirium
and mydriasis and in higher doses can be fatal.
Figure 2.4 Quaternary salt of atropine; ipratropium 61, atropine methonitrate 62
and amprotropine 63.
Plant-containing tropane alkaloids are commonly found in three major genera. These
are Atropa, Datura, and Hyoscyamus, of the Solanaceae family (potato family).
Chiefly the tropane alkaloid constituents, hyoscyamine and scopolamine are
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distributed in the whole plants and particularly the roots, leaves and berries. Atropine
is present as a trace tropane alkaloid. Solanacea plants have long been associated with
ritualistic, mystery and early medical procedures. They were essentially sources of
poison, hallucinogens, and medicine in ancient and medieval times. Cleopatra
systematically tested the poison of Atropa belladonna (the deadly nightshade) and
Hyoscyamus niger (henbane) on her slaves in search for the best poison for suicide,
although she chose the asp venom in the end. The wives of Roman emperors, Livia
(wife of Augustus) and Agrippina (wife of Claudius) poisoned their husbands with the
juice of deadly nightshade.6 Although it is poisonous, this juice was wildly used by
ladies during Renaissance Italy to exaggerate the size of their eyes by dilating their
pupils, hence making them more attractive to the opposite sex. The name, Atropa
belladonna derives from this well known effect, “bella donna” meaning beautiful
lady. Datura stramonium, known as ‘thorn apple’ or Jimson weed, is commonly
distributed in Europe, North America and Asia Minor. The seeds and berries of thorn
apple are particularly poisonous as they contain hyoscyamine and scopolamine at
toxic levels. Ingestion of a few berries can be lethal. The seeds and plant extracts of
thorn apple were used for a wide variety for medicinal purposes, including the
treatment of mania, epilepsy, melancholy, rheumatism, convulsion, and madness.7 It
was once believed that smoke from Jimson weed could relieve the respiratory
symptoms of asthma and the Spanish sold it in the form of herbal cigarettes during the
nineteenth century.6, 8 Cancer cures and motion sicknesses were reported.9 The
Columbian Indians used Datura species for infanticide by smearing extracts on the
nipple of the mother. The Mexican Indian rain priests chewed the roots to
communicate with the spirits of the dead to intercede with the gods for rain. Extracts
of tropane alkaloids are used for adolescent initiation rites for many tribes. While
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others believe it possible to obtain supernatural powers through drug-induced visions.7
The Solanaceas plants have been closely associated with magic and witchcraft.
Deadly nightshade, henbane, and mandrake (Mandragora officinarumm) were used in
witches’ brews in the Middle Age. There is little doubt that the tropane alkaloids in
the brew induced hallucination and produced what had been described as animal
behaviour as well as experiencing a fanciful flying and inducing a frenzied dancing.
In particular, mandrake has much associated folklore. Upon hearing the terrible shriek
when uprooting the mandrake the collector would die.6 To avoid the fate the collector
used dogs to uproot mandrake and plugged their ears with wax. Due to the Y-shaped
root, mandrake has also been associated with enhancement of fertility.
2.3 Biosynthesis of tropane alkaloids
2.3.1 Total synthesis of tropine and the structural elucidation of tropine
The synthesis and elucidation of the tropine structure was very much on the agenda in
late nineteenth century organic chemistry. In 1863 Kraut obtained atropic acid and
tropine (64) after boiling atropine with BaSO4, and later Lossen showed that the initial
product of the hydrolysis atropic acid, was tropic acid. The reverse synthesis was
demonstrated by Ladenburg a year later, when upon treatment of tropine and atropic
acid under dry hydrochloric acid conditions, he generated atropine. However, the
structure was still unsettled.10-12 It was not until 1903 that the first total synthesis of
tropine was successfully performed by Robert Martin Willstätter, and as a
consequence he successfully elucidated the structure of tropine.12 He is also credited
for the first synthesis of cocaine, another tropane alkaloid. In 1915 Willstätter
received the Nobel Prize in chemistry for his work on pigments and especially
chlorophyll.
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Scheme 2.1 Summary of Willstätter’s first total synthesis of tropine.12
In 1917 Robert Robinson published a one pot synthesis of tropinone (65) a reaction
which has become a synthesis classic.13 The possibility that tropine might result from
the condensation of succindialdehyde (66) and methylamine (67) occurred during
discussions between Robinson and Lapworth.13-15 Robinson then demonstrated that by
adding succindialdehyde to an aqueous solution of methylamine (67) and acetone he
could obtain tropinone. The yield was improved significantly when the calcium salt of
acetonedicarboxylic acid (68) was employed at physiological pH. This short and very
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direct route to tropinone led Robinson to speculate that the in vivo biosynthesis of
tropinone might parallel this chemistry.14
Scheme 2.2 Robert Robinson’s 1917 classic one-pot synthesis of tropinone.13, 16
2.3.2 Biosynthesis of the tropane ring
The biosynthesis of the tropane ring arises from two origins. The C4N pyrrolidine,
carbon atoms 1, 5, 6, 7 have an amino acid origin and the C3 ketone fragment
comprising carbon atoms 2, 3, and 4 derive from acetate. There were two hypotheses
at that time on the biosynthesis of the tropane nucleus. The Robinson hypothesis
suggested that the amino acid ornithine could be a precursor of succindialdehyde. The
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second was presented by Mortimer based on a previous hypothesis by Dawson which
suggested tryptophan as the biosynthetic precursor of the entire tropane ring via
known biosynthetic intermediates to nicotinic acid.17 However, Robinson suggested
that this was less likely as it would require the oxidative fission between C-1 and C-2
of compound 71. Also it was known that piperidine alkaloids are related to the amino
acid lysine, thus in the same way, these pyrrolidine alkaloids would be related to
ornithine.18
N
H
NH3
O
O
69 70
NH2
O NH3
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Scheme 2.3 Dawson’s incorrect biosynthesis hypothesis of tropinone (65) from
tryptophan (69).
2.3.2.1 The amino acid derived fragment
The amino acids argentine (73) and ornithine (74) had been suggested precursors for
the biosynthesis of the pyrrolidine moiety of the tropane skeleton by Robinson, after
his 1917 in vitro synthesis.14 Initial studies revealed that the feeding of L-(+)-
argentine and L-(+)-ornithine to leaves of A. belladonna increased the alkaloid
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content to a greater extent than other amino acids. Also ornithine was detected in the
pressed juice of A. belladonna sprouts, supporting this hypothesis.19, 20 Leete’s
radiolabelled experiments by feeding (RS)-[2-14C]-ornithine (74a) to mature D.
stramonium plants revealed that the radioactivity was located at C-1.21-24
Complementary feeding experiments were also carried out by Bothner-By.
Presumably, feeding of sodium [1-14C]-acetate (75a) to root culture of D. stramonium
produced the [5-14C]-ornithine (74b) which then biotransformed to hyoscyamine.
Chemical degradation of hyoscyamine revealed that radioactivity was found to be
located at C-5 of the pyrrolidine moiety of hyoscyamine (46a, 46b).25
Scheme 2.4 Leete’s feeding experiment demonstrated the regiospecific
incorporation of radioactivity into C-1 and C-5 of the pyrrolidine ring of hyoscyamine
(46a, 46b).24 This was also supported by Bothner-By’s feeding experiments of
sodium [1-14C]-acetate (75a).25
Other intermediates in the biosynthesis of the tropane alkaloids have been revealed.
Feeding of radiolabelled [N-methyl-14C,2-14C]-ornithine (74c) to Datura plants
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indicated N-methylputrescine as a precursor of the tropinone ring.26 Also
administration of DL-[5-14C]- and DL-[5-3H]-ornithine (74d, 74e)27 to A. belladonna
supported the involvement of N-methylornithine (76) as a biosynthetic precursor of
the pyrrolidine moiety, and 76 was also identified as a natural metabolite by
isolation.27 N-Methylputrescine (77) had been found to be an intermediate of the
tropanes in Datura metel,28 whilst radioactive 4-methylaminobutanal(78a) had been
detected in Datura plants which were fed with [2-14C]-ornithine (74a).29
Leete’s early proposal of the biosynthetic pathway is shown in Scheme 2.5.26 The
amino acid ornithine (74) is first methylated, followed by decarboxylation to yield N-
methylputrescine (77). Oxidative deamination would then deliver 4-
aminobutylaldehyde 78, a substrate for cyclisation to N-methylpyrrolinium salt (79).
Condensation of 79 with an acetate derived fragment (see below) would then generate
tropinone 65. It is noteworthy that intermediates after 76 in this biosynthetic proposal
are asymmetric.
Scheme 2.5 Leete’s early proposal for the biosynthetic pathway to tropinone.26
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Leete’s proposal required ornithine and other intermediates to become incorporated in
an asymmetric manner into the pyrrolidine moiety of the tropane ring. However,
symmetrical incorporations of radiolabelled substrates into the tropane alkaloids in
Datura plants30, Hyoscyamus niger31, H. niger,32 and Erthroxylon coca33 have been
reported. The doubly labelled [1,4-14C]-putrescine (80a) feeding experiment with D.
mentel incorporated equally into C-1 and C-5 of the pyrrolidine moiety.34
Additionally, feeding experiments of [2-13C, 2H3]-acetate (75b) to root cultures of D.
stramonium confirmed the symmetrical incorporation into hyoscyamine (46d, 46e) as
shown in Scheme 2.7.35
Scheme 2.6 Feeding experiment demonstrating the regiospecific incorporation of
[1,4-14C]-putrescine (80a) into C-1 and C-5 of hyoscyamine (46c).34
Scheme 2.7 Feeding of [2-13C, 2H3]-acetate (75b) into root cultures of D.
stramonium revealed the symmetrical incorporation into C-6 and C-7 of hyoscyamine
(46d, 46e).35
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These apparent inconsistent results from feeding experiments were rationalised.12
Pyrrolinium (79) may tautomerise in vivo to result in a symmetrical incorporation.
This was shown when deuterium in [2-2H]-N-methylpyrrolinium chloride (79a) was
incorporated into both C-1 and C-5 of the tropane ring of 7β-hydroxytropine (81a,
81b) after feeding experiments to D. stramonium.12, 36 However, in a contradictory
study, radioactivity was only located at C-2' of nicotine (82a) when Nicotina tabacum
was fed with N-methyl-[2-14C]-pyrrolidinium chloride (79b), inconsistent with an in
vivo tautomerisation.37
Scheme 2.8 Tautomerism in N-methylpyrrolidinium (79) salt would lead to the
observed symmetrical labelling.36
Scheme 2.9 [14C]-Feeding experiments in Nicotiana tabacum showed asymmetric
labelling into nicotine (82a).37
Alternatively, Leete has proposed38 the involvement of PLP in the biosynthesis of the
tropane alkaloids and more recent studies32, 39 on enzyme activities involved in the
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biosynthesis of hyoscyamine support this hypothesis (Scheme 2.10). Decarboxylation
of ornithine by ornithine decarboxylase (ODC, EC 4.1.1.17) will generate Schiff base
(84). Hydrolysis of 84 would give the aminoaldehyde (85), followed by methylation
to generate 4-N-methylaminobutanal (78). Tautomerisation of 84 to Schiff base 86
followed by hydrolysis would however result in a loss of the symmetry in the
labelling of putrescine (80). Methylation mediated by putrescine N-methyltransterase
(PMT, EC 2.1.1.53)32, 39 would then form N-methylaminobutyraldehyde (78),
followed by cyclisation to generate 79. Recent investigations have shown S-adenosyl-
L-methionine acts as a methyl donor for PMT.40 This was proven by the
administrating [2H3-methyl]-methionine to transformed root cultures of D.
stramonium.35
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Scheme 2.10 Proposed involvement of PLP dependent ornithine decarboxylase in
the biosynthesis of tropane.38
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L-ornithine is an accepted precursor for the biosynthesis of tropane alkaloids and
more recent studies suggest a role for arginine (87) since ornithine and arginine are
metabolically inconvertible via the urea cycle. An investigation with H. albus, feeding
with L-[2,3-3H3]-arginine (87a), found that radioactivity in N-methylputrescine
became incorporated into hyoscyamine.41 Tracer studies in Datura cultures feeding
DL-[5-14C]-ornithine (74a), L-[U-14C]-arginine (87b), [U-14C]-agmatine (88a), all
showed incorporations into hyoscyamine. Interestingly, hyoscyamine production was
substantially inhibited by the arginine-decarboxylase inhibitor, DL-α-
difluoromethylarginine (89), but not by the corresponding ornithine decarboxylase
inhibitor, DL-α-difluoromethylornithine (90). This suggests that arginine is the more
direct precursor of tropine biosynthesis by decarboxylation to agmatine 88.39
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Scheme 2.11 Ornithine (74) and arginine (87) are interconvertable via the urea cycle
Figure 2.5 DL-α-difluoromethylarginine (89), an arginine decarboxylase inhibitor
and DL-α-difluoromethylornithine (90), an ornithine decarboxylase inhibitor.39
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2.3.2.2 The acetate derived fragment
It is obvious that the biosynthesis of the tropane alkaloids requires the condensation of
N-methylpyrrolinium (79) with an acetate derived unit. Either acetone, acetate (75) or
acetoacetate (91) have been discussed as candidate intermediates in Robinson’s
hypothesis.14 Early studies involving radiolabelling experiments by feeding sodium
[1-14C]-acetate (75a), sodium [2-14C]-acetate (75c), and [2-14C]-ornithine (74a)
pointed to the involvement of the alkaloid hygrine (92) as an intermediate in tropane
alkaloid biosynthesis.42-44 In addition, feeding experiments with (RS)-[N-methyl-
14C,2'-14C]-hygrine (92a), (2R)-[2'-14C]-hygrine (92b) and (2S)-[2'-14C]-hygrine (92c)
with D. innoxia, H. niger, and A. belladonna all resulted in radioactive
hyoscyamine.43, 45, 46 However, there were inconsistencies in stable isotope labelling
studies indicating that hygrine may not be involved hyoscyamine biosynthesis. This
was revealed by the feeding of [1,2,3,4-13C]-acetoacetate (91a) which showed a
similar labelling pattern to feeding sodium [1,2-13C2]-acetate (75d).36, 47 Additionally,
the incorporation of (RS)-[2',3'-13C2]-hygrine (92d) into hyoscyamine and
scopolamine D. innoxia was very low.48 Ethyl (RS)-[2,3-13C2,3-14C]-4-(1-methyl-2-
pyrrolidinyl)-3-oxobutanone (95a) was successfully incorporated into scopolamine
and hyoscyamine at high levels in both D. innoxia48 and D. stramonium.49
Presumably, the ethyl ester was hydrolysed in vivo and was incorporated as its free
acid or perhaps as a co-enzyme A ester (95b). Interestingly, the feeding, by
hydroponics to D. innoxia roots showed no preference for (R)- or (S)- 95 into
scopolamine (59). Also the possibility that (RS)-[2,3-13C2,3-14C]-4-(1-methyl-2-
pyrrolidinyl)-3-oxobutanone (95a) could undergo decarboxylation to (RS)-[2',3'-
13C2,2'-14C]-hygrine (92e) was ruled out, since labelled (RS)-[2',3'-13C2]-hygrine (92d)
was incorporated at a very low level.48 The hypothesis is shown in Scheme 2.12.
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Pyrrolinium salt (79) reacts consecutively with two acetate (or acetyl-CoA, 75e) units
to form thioester (95b), as suggested by Hemscheidt and Spenser.36 Cyclisation via
the pyrrolinium salt (96) forms the thioester of 2-carboxy-3-tropinone (97), followed
by hydrolysis and decarboxylation to deliver tropinone (65).
Scheme 2.12 Proposed biosynthesis of tropinone via the consecutive incorporation
of acetyl-CoA (75e). Hygrine is not an intermediate.48, 49
Richard Robins and co-workers49 re-evaluated the intermediacy of ethyl (RS)-[2,3-
13C2,3-14C]-4-(1-methyl-2-pyrrolidinyl)-3-oxobutanone (95a) in transformed root
cultures of D. stramonium. The results confirmed that hygrine (92) was not
incorporated into hyoscyamine. There was no preference for the (R)- over the (S)-
isomer of (RS)-[2,3-13C2,3-14C]-4-(1-methyl-2-pyrrolidinyl)-3-oxobutanone (95a) or
its thioester (95b). However, a feeding experiment with sodium [1,2-13C2]-acetate
(75d) suggested the involvement of an intact C3 unit because this gave an
incorporation of label at C-2 and C-4 in hyoscyamine, but there was also a significant
level of triply-labelled molecules. Also, the shorter monoacetate derivative 94a did
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not become incorporated into the tropane ring, so a stepwise process as shown in
Scheme 2.12, is not supported by this experiment.
Scheme 2.13 Re-evaluation of β-ketoester 95a in tropane biosynthesis.49
Alternatively, there has been a suggestion that 1,3-acetonedicarboxylic acid (68)
could be a precursor to the acetate derived fragment of the tropane ring.12, 36, 50, 51 A
closely related biosynthesis had been explored for lycopodine (99) in Lycopodium
tristachyum. Feeding of [1,2,3,4-13C4]-1,3-acetonedicarboxylate (68a) resulted in the
incorporation of an intact C3 unit into two separate fragments (Scheme 2.14).52 The
condensation of piperidinium ion (100) with acetonedicarboxylate would generate
intermediates 101 and 102 which would then condense to generate lycopodine. A
condensation of the pyrrolinium salt (79) with acetondicarboxylate (68) for tropane
biosynthesis would mirror this observation (Scheme 2.15), however this hypothesis
has yet to be proven experimentally.
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Scheme 2.14 The incorporation of [1,2,3,4-13C]-acetonedicarboxylate (68a) into
lycopodine (99a) in L. trischyum.52
Scheme 2.15 Proposed incorporation of acetonedicarboxylate (68) into tropinone
(65).12, 36, 50, 51
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2.3.2.3 The reduction of tropinone to tropine
[Methyl-14C]-Tropinone is an established precursor to tropine.53 Two NADPH
dependent enzymes have been isolated and purified from transformed root cultures of
D. stramonium. Tropinone reductase I converts tropinone to tropine, whereas
tropinone reductase II generates pseudotropine (ψ-tropine, ).54 The structures of TR-II
has been solved by X-ray structure analysis.55
Scheme 2.16 The reduction of tropinone by tropane reductases (TR I and II).54
2.3.3 Biosynthesis of hyoscyamine
2.3.3.1 Littorine as a precursor
Robinson recognised that tropic acid is an isomer of the phenylpropanoic acid
skeleton and he proposed that tropic acid may originate by a rearrangement of the
phenylpropanoid skeleton.56 Several researchers have shown that the
phenylpropionate moiety of littorine (45) is derived from phenylalanine (13).57-59
Further feeding experiments by administrating [1,3-13C2]-phenylalanine (13a) to D.
innoxia have demonstrated the incorporation of 13C into C-1 and C-2 of the tropic acid
moiety of hyoscyamine, as evident by 13C-NMR satellites peaks due to 13C-13C
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coupling.60 Remarkably this experiment demonstrated an intramolecular
rearrangement where the two isotopes become contiguous in the resultant tropate.
Scheme 2.17 Leete’s feeding of [1,3-13C2]-phenylalanine (13a) proved an
intramolecular rearrangement in the biotransformation of the tropate ester.60
It is known that phenylalanine is metabolically interconvertable in vivo with
phenyllactate (103) presumably via phenylpyruvate (104), so the role of phenyllactate
in the biosynthesis of the tropane alkaloids then attracted attention. Phenyllactate was
shown to incorporate into tropic acid in D. sanguinea61 and a radiolabelled study
showed that the 3H:14C ratio from feeding of (RS)-phenyl-[1-14C,2-3H]-lactate (103a)
remained essentially constant in the recovered hyoscyamine and scopolamine.62
Further, feeding experiments with phenyl-[1,3-13C2]-lactic acid (103b)63 in D.
stramonium resulted in the similar spin-spin couplings by 13C-NMR at C-1 and C-2 of
the tropic acid recovered by hydrolysis of hyoscyamine and scopolamine. These
findings clearly suggested that phenyllactate is an obligatory intermediate in the
biosynthesis of tropic acid and that the rearrangement of the side chain takes place at
the phenyllactate level, not the phenylpyruvate level.62 Feeding experiments
supplementing D. stramonium transformed root cultures with sodium (R,S)-phenyl-[2-
13C,2-2H]-lactate (103c) resulted in a substantial retention of 13C-D attached to C-3' of
tropate ester.64 Further experiments with (R)- [2-13C,2H] and (S)- [2-13C,2H]-
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phenyllactates (R-103d, S-103d) showed that only the (R)-isomer resulted in
hyoscyamine containing a dual labelled 13C-D (28.9%) indicating that the bond
remained intact during the biosynthesis (Scheme 2.18). For the (S)-isomer the
deuterium was lost, indicating this bond had been broken during hyoscyamine
formation. Presumably, (S)-phenyllactate is converted in vivo to (R)-phenyllactic acid
perhaps via phenylpuruvate, prior to incorporation into hyoscyamine biosynthesis. 65,
66
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Scheme 2.18 An in vivo interconversion between (R)- [2-13C,2H] and (S)- [2-13C,2H]-
phenyllactate (R-103d, S-103d) via phenylpyruvate (104a) resulted in a loss of 13C-D
bond in hyoscyamine for the (S)-isomer and remaining intact for the (R)-isomer.65, 66
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The most direct precursor of tropane biosynthesis emerged when the quintuply
labelled of littorine, (RS)-phenyl-[1,3-13C2]-lactoyl-[methyl-2H3]-tropine (45a), was
fed to transformed root cultures D. stramonium. This revealed an intact incorporation
of the quintuply labelled precursor into hyoscyamine.67, 68 Additionally, the
intramolecular rearrangement was again confirmed by NMR with 13C spin-spin
coupling due to the adjacent enriched C-1' and C-2' carbons of hyoscyamine (46k).
These experiments clearly suggest that littorine is the true substrate for rearrangement
to hyoscyamine.
Scheme 2.19 The feeding of (RS)-phenyl-[1,3-13C2]-lactoyl-[methyl-2H3]-tropine
(45a) to D. stramonium resulted in the quintuply labelled hyoscyamines (46k)
securing littorine (45) as a direct precursor to hyoscyamine (46).67, 68
2.3.3.2 Stereochemistry of the rearrangement
The studies described above have shown the intramolecular rearrangement of
phenylalanine to tropane alkaloids.60, 69, 70 In order to establish the stereochemical
course of the rearrangement of littorine (45) to hyoscyamine (46), isotopic labelling
experiments were carried out in D. stramonium. Initially, the migration centre at C-3
of littorine to C-2 of hyoscyamine was investigated by feeding (2R,3R)-[2-13C,3-
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2H1,phenyl-2H5]-phenyllactate (103e) carrying deuterium at the 3-pro-S site, and
separately (2R, 3S)-[2-13C,3-2H1]-phenyllactate (103f), carrying deuterium at the
3-pro-R site. These experiments revealed that the 3-pro-R deuterium was lost during
the transformation and that the 3-pro-S deuterium was retained. The resultant tropate
ester has the (S)-configuration so it was deduced that there is an overall inversion of
configuration at C-3 of (R)-phenyllactate during the rearrangement.71
Scheme 2.20 Exploring the stereochemistry of C-3 of phenyllactic acid during its
conversion to tropic acid in D. stramonium.71
The stereochemical course at C-2 of littorine as it progressed to C-3 of hyoscyamine
was established by feeding (RS)-[2-3H]-phenyllactate (103g) to generate radiolabelled
hyoscyamine (46m) with tritium located at C-2.72 After in vivo isomerisation the
radiolabelled hyoscyamine was isolated and the resultant configuration of the C-T
bond was revealed by oxidation to acetic acid and then chiral acetic acid analysis. The
resultant [2H,3H]-acetic acid (108) had the (R)-configuration (Scheme 2.21). Thus, by
deduction, the tritium must have occupied the 3-pro-S site in the isolated
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hyoscyamine. Clearly, again, there is an overall inversion of stereochemistry in going
from littorine to hyoscyamine at this migratory terminus. This was consistent with a
previous study by Haslam which indicated inversion of configuration at C-2'.73 A
summary of the stereochemical course of the rearrangement is shown in Scheme 2.22.
Scheme 2.21 Incorporation of (RS)-[2-3H]-phenyllactate (103g) to D. stramonium
and the chemical manipulation of hyoscyamine (46m) to chiral acetic acid (108).72
Scheme 2.22 Summary of the stereochemical course of the rearrangement of littorine
(45) to hyoscyamine (46).65, 72
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2.4 Enzymes that mediate a molecular rearrangement.
2.4.1 Co-enzyme B12 and SAM. ‘Poor man B12’ is not involved.
The carbon skeleton rearrangement of littorine to hyoscyamine finds some precedence
in B12 mediated isomerisations such as that catalysed by methylmalonyl-CoA
mutase74, 75 and glutamate mutase (Section 1.2, Chapter 1).76 These rearrangements
involve a vicinal interchange between a carboxyl moiety with the subsequent 1,2-back
migration of a hydrogen atom. The similarity of the littorine rearrangement process to
that of the conversion of methylmalonyl-CoA (3) to succinyl-CoA (4)70 led to the
hypothesise that co-enzyme B12 may mediate this process. However, no co-enzyme
B12 dependent enzymes have been identified in plants to date.
Scheme 2.23 Vicinal interchange mediated by co-enzyme B12.
Scheme 2.24 1,2-Vicinal interchanges mediated by co-enzyme B12.74, 76
Nature utilises the 5'-deoxyadenosyl radical (2) to abstract a hydrogen atom from non-
activated positions. In animals and bacteria, co-enzyme B12 is the major source for
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this radical, however it has been reported that SAM (109) mediated lysine 2,3-
aminomutase from Clostridia catalyses the interconversion of L-lysine to L-β-
lysine.77, 78 The enzyme contains iron-sulphur clusters and is activated by the 5'-
deoxyadenosyl radical (2) and pyridoxal 5'-phosphate. This led researchers to call
SAM “poor man’s B12”. In an effort to demonstrate79 the transfer of hydrogen from
the methylene group of the adenosyl radical into the alkaloid, [2,8,5'-3H] SAM (109a)
(65% 3H at 5' position) was administered to cell free extracts of D. stramonium.
However, only a very low incorporation of tritium into littorine or hyoscyamine was
observed.
Scheme 2.25 5'-Adenosyl radical (2) generates from SAM (109).
More recent studies using stable isotope methodology failed to detect any back
migration of the deuterium isotope.71 The re-investigation by feeding (RS)-[2-2H]-,
(RS)- [3,3-2H2]-, and (RS)-[2,3,3-2H3]-phenyllactic acids (103h, 103i, 103j) to D.
stramonium did not provided evidence of a vicinal interchange process (Scheme
2.26). The complete loss of deuterium at C-3' of 46n during the isomerisation to
hyoscyamine and the absence of deuterium redelivery back to C-3' of hyoscyamine, is
inconsistent with a vicinal interchange process.80 These experiments ruled out the role
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a vicinal interchange process and the involvement of co-enzyme B12 or SAM. This
also illustrated the shortcoming of radiolabelled experiments, particularly in
interpreting low levels of incorporation.
Scheme 2.26 A series of feeding experiments did not provide any evidence for a 1,2-
vicinal interchange operating in the rearrangement of littorine to hyoscyamine.80
2.4.2 The role of cytochrome P450 enzymes.
It has been reported that some plants utilise cytochrome P450, iron-oxo enzymes, to
mediate isomerisation processes.81, 82 Also the P450 inhibitor chlotrimazole suppresses
the conversion of littorine to hyoscyamine in D. stramonium transformed root
cultures. This implicates P450 involvement in the biotransformation.83 In recent
studies,84 a virus silencing cytochrome P450 gene, identified CYP80F1 P450 the
gene/enzyme from H. niger (black henbane) responsible for the conversion of littorine
to hyoscyamine. Hyoscyamine was observed when CYP80F1 was expressed in
tobacco hairy roots supplemented with (R)-littorine. Expression in yeast confirmed
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that CYP80F1 catalysed the oxidation of (R)-littorine to form the hyoscyamine
aldehyde, the putative precursor to hyoscyamine, along with the side product 3'-
hydroxylittorine (110). A mechanism for the rearrangement of littorine to
hyoscyamine involving radicals has been proposed by analogy to the study in
Pueraria lobata plants (Section 1.4, Chapter 1).66, 82 Abstraction of the benzylic
proton of littorine (45) generates radical 111. Rearrangement of this radical
intermediate, followed by an “oxygen rebound” process would give gem-diol 112.
Dehydration to an aldehyde and subsequent reduction by a dehydrogenase then gives
hyoscyamine. The feeding of (R,S)-[2-2H,18O] phenyllactic acid to root cultures of D.
stramonium had shown that 25-29% of the 18O isotope was lost during the
rearrangement.85 The proposed oxygen rebound process requires the intermediacy of
aldehyde (113). Exchange of the aldehyde oxygen with the aqueous medium prior to
reduction could account for some loss of the isotope. In addition a partially
stereoselective dehydration of the gem-diol could lead also to some loss of the
isotope.
Scheme 2.27 A putative cytochrome P 450 dependent mechanism for the
rearrangement of littorine (45) to hyoscyamine (46) via a radical process.66
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Alternatively a carbocation type migration, arising from a P450 mediated two electron
oxidation could occur. The resultant benzylic carbocation could undergo a carbon
skeleton rearrangement by 1,2-sigma bond migration. This would result in the direct
formation of a product carbocation which could collapse to an aldehyde intermediate.
Reduction would then give hyoscyamine (Scheme 2.28).
Scheme 2.28 An alternative carbocation mechanism for hyoscyamine biosynthesis.66
Although, the cytochrome P450 enzyme, CYP80F1 gene responsible for the
rearrangement of littorine to hyoscyamine has been identified by Covello and co-
workers,84 mechanistic details of the rearrangement of littorine to hyoscyamine
remain unknown. It is not clear whether the mechanism involves a carbocation or a
radical.
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2.5 Reactive species involved in P450 transformations.
Cytochrome P450’s (CYP450 or P450) are a superfamily of heme-containing
monooxygenase enzymes which are present in all aerobic organisms. They exhibit a
characteristic absorption band at 450 nm when coordinated to carbon monoxide, thus
they are dubbed P450’s. Structurally, the prosthetic group of cytochromes P450
consists of an iron(III) protophophyrin IX which links to a cysteine residue by a
covalent bond as shown in Figure 2.6.86 Probably the most remarkable reactions
mediated by cytochromes P450 are hydroxylation of unactivated C-H bonds and
epoxidation of double bonds. The generally accepted catalytic cycle for the
hydroxylation of C-H bond is shown in Scheme 2.29.87-89 The resting state of the P450
has iron(III) coordinated to water as a distal ligand and thiolate as a proximal ligand.
The approaching substrate induces an electron transfer process from NADP(H) via an
electron transfer chain (flavin reductase-Fe2S2 system, or without Fe2S2 system) to
generate an iron(II), allowing this species to bind with dioxygen and form iron(III)-
superoxide. A second single electron transfer and protonation generates an iron(III)-
peroxide, the so-called Compound 0 (Cpd 0). The second protonation allows water to
leave, generating the high-valent ferryl moiety [Fe(IV)=O] and a porphyrin radical
cation, Compound I (Cpd I). Abstraction of a hydrogen atom from the substrate by
Cpd I, followed by the return of a hydroxyl radical in an ‘oxygen rebound process’,
regenerates the iron(III) species.
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Figure 2.6 Structure of iron (III)-protoporphyrin IX.86, 89
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Scheme 2.29 P450 cycle for substrate hydroxylation.87-89
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The intermediates in the catalytic cycle have been extensively studied both
computationally and experimentally, however Cpd I, has not yet been fully
charaterised. Generation of Cpd I has recently been accomplished by photooxidation
of Cpd II to perform hydroxylation.90 Recently, radical clock experiments by
Newcomb have cast doubt on the true oxidant species utilised by P450 enzymes.91-95
He proposed a two oxidant hypothesis.96 Newcomb observed oxidation of a
substituted cyclopropane 115 by a cationic rearrangement process along with the
expected hydroxylation product (Scheme 2.31). It is well known that Cpd I is the
primary oxidant in P450 enzymes, operating via a radical process. Newcomb, therefore
suggested that Cpd 0 might act as the secondary oxidant responsible for the insertion
of hydroxonium ion (+OH) into C-H to initiate a cation rearrangement. This is
summarised in Scheme 2.30.
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Scheme 2.30 Reactive species in P450 mediated hydroxylation reactions96
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2.6 Radical or carbocation rearrangement process
In order to discriminate radical and carbocation intermediates in P450 enzymes, a
mechanistic probe has been developed.97 The cyclopropylcarbinyl cation 115b opens
preferably towards the oxygen in a ratio of 1000:1. This has a similarity to the
rearrangement process of littorine to hyoscyamine in the forward direction. On the
other hand the cyclopropylcarbinyl radical 115a opens preferentially towards the aryl
ring with a ratio of 170:1. This is opposite to the direction of the rearrangement. In
addition, these probes were applied to in vivo incubations with cytochrome P450
enzymes.93 The unrearranged product (118) predominated in those experiments along
with small amounts of rearranged products (119 and 120). The 6:1 preference of
cationic rearranged product (119) over radical derived product (120) implied that the
P450 enzymes could generate carbocations and lends support to the intermediacy of
carbocations, e.g. in the rearrangement of littorine to hyoscyamine.
Scheme 2.31 A mechanistic probe to partition radicals from carbocations as devised
by Newcomb.97
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Scheme 2.32 Cytochrome P450 mediates hydroxylation and rearrangement to give
118, 119 and 120 with ratios shown in parentheses, suggesting significant cationic
character in P450 processes.93
In a biomimetic model reaction, a carbocation isomerisation has been demonstrated in
vitro by Wemple.98, 99 The rearrangement was mediated by Lewis acid catalysis and
reaction resulted in the α-formylphenylthioacetate (122). This product was then
converted into the thioester of tropic acid (123) by treatment with sodium
cyanoborohydride (Scheme 2.33).
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Scheme 2.33 α-Formylphenylthioacetate (122) is converted to a thioester of tropic
acid (123) via a cationic rearrangement.
2.7 Computational studies
Recently in a computational study in 2008 Radom et. al., the rearrangement of methyl
phenyllactate (124) to methyl tropic acid was explored.100 The high-level quantum
chemistry calculation (G3(MP2)-RAD, level) considered two possible pathways, a
stepwise and a concerted rearrangement. In the stepwise process (Scheme 2.34) the
energy barrier to form radical 125b from 124 was calculated to be 136.3 kJmol-1 and
the recombination of 125b to form the radical product 126b was 106 kJ mol-1, but the
overall reaction for the radical rearrangement was calculated to be endothermic by
29.4 kJmol-1. For the carbocation process, the relative energy barrier to form 125a
was slightly higher at 170.9 kJmol-1, however the overall reaction for this process was
calculated to be exothermic by 26.8 kJmol-1.
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Scheme 2.34 High-level quantum chemistry calculations using G3(MP2)-RAD
considered the stepwise rearrangement via radical and cationic intermediates.100
For the concerted rearrangement process (Scheme 2.35), the energy barrier for radical
rearrangement was calculated to be similar in magnitude to the stepwise radical
process. On the other hand, the barrier associated with cationic concerted
rearrangement (124 to 127a) was calculated to be as low as 47.4 kJmol-1 and the
overall reaction was calculated to be exothermic by 26.8 kJ mol-1. The ionization
energy of the substrate-derived radical to generate a carbocation was calculated to be
7.01 eV, suggesting that its oxidation to generate the substrate-derived carbocation
ought to be facile. These calculations led the authors to suggest that a concerted
rearrangement mechanism involving a carbocation constitutes a more viable pathway
for carbon skeleton rearrangement in tropane alkaloid biosynthesis.
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Scheme 2.35 High-level quantum chemistry calculations using G3(MP2)-RAD
considered the concerted rearrangement via radical and cationic pathways.100
2.8 Fluorine as a mechanism probe
2.8.1 Effect of fluorine on the aromatic ring.
Fluorine is the most electronegative element (4.0) in chemistry. Its size is similar to
that of hydrogen (the Van der Waal’s radii of fluorine: 1.35 Å; of hydrogen: 1.1 Å).
Thus, the substitution of hydrogen by fluorine in an organic compound does not
change the steric profile of a molecule, although the electronic profile alters
significantly. For aromatics, the replacement of hydrogen by fluorine is deactivating
but ortho-, para-directing in electrophilic substitution reactions. This can be explained
by donation of the fluorine lone pairs into the aromatic ring system stabilising reaction
intermediates. The short C-F bond and similar size of the oribitals result in a maximal
p- interaction. However, the powerful inductive effect of fluorine which acts most
strongly at the ortho-position relative to the para- position, leads to a preference for
para- substitution in electrophilic substitution reactions of fluorobenzene.101
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2.8.2 Effect of fluorine on benzylic carbocation and radical intermediates.
Benzylic carbocations are stabilised by ortho- and para- fluoro substituents via
donation of electron density from fluorine lone pairs into the aromatic π-system with a 
significant stability preference of para- over ortho-. Meta substitution does not
significantly stabilise the benzylic carbocation since electron resonance and inductive
effects are small.101-103 Unfortunately, there is very little in the literature on the
influence of aryl fluorine substituents and their ability to stabilise a benzylic radical. It
appears that a meta-fluoro and para-fluoro substituents will destabilise the benzylic
radical although the effect is small.104-107 There was no information prior to this
research, on the behavior of a 2-fluoro substituents on the stability of a benzylic
radical. Theory calculations on the effect of fluorine on benzylic intermediates will be
discussed in Section 2.10.1.
2.8.3 The use of fluorine as a mechanism probe in tropane alkaloids
biosynthesis
O’Hagan and co-worker108 have demonstrated that 2'-, 3'- and 4'- fluorophenyl-DL-
lactic acids (103k, 103l, 103m) were esterified in vivo with tropine in D. stramonium
root cultures. The resultant fluorinated littorines were then isomerised to the
corresponding fluorinated hyoscyamines (46p, 46q, 46r). If the mechanistic
intermediate is a carbocation, then ortho-, meta-, and para-fluorinated littorines would
be anticipated to rearrange in the order 4F-littorine> 3F-littorine > 2F-littorine.
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However, interestingly, the efficiency of the conversion of fluorolittorine to
fluorohyoscyamine was in the order 3'-F-lit > 4'-F-lit >> 2'-F-lit. Clearly, the
inductive effect of fluorine is greatest at the ortho- position, but the result did not
indicate a progressive inductive effect for substitution at the other sites and
surprisingly the meta fluorine was most efficient. So it was suggested that different
binding affinities of the isomers to the isomerase may also contribute to this overall
activity profile, and this complicates a straightforward analysis of the results.
Scheme 2.36 The conversions of rac-fluorophenyllactic acids in D. stramonium
showed the production of fluoroarylhyoscyamines with the in vivo conversions (at day
17) shown in parentheses.108
2.9 Aims of the study
The availability of a cytochrome P450 enzyme involved in hyoscyamine biosynthesis
from H. niger in Prof. Patrick Covello’s laboratory, provided an opportunity to
explore the mechanism of the rearrangement of littorine to hyoscyamine. Therefore
the objectives of this study were:
1. Preparation of the rac-(45e-g) and enantio-enriched fluorolittorines (S-45e-g,
R-45e-g).
2. Preparation of enantio-enriched dideuterio-littorines (S-45h, R-45h) for
measurement of the kinetic isotope effect of this intriguing rearrangement reaction.
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3. DFT calculations on fluorine substituent effects particularly exploring the stability
of benzylic carbocations and radicals. (Carried out by David J. Tozer at Durham
University)
4. The enzyme assays carried out in Prof. Covello’s laboratory in Canada.
Figure 2.7 Target molecules to explore the mechanism of hyoscyamine formation.
2.10 Results
2.10.1 DFT study on the relative energies of ortho-, meta- and para- fluorobenzyl
radicals and cations.
The results from the DFT calculations carried out at Durham University are shown in
Table 2.1. These were consistent with the literature in that fluorine can stabilise a
benzylic carbocation. The stability order of fluorobenzylic carbocations is para- >
ortho- > meta- as expected. Calculation of the relative stabilities of benzyl radicals
revealed that there was no significant difference in relative energy between these three
isomers, but it appears that the meta-fluorobenzyl radical is the most stable, with the
para- and ortho- only a little higher in energy. In this case the stability order appears
as meta-, ortho-, and para-. Interestingly, the relative energy differences for the three
benzyl radicals are small compared with that of the benzylic cations (and anions).
Additionally, the relative stability of the ortho-, meta- and para- fluorobenzyl anions
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was calculated and showed the reverse order, but similar in magnitude to that of the
fluorobenzylic cations. The calculated C-F bond lengths are shown in Table 2.1 and
are consistant with the conjugative interactions expected for fluorine. Generally, the
C-F bond lengths are shorter in the cations and longest in the anions, and the C-F
bond length in the p-fluorobenzylic cation is shortest, consistent with its conjugative
stabilising influence.
Fluorobenzylic intermediate Relative energy
(kcalmol-1)
C-F bond length
(Å)
Carbocation
ortho-
meta-
para-
F
+3.57
+6.75
0.00
1.308
1.319
1.301
Radical
ortho-
meta-
para-
F
+0.20
0.00
+0.15
1.345
1.347
1.344
Anion
ortho-
meta-
para-
F
+2.18
0.00
+5.67
1.376
1.377
1.385
Table 2.1 The relative energies of o-, m- and p- fluorobenzylic cations, radicals
and anions. Relative values from DFT calculations are indicated in kcal mol-1.
Calculated C-F bond lengths are in shown (Å). (D. J. Tozer, the University of
Durham)
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2.10.2 Ionisation potentials
The ionization energies required for the oxidation of the benzylic radicals to benzylic
carbocations was also calculated (Table 2.2). The oxidation potentials of the o-, m-
and p- fluoro radicals to carbocations is predicted to be facile since the oxidation
potentials were found to be low at 7-7.35 eV. The potential trend reflects the relative
stability of the fluorobenzylic carbocations. Clearly, the electronegative fluorine
exerts a small but significant effect on the oxidation potential relative to the non-
fluorinated benzyl case.
fluorobenzylic radical Ionization energy (eV)
ortho-
meta-
para-
7.21
7.35
7.05
benzylic radical 7.09
Table 2.2 Ionisation potentials (eV) for the oxidation of benzyl radicals to
cations. (D. J. Tozer, the University of Durham)
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2.10.3 Synthesis
2.10.3.1 The synthesis of rac-fluorolittorines
2.10.3.1.1 Synthesis of rac-2', 3' and 4'-fluorophenyllactic acid (103k, 103l,
103m)
Preparation of rac-fluorophenyllactic acids followed the method previously described
by Wong.109 Starting from commercially available rac- 2', 3' and 4'-
fluorophenylalanines (13c, 13d, 13e), each isomer of fluorophenyllactic acid (103k,
103l, 103m) was synthesized in a racemic form via a diazotization reaction, with
sodium nitrite and concentrated hydrochloric acid (Scheme 2.37). The mechanism
proceeds with the formation of a diazonium ion (128) which decomposes to release
N2, assisted by the neighboring carboxylate group, to form an intermediate α-lactone 
(129). Nucleophilic attack by water then opens the α-lactone to generate rac-
fluorophenyllactic acid. In all cases the yields were low (20-32%). This was the
consequence of incomplete reaction, as starting material was recovered in the
individual reactions.
2.10.3.1.2 Synthesis of rac-2', 3' and 4'-fluorophenyllactoyl tropines (rac-
fluorolittorine)
Following a previously described procedure,51 each of the rac-fluorophenyllactic
acids was mixed intimately with tropine under a stream of dry HCl gas at 135 °C. The
crude product was then worked-up and purified by preparative TLC and extracted into
methanol to give each of the three isomers of rac-fluorolittorine.
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Scheme 2.37 Synthesis of rac-fluorolittorines (45e, 45f, 45g): Reagents and
conditions: i) cHCl, NaNO2, H2O, 20-32% ; ii) tropine, dry HCl(g), 20-48%.
2.10.3.2 The synthesis of enantio-enriched 2', 3', and 4'fluorolittorines (S-
45e-g, R-45e-g)
2.10.3.2.1 Resolution by preparation of (-)-menthyl derivatives (131)
The resolution of the racemic esters was explored by derivatisation with (-)-menthol.
Such an approach has been successfully applied to the resolution of atrolactinic and α-
hydroxy-β-phenylpropionic acids.110 The acids and (-)-menthol (130) were esterified
by acid catalysed reaction and the diastereoisomeric mixture was then worked-up and
each diastereoisomer was purified by means of crystallization. Accordingly the m-
fluorophenyllactic acid (103l) was mixed with (-)-menthol and heated at 120 °C,
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periodically passing a stream of dry HCl gas over the reaction. After work-up, the
product was analysed by 1H and 19F NMR spectroscopy. The 19F NMR spectrum
exhibited two sets of ddd at -113.9 ppm and -114.2 ppm in a 1:1 ratio as shown in
Figure 2.8. Despite considerable effort crystallisation and conventional
chromatography failed to separate the diastereoisomers. An attempt to reduce the
polarity of the stereoisomers was made by acetylation of the 2'-OH group using acetic
anhydride, however the mixture still co-eluted in all common eluting systems.
Scheme 2.38 Synthesis of menthyl m-fluorophenyllactate (131) and α-acetyl 
derivative (131a). Reagents and conditions: i) dry HCl (g), 120 °C, 6 h; 73.2% ii)
Ac2O, dry pyridine, overnight, 89%.
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Figure 2.8 1H and 19F NMR of menthyl m-fluorophenyllactate (131).
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Figure 2.9 1H NMR of α-acetyl menthyl m-fluorophenyllactate (131a).
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2.10.3.2.2 (1S)-(-)-Camphanoyl chloride derivative (133)
Due to the failure to separate the menthyl ester stereoisomers, another chiral resolving
reagent, (1S)-(-)-camphanoyl chloride was explored. The free carboxylate of rac-p-
fluorophenyllactic acid (103m) was first esterified with methanol and was then treated
with (1S)-(-)-camphanoyl chloride (132) in dry pyridine/DCM. The reaction went
smoothly and was completed within 2 hrs. After work-up, the 19F and 1H NMR
(Figure 2.10) clearly indicated a mixture of two diastereoisomers. Unfortunately,
however, separation of these mixtures (133) by chromatography was also
unsuccessful.
Scheme 2.39 Synthesis of (-)-camphanoyl methyl fluorophenyllactate (133).
Reagents and conditions: i) dry pyridine, DCM, 0 °C, 90%.
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Figure 2.10 19F NMR and 13C NMR of camphanoyl methyl fluorophenyllactate
(133). The carbonyl signals in the lower 13C-NMR spectrum are expanded to show the
pair of signals.
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2.10.3.2.3 Resolution by preparation of amides
Attention then turned to the generation of amide diastereoisomers for this resolution.
There are various coupling methods to form an amide bond in the literature.111
Carbodiimide-mediated coupling has been regularly used since first introduced into
peptide synthesis by König and Greiger.112 A disadvantage of the DCC/HOBt
(134/136) coupling system is that the urea by-product of the reaction is highly
insoluble in most solvents and can cause purification problems. So, new additives
such as EDCI (135), HBTU (137a), and TBTU (137b) have been developed. The urea
by-products in these cases are most easily removed by an acid wash during the work-
up.
N C N N C NNHCl
N
N
N
OH
N
N
N
O
N
N
X
137a; X = PF6
137b; X = BF4
134
135
136
Figure 2.11 Common coupling reagents for amide formation.113
The accepted mechanism (Scheme 2.40) for the coupling reaction involves a rapid
reaction of the carboxylate group with the carbodiimide to generate a highly reactive
O-acylisourea (138). This intermediate can undergo either aminolysis to give a
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corresponding amide (143) or it can react with another acid to form a symmetric
anhydride (140). The highly reactive O-acylisourea can isomerise to form a stable N-
acylurea (139) via an intramolecular acyl transfer. This side reaction may compete
with aminolysis, lowering the yield of the reaction and causing purification problems.
However this difficulty can be avoided by the addition of HOBt (136) which is able to
react rapidly with the O-acylisourea to form an acyl-OBt adduct (141). This adduct
has been reported to exist in two isomeric forms where both isomers react with amine
to form an amide.114, 115
R O
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N
N
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N
N
H
R N
O
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R OBt
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R NHR'
O
R
O
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R' NH2
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Scheme 2.40 A general mechanism for peptide coupling.111
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2.10.3.2.4 Resolution by D-phenylalanine methyl ester hydrochloride (144)
and (S)-phenylethylamine (145)
D-Phenylalanine methyl ester hydrochloride (144) and (S)-phenylethylamine (145)
were chosen to explore the methodology. According to a procedure previously
described by M. Shuller,116 (RS)-α-acetyl-p-fluorophenyllactic acid (103n) was treated
with D-phenylalanine methyl ester hydrochloride (144), using HOBt/EDCI·HCl as
coupling system. The amide (146) was obtained in high yield after work-up, although
the diastereoisomers could not be separated by chromatography. The 1H NMR (Figure
2.12) analysis of the purified diastereoisomers showed well separated signals for the –
OMe groups at 3.61 ppm and 3.64 ppm. Interestingly the –NH protons also appeared
as two sets of doublets at 6.29 ppm and 6.37 ppm with the same coupling constant
(6.9 Hz). The 19F NMR spectrum (Figure 2.12) revealed two sets of dddd at -116.2
and -116.4 ppm. The individual diastereoisomers could not be assigned.
Scheme 2.41 Preparation of diastereoisomers amide 146. Reagents and conditions: i)
DMF, NMM, HOBt, EDCI, CHCl3, rt, overnight, 75%.
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Figure 2.12 1H and 19F NMR of the α-acetyl diastereoisomers of 146.
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In a similar manner to that previously described, (RS)-α-acetyl-p-fluorophenyllactic
acid (103n) acid was also coupled with (S)-phenylethylamine (145) and the amide
product was obtained in high yield. Attempts to separate these diastereoisomers by
chromatography were however unsuccessful. In a continuous search for a system to
separate the isomers, the free α-hydroxy acids were explored. According to the 
standard coupling procedure, m-fluorophenyllactic acid (103l) was treated with (S)-
phenylethylamine (145) and the amide product was obtained with a good conversion.
This time the diastereoisomers showed a promising resolution by chromatography in a
system of 80% EtOAc/20% cyclohexane. Subsequent purification over silica gel
eluting with 60% EtOAc/40% cyclohexane finally led to a successful separation of
(S,S)-148 and (R,S)-148 as single stereoisomers.
Scheme 2.42 Resolution of m-fluorophenyllactic acid (103l). Reagents and
conditions: HOBt, EDCI·HCl, CHCl3, DMF, rt, overnight, (S,S)-148; 46.8% and
(R,S)-148; 44%.
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Figure 2.13 1H and 19F NMR of the amide diastereoisomers of 148.
This protocol proved to be very straightforward and was general for all three of the
isomers. Thus the ortho-, meta-, and para- fluorophenyllactic acid stereoisomers were
prepared as single stereoisomers of each enantiomeric series, by converting the
corresponding rac-fluoroaryl acids into these amide diastereoisomers, followed by
chromatographic separation.
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Scheme 2.43 Resolution of rac-fluoroaryl acids by amide formation. Reagents and
conditions: (S)-phenylethylamine, HOBt, EDCI·HCl, CHCl3, DMF, rt, overnight, 84-
91%.
The absolute configuration of the amides was assigned by X-ray crystallographic
analysis. Re-crystallisation of all six enantio-enriched fluoroaryl amides from the
hexane/DCM system yielded two crystals which were suitable for X-ray structure
analysis. Separation of o-fluoroaryl amides (147) afforded a crystal of the higher
polarity diastereoisomer. This emerged with the (S,S)- absolute configuration. A
crystal of the lower polarity amide was obtained from p-fluoroaryl amides (149) and
this indicated an absolute configuration as (R,S)-149 after X-ray structure analysis.
Thus, it appeared that the (S,S)-fluoroaryl amide eluted first in these two cases using a
60%EtOAc/20%cyclohexane solvent system. The absolute stereochemistry of the
meta- fluoroarylamides was assumed relative to these two experimentally determined
cases.
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Figure 2.14 X-ray crystal structures of (S,S)-o-fluoroaryl amide (S,S-147) and
(R,S)-p-fluoroaryl amide (R,S-149) were used to confirm the absolute stereochemistry.
2.10.3.2.5 Hydrolysis of the enantio-enriched fluoroarylamides
In order to obtain the enantio-enriched fluoroaryl acids, amide hydrolysis conditions
were explored. Initially, m-fluoroarylamide (S,S-148) was heated under reflux with
2M H2SO4 for 24 hrs, but only starting material was recovered. Treatment with 2M
HCl under reflux for 20 h also gave only recovery of starting material. A basic
hydrolysis with 10% NaOH was also unsuccessful. Interestingly, a facile and mild
hydrolysis of amides has been reported117, 118 involving sodium peroxide (Na2O2).
This method efficiently converted both primary and secondary amides to their
corresponding acids along with small amounts of decarboxylated products. The
mechanism has been suggested as shown in Scheme 2.44. Therefore m-
fluoroarylamide (S,S-148) was treated with aq.solution of Na2O2 at 50 °C for 2 hrs.
Unfortunately, these conditions proved unsuccessful with only starting material
recovered.
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Scheme 2.44 Proposed mechanism for hydroperoxide mediated hydrolysis.117, 118
Failure to hydrolyse the amides under the above conditions forced a re-evaluation of
acidic hydrolysis. Fortunately, with 6M HCl and under refluxing condition for 24 hrs,
the hydrolysis of the m-fluoroarylamide (S,S-148) was achieved in high yield after
work-up. Purification of the product by re-crystallisation from EtOAc/hexane gave the
carboxylic acid as a white solid. All six of the fluoroaryl acid stereoisomers were
recovered by this method and in good yields (> 98%).
Scheme 2.45 Hydrolysis of enantio-enriched fluoroarylamides yielded enantio-
enriched fluoroaryl carboxylic acids in good yields (>98%).
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2.10.3.2.6 Determination of enantiomeric excess of the resolved
fluorophenyllactic acids (S-103k, 103l, 103m) and (R-103k, 103l,
103m)
It was important to determine the enantiomeric excess (ee) of the resolved
fluorophenyllactic acids, particularly due to the harsh hydrolysis conditions. Since, the
diastereoisomers of fluoroaryl amides exhibited distinguishable signals by 1H and 19F
NMR (Figure 2.13), the free fluoroaryl acids were subjected to enantiomeric assay by
re-forming the amides with (S)-phenylethylamine. Therefore, the crude reaction
products after recoupling the fluorophenyllactic acids with (S)-phenylethylamine were
subject to 1H or 19F NMR analysis. The %ee in each case was calculated from the
integration of signals from each diastereoisomer.
For instance, the enantio-enriched (R)-103l and (S)-103l isomers were independently
coupled with (S)-phenylethylamine (145) and the crude amides were directly
subjected to 1H NMR spectroscopy. The crude (S,S)-amide 148 showed a single
doublet for the methyl group at 1.36 ppm (J 6.92 Hz) and no apparent signal for the
other diastereomer appeared (Figure 2.15, A), indicating that the diastereoisomeric
purity of this amide was >95% de. Thus, the enantiomeric excess of the starting (S)-
m-fluorophenyllactic acid was at least >95%. The crude (R,S)-amide 148 product also
showed a doublet at 1.39 ppm (J 6.92 Hz) and the diastereoisomeric purity was also
calculated to be >95%ee (Figure 2.15, B). This procedure was re-evaluated by mixing
equal amounts of the crude (S,S)-amide 148 and crude (R,S)-amide 148. The resultant
1H NMR spectrum clearly showed two doublets for the methyl groups at 1.35 and
1.28 ppm (Figure 2.16). According to this protocol, the enantiomeric excesses for the
rest of the fluorophenyllactic acids was shown to be >95%ee.
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Figure 2.15 1H NMR of the crude coupled product of; A) (S,S)-m-fluoroarylamide
148 and B) (R,S)-m-fluoroarylamide 148.
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Figure 2.16 1H NMR obtained by mixing the crude (S,S)-148 and (R,S)-148.
2.10.3.2.7 Preparation of enantio-enriched fluorolittorines.
In a similar manner to that previously described for the preparation of rac-
fluorolittorines, the individual fluoroaryl acid diastereoisomer were coupled to tropine
as previously described in the preparation of rac-fluorolittorines. This gave
preparative samples of enantio-enriched (>95%ee) fluorolittorines in moderate yields
(32-51%) after chromatography.
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Scheme 2.46 The synthesis of enantio-enriched fluorolittorines.
2.10.3.3 Enzymatic resolution
During the resolutions described in the previous section, a lipase resolution strategy
was also expanded as a measure to resolve the fluorophenyllactic acids into their
individual enantiomers.
Lipases (triacylglycerol acylhydrolases EC 3.1.1.3) are probably the most frequently
used enzymes in the kinetic resolution of racemic alcohols and carboxylic acids. The
wide substrate range of lipases and the ability of such processes to be carried out in
organic solvents make lipases particularly attractive for the preparation of
enantiomerically pure substances. Either dry powder enzymes or enzymes in an
immobilized form have been widely employed. The kinetic resolution can be
successful if the two enantiomers react with the enzyme at substantially different
rates. The theoretical yield of such a kinetic resolution is 50% and high optical purity
of organic substances can be achieved if conditions and enzymes are optimised.119
Three commercially available lipase enzymes were explored in this study. These were
the porcine pancreatic lipase (PPL), the Candida rugosa lipase, and the Candida
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antarctica lipase. Initially the transesterification of rac-fluorophenyllactic acid was
performed. Vinyl acetate (153) has been used as acyl donor in such reactions and
methy t-butyl ether (MTBE) is a solvent of choice. This system has an advantage
since the vinyl alcohol formed as a by-product is then tautomerised to acetaldehyde,
making the reaction irreversible. Following a previously described protocol,120 rac-m-
fluorophenyllactic acid (103l) was treated separately with PPL, Candida antarctic
(fraction-B, CAL-B), and Candida rugosa using MTBE as the solvent. The reactions
were stirred at ambient temperature for 4 days. Following the reactions by TLC or 1H
NMR spectroscopy did not indicate any conversion after 4 days, so the reaction was
stopped and the starting material was recovered.
Scheme 2.47 Attempted kinetic resolution by lipase enzymes.
Alternatively, lipases are regularly used to perform kinetic resolutions of racemates by
ester hydrolysis.121 Accordingly the rac-m-fluorophenyllactic acids were treated with
acetic anhydride to obtain the 2-acetyl ester derivatives and then these were used as
resolution substrates. The racemate acetates were dissolved in acetone and each was
treated separately with PPL, CAL-B, or Candida rugosa in a phosphate buffer (pH 7)
with shaking at 30 °C. The progress of the reactions was monitored by TLC and 1H
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NMR spectrum (Figure 2.17). This showed that hydrolysis occurred only with the
PPL.
Figure 2.17 The 1H NMR of the kinetic resolution of acetyl m-fluorophenyllactic
acid recorded at; A) 6h, B) 12h and C) 20 h.
After 20 hrs, the reaction was quenched by centrifugation of the enzyme. Careful
chromatography (×3) gave the resultant carboxylic acid but with a low recovery.
Crystallization of the resultant stereoisomer from EtOAc/hexane gave colourless
needles and the X-ray crystal structure is shown in Figure 2.18. However the absolute
configuration could not be assigned. Instead, the unreacted enantiomer was coupled
with (S)-phenylethylamine to give another suitable crystal for structure analysis after
re-crystallisation from DCM/hexane. The resultant X-ray structure is shown in Figure
2.18 which revealed the absolute configuration of the amide as (R,S)-148a. Therefore,
the PPL hydrolyses the (S)-enantiomer in preference to the (R)-enantiomer. This result
is consistent with the previously demonstrated kinetic resolution of rac-
phenyllactic.121 Due to the difficulty encountered in the purification process, the
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resolution of the hydroxy acids was achieved by the chemical resolution method as
described in the previous section 2.10.3.2.4.
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F
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OH
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+
acetone,
phophate buffer pH 7, 30 C
103o
(S)-103l
(R)-103o
Scheme 2.48 Kinetic resolution of (RS)-α-acetyl-m-fluorophenyllactic (103o) acid
by porcine pancreatic lipase.
Figure 2.18 X-ray crystal structure of (S)-m-fluorophenyllaic acid and an amide
derivative of (R)-α-acetyl-m-fluorophenyllactic acid (103o).
2.10.3.4 The preparation of enantio-enriched (S)-[3,3-2H2]-littorine
(S-45h) and (R)-[3,3-2H2]-littorine (R-45h)
rac-[3,3-2H2]-Phenyllactic acid had previously been prepared by N. C. J. E.Chesters
in the research group in 1995.122 In order to prepare an enantio-enriched [3,3-2H2]-
phenyllactic acid, that method was employed again. According to the literature, the
commercially available phenylpyruvate (104) was dissolved in D2O and the pH
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adjusted to 11. The reaction was kept stirring at ambient temperature. The progress of
the deuterium exchange was monitored by 1H NMR. The benzylic hydrogen
completely disappeared indicating an efficient exchange process. The reaction
mixture was then neutralised by careful addition of D2SO4. The resultant
phenylpyruvic acid was treated directly with NaBH4 to afford the rac-[3,3-2H2]-
phenyllactic acid. Subsequently rac-[3,3-2H2]-phenyllactic acid was treated with (S)-
phenylethylamine to afford (R,S)- and (S,S)-amides (12-14% in three steps) such that
the individual diastereoisomers could be separated. Hydrolysis (6 M HCl) then gave
the desired enantio-enriched (S)- and (R)- [3,3-2H2]-phenyllactic acids ((S)-103i and
(R)-103i, 95 and 96%). Again the enantiomeric purity of the acids was assayed in the
same manner as that for the preparation of the enantio-enriched fluoraryl acids. The
diastereoisomeric purity was again found to be >95%. Finally, the free acids were
coupled with tropine to yield (S)-[3,3-2H2]-littorine and (R)-[3,3-2H2]-littorine (40
and 41%).
Scheme 2.49 Preparation of enantio-enriched (S)- and (R)-[3',3'-2H2]-littorine (S-
45h, R-45h) from phenylpyruvic acid (104). Reagents and conditions: i) D2O, K2CO3;
ii) NaBH4; iii) (S)-phenylethylamine, HOBt, EDCI, DMF, rt, 16h, 11.5% over 3 steps.
iv) 6 M HCl, 100 ˚C, 24 h, 95%, > 95%ee; v) tropine, dry HCl(g), 130 ˚C, 4 h, 40-41%.  
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2.10.4 Bioassay results
The bioassays were carried out by Dr. Darwin W. Reed in the laboratory of Dr.
Patrick Covello at the Plant Biotechnology Institute, 110 Gymnasium Place,
Saskatoon, SK, Canada, S7N OW9.
2.10.4.1 Kinetic isotope effect study
The enantio-enriched (S)-[3,3-2H2] and (R)-[3,3-2H2]-littorines were assayed in
incubations with CYP80F1 and the kinetic isotope effects on the hydroxylation and
the rearrangement processes were evaluated by direct competitive and indirect
comparative methods. The hydroxylation of (S)-[3,3-2H2]-littorine (S-45h) showed a
similar primary KIE when measured by the different methods (2.55 and 2.86, Scheme
2.51 and Table 2.3). The KIE for the (R)-[3,3-2H2]-littorine (R-45h) from the direct
competitive experiments could not be measured due to the enolisation of hyoscyamine
aldehyde. For the rearrangement, the non-competitive experiments showed a KIE of
3.81, a value which agrees, within experimental error, with the hydroxylation results.
The primary KIE's from these experiments confirm that the removal of the 3'-pro-R
hydrogen is the rate limiting step for both rearrangement of (R)-littorine to
hyoscyamine aldehyde and hydroxylation of the unnatural (S)-substrate at the 3'-
position.
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Scheme 2.50 The hydroxylation reaction of (S)-[3,3-2H2]-littorine (R-45h) and
rearrangement reaction of (R)-[3,3-2H2]-littorine (R-45h) mediated by the CYP80F1.
Assay
CYP80F1
Substrate
littorine
Reaction KIE
Non-competitive (S)-[3, 3-2H2]-45h 3'-hydroxylation 2.86 (0.23)
(R)- [3, 3-2H2]-45h hydroxylation/
Rearrangement
3.81 (1.1)
Competitive (S)-[3, 3-2H2]-45h 3'-hydroxylation 2.55 (0.14)
Table 2.3 KIE data for CYP80F1 incubations of (S)-[3,3-2H2] and (R)-[3,3-
2H2]-littorine. Means and standard deviations (in parentheses) are indicated for five
(non-competitive) and nine (competitive) replicates. (D. W. Reed and P. Covello;
Plant Biotechnology Institute, 110 Gymnasium Place, Saskatoon, SK, Canada, S7N
OW9)
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2.10.4.2 The enzyme assays of rac-2', 3' and 4'-fluorolittorines (45e, 45f,
45g) with CYP80F1.
The rac-fluorolittorines (45e, 45f, 45g) were incubated independently with CYP80F1
expressed in yeast microsomes. The natural substrate (R)-littorine was mostly
converted to hyoscyamine aldehyde as expected and its fluorinated analogues also
underwent rearrangement to the corresponding fluorohyoscyamine aldehydes (Figure
2.19). The fluorine substituents at the ortho, meta- and para- position did not have a
significant effect on the production. All three isomers were almost equally rearranged
to fluorohyoscyamine aldehyde. However their efficiencies were approximately half
that of the non-fluorinated (natural) substrates.
Hyoscyamine aldehyde from 50 mg littorine
0
0.2
0.4
0.6
0.8
1
1.2
(S)-littorine (R)-Littorine o-F-littorine m-F-littorine p-F-littorine
mg
/a
ss
ay
hyoscyamine aldehyde
hyoscyamine aldehyde minor
isomer
Figure 2.19 The incubation of rac-fluorolittorines with CYP80F1.
Interestingly, for the unnatural substrates, (S)-littorine was hydroxylated at the C3'
position to release hydroxylittorine in the CYP80F1 assay as shown in Figure 2.20.
The rac-fluorinated analogues produced the corresponding fluorinated 3'-
hydroxylittorines. Clearly, the fluorine substituents appear to exert a clear effect on
the efficiency of fluoro 3'-hydroxylittorine production. The meta- fluorine strongly
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suppressed the hydroxylation reaction whereas the ortho- and para- fluorines showed
a much higher efficiency. Nearly three times the level of fluorohydroxylittorine
production was observed. As shown in the theory calculation (Table 2.1), the ability
of ortho-/para- fluorine to stabilise benzylic intermediates, suggests a carbocation
type mechanism operating in the hydroxylation reaction.
hydroxylittorine from 50 ug littorine
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Figure 2.20 The incubation of rac-fluorolittorines with CYP80F1.
Clearly, the unnatural substrate, (S)-littorine is hydroxylated by CYP80F1 to give 3'-
hydroxylittorine. The (R)-enantiomer rearranges to hyoscyamine aldehyde as
summarized in Scheme 2.51.
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Scheme 2.51 The products obtained from the feeding of (R)-littorine and (S)-littorine
(45) to CYP80F1.
2.10.4.3 Assay on enantio-enriched (R)-fluorolittorines (R-45e, 45f, 453g)
Incubation of (R)-littorine and its arylfluorinated analogues with CYP80F1 revealed
that not only the expected aldehydes (113a-c) were formed but also that
hydroxylittorines (R,S-113b-d) were detected. With the natural substrate (Figure
2.21), hyoscyamine was predominantly formed along with only a trace of the 3'-
hydroxylittorine as a minor product. For the ortho/para-(R)-fluorolittorines, however
almost equal amounts of fluorohydroxylittorines and fluorohyoscyamine aldehydes
were generated, indicating a significant competition between the hydroxylation and
the rearrangement processes promoted by fluorine. On the other hand the meta-
fluorine strongly suppressed the hydroxylation process and rearrangement to
fluorohyoscyamine aldehyde was the primary process. This tendency to hydroxylation
reflects the ability of the ortho/para fluorine substituents to stabilise a fluorobenzylic
cation. For the rearrangement process, the meta- fluorine suppressed hydroxylation
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relative to the rearrangement. This outcome is consistent with hydroxylation by a
carbocation process, but rearrangement via a benzylic radical intermediate.
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Figure 2.21 Production profiles after incubation of (R)-fluorolittorines with
CYP80F1 expressed in yeast microsomes.
Scheme 2.52 The products from the bioassay suggest that hydroxylation occurs via a
carbocation whereas rearrangement occurs via a benzylic radical.
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2.10.4.4 Assays on the enantio-enriched (S)-fluorolittorines (S-45e, 45f,
45g)
Incubation of the unnatural (S)-littorines isomers and its arylfluorinated analogues
with CYP80F1 showed similar productivity profiles to that of the rac-fluorolittorines
(Figure 2.22). The (S)-littorine was predominantly hydroxylated to (2'S,3'S)-
hydroxylittorine (2'S,3'S-110). The other diastereoisomer (2'S,3'R)-hydroxylittorine
(2'S, 3'R-110) was only a minor product. Interestingly a trace of hyoscyamine
aldehyde was also detected. For the (S)- fluorolittorine substrates, the fluorine
substituents clearly exert a significant influence on the product profile. The
ortho/para-fluorine promoted the hydroxylation reaction whereas the meta-fluorine
suppressed hydroxylation. In particular, the para-fluorine was the most efficient
substrate for hydroxylation and was surprisingly even better than the non-fluorinated
substrate. Clearly, hydroxylation efficiency reflects the stability trend of the
fluorobenzyl carbocations as indicated by the theory calculations (Table 2.1).
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Figure 2.22 Production profiles from the incubation of (S)-fluorolittorines
CYP80F1 suggest the hydroxylation of (S)-fluorolittorines occurs via a carbocation.
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2.11 Discussion
In order to explore the mechanism of the rearrangement of littorine to hyoscyamine
rac- and enantio-enriched fluorolittorines were prepared and incubated with the
CYP80F1 enzyme expressed in yeast microsomes. The unnatural (S)-littorine and its
fluorinated analogues were hydroxylated by the CYP80F1 to give the corresponding
3'-hydroxylittorines (2'S, 3'R-110b-d). The fluorohydroxylittorine product profiles are
clearly influenced by the nature of the fluorine substituent. The para-fluorine is the
best substrate followed by the ortho-substate, whereas the meta-substrate had the
lowest efficiency. This convincingly indicates the involvement of a benzylic
carbocation mechanism operating during the 3'-hydroxylation reaction.
Incubations of the (R)-enantiomers (natural series) with CYP80F1 revealed competing
hydroxylation and rearrangement reactions. The hydroxylation reaction is strongly
suppressed by the meta- fluorine substituent and significantly promoted in the
ortho/para isomers, also suggesting a carbocation process operating. On the other
hand, the product profile for the competing rearrangement reaction suggests a radical
stability trend, i.e. meta- is the most efficient relative to the ortho/para-substrates.
Conventional wisdom suggests that cytochrome P450 enzymes hydroxylate via a
radical process, however the present experiments point to a cationic hydroxylation
pathway. The observation that the para- and ortho- fluorine substituents promote 3'-
hydroxylation relative to the meta-, is consistent with the involvement of a benzylic
carbocation.
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It has been suggested that P450 enzymes utilise multiple oxidants during mono-
oxygenation reactions. The two-state reactivity hypothesis96 proposes Cpd I as an
oxidant which equilibrates between high and low spin states. Also there are
suggestions from Newcomb that Cpd I may act as the primary oxidant and that the
iron hydroperoxy intermediate Cpd 0 is a secondary oxidant.95, 96 The insertion of a
hydroxonium species into the C-H bond by Cpd 0 would fit our experimental
observations for hydroxylation. The cationic character developing during the reaction
course would be stabilised by the ortho/para- fluorine substituents, hence the high
production of ortho/para- fluorohydroxylittorines.
On the other hand, Cpd I mediates mono-oxygenation by inserting oxygen into the
C-H bond by the abstraction of hydrogen generating a radical intermediate. The
radical is then quenched by the well known “oxygen rebound” process. This
circumstance would fit our experimental outcome for the rearrangement process.
Homolytic abstraction of the 3'-pro-R hydrogen would generate a benzylic radical.
The stability would not differ much between the ortho-, meta-, and para- fluoro
substituents. The fact that Cpd I can be generated from Cpd 0, suggests the possibility
that these two reactive species may be partitioned as shown in Scheme 2.53. For
hydroxylation (pathway A) Cpd 0 inserts +OH into 3' pro-R-hydrogen to generate 3'-
fluorohydroxylittorine. The competitive rearrangement reaction (pathway B) is
promoted by the Cpd I where the 3' pro-R-hydrogen is removed, generating a radical
intermediate, which then rearranges and is quenched by an oxygen rebound process.
Following collapsing of the resultant hydrate this gives fluorohyoscyamine aldehyde.
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Scheme 2.53 Working hypothesis for partitioning between Cpd 0/Cpd I for reaction
on fluorolittorine stereoisomers.
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2.12 Conclusion
(rac)-Fluorolittorine isomers and enantio-enriched fluorolittorine isomers were
prepared as a tool to explore the mechanism of the rearrangement of littorine to
hyoscyamine by the P450 CYP80F1 enzyme. Incubations of (rac)-fluorolittorines
isomers with CYP80F1 enzyme indicated that the (S)-enantiomer is hydroxylted to
give 3'-hydroxylittorine whereas the (R)-enantiomer rearranges to hyoscyamine.
Incubation of enantio-enriched (R)- and (S)- fluorolittorines isomers suggest that the
hydroxylation reaction to 3'-hydroxylittorine occurs via a carbocation intermediate
whereas the rearrangement to hyoscyamine is a radical process.
Incubations with enantio-enriched (S)-[3,3-2H2]-littorine and (R)-[3,3-2H2]-littorine
with CYP80F1 showed a primary KIE. This also suggests the abstraction of the C3'
benzylic hydrogen of littorine as the rate determining step.
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Synthesis of ribose phosphonates
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3.1 Introduction
Streptomyces cattleya is one of only two bacteria which have been identified that are
capable of elaborating organofluorine metabolites.1 This soil bacterium is known to
produce the β-lactam antibiotic, thienamycin.2 Remarkably, S. cattleya also produces
fluoroacetate (155) and an antibiotic 4-fluorothreonine (156) when a fluoride ion is
available.3 Fluoroacetate is a well known mammalian toxin. Presumably, these two
fluorinated compounds are produced as defence substances. Uncovering the
fluorometabolic pathway to these metabolites attracted much intention over the last 15
years and the details have largely been elucidated. Most of the enzymes are now
known and recently, the whole biotransformation was demonstrated by reconstitution
in vitro in St Andrews.4
Figure 3.1 Fluoroacetate (155) and 4-fluorothreonine (156) are secondary
metabolites produced by S. cattleya.
3.2 The biosynthesis of fluoroacetate (155) and 4-fluorothreonine
(156) in S. cattleya
An overview of the biosynthetic pathway is summarised in Scheme 3.1. The first
committed step in the biosynthesis of fluoroacetate (155) and 4-fluorothreonine (156)
involves the conversion of SAM 109 to 5'-FDA 157. The reaction is mediated by a 5'-
fluoro-5'-deoxyadenosine synthase (5'-FDA synthase, EC 2.5.1.63), an enzyme which
has been informally named the “fluorinase”.5, 6 In the event, inorganic fluoride ion
Chapter 3
108
attacks the C5' carbon of SAM (109) to form a C-F bond in an SN2 type reaction,
releasing L-methionine (158). Studies have shown that the fluorinase can also utilise a
chloride ion to produce a 5'-ClDA, however, bromide and iodide ion do not appear to
be substrates.7 In the next enzymatic step, the adenosine moiety of 5'-FDA (157) is
replaced by a phosphate group to generate 5-fluoro-5-deoxyribose-1-phosphate (5-
FDRP, 47). This phosphorolysis reaction is catalysed by a purine nucleotide
phosphorylase (PNP) and is a reversible process.8 This type of enzyme is found quite
widely in nucleotide metabolism. An isomerase then mediates a ring opening
isomerisation reaction of 47 to generate 5-fluoro-5-deoxyribulose-1-phosphate (48).9
This ribulose-phosphate is then acted upon by an aldolase, which catalyses the
cleavage of 48 in a retro-aldol reaction to give fluoroacetaldehyde (159),10 a precursor
to both 155 and 156. Fluoroacetaldehyde (159) is oxidised by a NAD+ dependent
fluoroacetaldehyde dehydrogenase to generate fluoroacetate (156).11 Separately, a
pyridoxal phosphate (PLP) dependent enzyme (4-FTase) mediates a trans-aldol
addition reaction of fluoroacetaldehyde with L-threonine to form the antibiotic, 4-
fluorothreonine (156) and acetaldehyde.12
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3.3 The isomerisation of 5-fluoro-5-deoxyribose-1-phosphate (5-
FDRP, 47) to 5-fluoro-5-deoxyribulose-1-phosphate (5-
FDRulP, 48)
3.3.1 The aldo-keto, MTR-1-P isomerase
There is an isomerase enzyme involved in fluorometabolite biosynthesis that has
similarity to an enzyme on the L-methionine salvage pathway. The L-methionine
salvage pathway is essential for bacteria, yeast, plants, and animals. These organisms
utilise this pathway to regulate L-methionine levels. This essential amino acid is
involved in many cellular functions, including methylation of DNA and rRNA, and
the biosynthesis of L-cysteine. Studies13 in Bacillus subtilis have established details of
the complete pathway which is summarised in Scheme 3.2.
Scheme 3.2 L-Methionine salvage pathway in B. subtilis.13
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5-Deoxy-5-methylthioribulose 1-phosphate isomerase (MTR-1-P isomerase) is a key
enzyme of the methionine salvage pathway. This aldose-ketose isomerase mediates
the interconversion of MTRP-1-P (161) to MTRul-1-P (162). The isomerisation of
161 to 162 in B. subtilis is analogous to the isomerisation from 47 to 48 in the
fluorometabolite pathway of S. cattleya. The only variation is that the -SMe group is
replaced by a fluorine atom.
3.3.2 Crystal structure of 5-deoxy-5-methylthio-α-D-ribose-1-phosphate
isomerase from Bacilus subtilis.
Several 5-deoxy-5-methylthio-α-D-ribose-1-phosphate isomerase (MTR-1-P
isomerase) enzymes have been structurally characterised from bacteria14 and yeast.15
Recently, the MTR-1-P isomerase from B. subtilis has been isolated16 and was co-
crystallised with the ring open product, 5-MTRul-1-P (Figure 3.2).17 The active site of
this enzyme can be divided into three regions; that involving hydrogen bonding with
the phosphate group, that which forms a hydrogen bond to backbone oxygens or
hydrogens of the ribulose, and that involving hydrophobic interactions with the
thiomethyl group. The putative catalytic residues that are involved in the
isomerisation of MTR-1-P to MTRul-1-P are thought to be the highly conserved
amino acids Asp240 and Cys160. During the catalysis, Asp240 appears to play a role
as a proton donor/acceptor, whilst Cys160 may be present in a deprotonated form at
the optimal pH (8.1) of MTRPI. Thus, Cys160 may stabilise a transient positive
charge developing at C1 (Scheme 3.6).
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Figure 3.2 Active site residues and product, bound to MTR-1-P isomerase from
B.subtilis (distances are given in Å).17
3.3.3 5-FDRulP is an intermediate in the fluorometabolite biosynthesis in S.
cattleya
It has been established that 5-FDRP (47) is the second formed intermediate on the
fluorometabolite pathway in S. cattleya and that it undergoes isomerisation to 5-
FDRulP (48) in a similar manner to the MTR-1-P isomerase.18, 19
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Scheme 3.3 Conversion of 5-fluoro-5-deoxyribose-1-phosphate (47) to generate
5-fluoro-5-deoxyribulose-1-phosphate (48) in S. cattleya (Pathway A) and conversion
of 5'-methioadenosine to ribose phosphate and ribulose in mammals (Pathway B).18, 19
When 5-FDRP (47) was incubated with cell-free extracts of S. cattleya then 5-
FDRulP (48) was obtained,9 clearly by the action of a related isomerase (5-FDRPi).
The stereochemistry of 5-FDRulP was confirmed by comparative structural studies
(Scheme 3.4). Firstly, the produced 5-FDRulP (48) was incubated with a commercial
phosphatase to obtain the free 5-FDRul (164) sugar. This was apparent by a shift of
the 19F NMR signal from -231.3 ppm to -231.2 ppm (164) which indicated that the
phosphate moiety had cleaved. Separately, 5-FDR (163) was incubated with glucose
isomerase in a reaction known to mediate an isomerisation to ribulose. These
experiments gave identical diastereoisomers as determined by 19F NMR. Moreover, as
a control, 5-FDX (165) was treated in a similar manner with glucose isomerase and
this resulted in a different 19F NMR signal (-228.5 ppm) which belongs to
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diastereoisomer 166. Therefore, the stereochemistry and intermediacy of 5-FDRP (47)
and 5-FDRulP (48) in fluorometabolite biosynthesis in S. cattleya was secured.9 The
mechanism of the isomerisation is intriguing, and several possibilities emerge which
will be discussed in due course in Section 3.4. The actual mechanism remains to be
elucidated.
Scheme 3.4 The absolute stereochemistry of 48 was deduced by comparative
structural studies. 9
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3.4 Identification of the putative isomerase gene in S. cattleya4
A homology search of the MTRPI gene of B. subtilis with the full genome sequences
of S. coelicolor and S. avermitilis revealed two genes which had a 35% amino acid
identity. These were the SCO3014 (S. coelicolor) and SAV6658 (S. avermitilis)
genes. Initially, these two genes had been annotated as eukaryotic translation
initiation factors 2B (elF2B), however they are now correctly assigned as isomerases.
The over-expression of the SCO3014 gene product in E. coli led to the isolation of the
protein. This enzyme clearly exhibited the ability to catalyse the isomerisation of 5-
FDRP (47) to 5-FDRulP (48). These findings have led to the design of a primer that is
now much more homologous to S. cattleya, and the identification of the putative
MTR-Sc. This enzyme was over-expressed and the purified protein has 1161 base
pairs and a 75% amino acid identity to the isomerase from S. coelicolor. As expected,
this protein showed the ability to catalyse the conversion of 47 into 48 and thus the
activity was identified now in S. cattleya. The abilities of these isomerases indicated
that the original ‘translation initiation factors’ designations had been misassigned.
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3.5 Putative mechanisms for the isomerisation of 5-FDRP (47) to 5-
FDRulP (48)
Three mechanisms for the isomerisation of 5-MTRP to 5-MTRulP have been
proposed. These involve enediol, hydride shift, and phosphate migration processes.
These are discussed below.
3.5.1 The cis-enediol and hydride shift mechanisms
Cis-enediol and hydride shift mechanisms have been proposed for the interconversion
of aldose and ketose sugars mediated by the aldose-ketose isomerase enzymes. These
mechanisms are shown in Scheme 3.5.
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Scheme 3.5 Proposed mechanisms for aldose (A) and ketose (B) isomerisations.
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MTRPI is also a aldo-keto isomerase enzyme, however its substrate bears a phosphate
group at C1 whereas the other aldose-ketose isomerase enzymes utilise a free
anomeric hydroxyl group. The proposed cis-enediol and the hydride shift mechanism
are shown in Scheme 3.6. A cis-enediol proton transfer requires to be triggered by
deprotonation of the C2 hydroxyl. Cys160 is a candidate base for this deprotonation
and would generate a cis-enediol (phosphoenolate). Asp240 would then mediate a
simultaneous transfer of a proton between O2 and O4. The catalytic cycle would
complete by redonation of the abstracted proton from Cys160 to generate MTRu-1-P.
The hydride transfer mechanism (Lower side, Scheme 3.6) would require a
nucleophilic attack at C2 of the substrate. A candidate for this nucleophile is Asp240,
triggering ring opening of the substrate. The transient positive charge which would
develop on C1 would be stabilised by Cys160, now as a thiolate. The hydride on C2
would then migrate to C1, generating the product with release of 5-MTRul-1-P.
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Scheme 3.6 Putative mechanism for the isomerisation of 5-MTR-1-P (161) to
5-MTRul-1-P (168) via the cis-enediol (upper side) and the hydride shift (lower side).
A study on the mechanism of D-xylose isomerase (XI) from Steptomyces
olivochromogenes has revealed that the ketose-aldolase mediated isomerisation of D-
xylose to D-xylulose operates via a hydride shift mechanism.20 The D-xylose
isomerase is a metalloenzyme requiring a divalent cation to assist hydride transfer. It
has however been established that the MTR-1-P isomerase from B. subtilis does not
require divalent ions such as Zn2+ or Mg2+. Such divalent cations are required for
keto-aldolases and in those cases the isomerisation proceeds via a cis-enediol
mechanism.16 In this case, incubations in D2O did not support the cis-endiol
mechanism, since there was no apparent incorporation of deuterium from the medium
into the products. Although, a negative result, this does suggest that the isomerisation
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reaction of B. subtilis may adopt a hydride transfer process. It is noteworthy that the
isomerase does not require divalent cations.
3.5.2 The phosphate migration mechanism.
A third mechanistic hypothesis for the isomerisation envisages an intramolecular
phosphate migration. This mechanism would be triggered by the migration of the
phosphate group from C1 to C2 in 47 to generate 170. Epimerisation of 170 would
then result in an equilibrium between 170 and 171, followed by a back migration of
the phosphate group from C2 to C1 to generate 172. The keto-enol tautomerisation of
172 would then deliver 5-FDRulP (48).
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Scheme 3.7 Putative phosphate group migration during the isomerisation of
5-FDRP (47) to 5-FDRulP (48).
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3.6 Aims of the project
This aspect of the research is focused on the synthesis of an isosteric analogue of 47
by the preparation of D-ribose-1-phosphonates 173a-b and 174a-b where the linking
phosphate oxygen has been replaced by a methylene group. These phosphonates are
envisaged to be potential inhibitors for either the PNP or the isomerase enzymes
involved in fluorometabolite biosynthesis (Scheme 3.1). They have potential utility as
tools to explore these enzyme mechanisms by inhibition studies and as candidate inert
substrate analogues for enzyme co-crystallisation studies.
The cyclic phostones 175a-b were also targeted. These phostones were viewed as
potential reaction intermediate analogues for co-crystallisation studies, and
particularly to explore the phosphate migration mechanism of the isomerase enzyme.
Figure 3.3 Target phosphonate analogues of D-ribose-1-phosphate 173a-b and
174a-b and the cyclic phostones 175a-b.
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3.7 Results and discussion
3.7.1 Synthesis
3.7.1.1 Synthetic plans
The target phosphonates 173a-b and 174a-b were prepared by routes A and B as
shown in Scheme 3.8. The synthetic routes start either from D-ribonic--lactone 176
or D-ribose 177. For each route the key synthetic step involves installation of the
methylenephosphonate moiety on a 2,3-isopropylidene ribofuranoside via a
Wadsworth-Emmons reaction. The 5-OH can be replaced by fluorine, prior (route A)
or after (route B) installation of the diethyl methylenephosphonate ester moiety.
Deprotections of 178a-b, 182a-b and 183a-b would then yield the free phosphonic
acids. The phosphonic acids are anticipated to be highly hygroscopic and therefore
they will be treated with cyclohexylamine to afford the target compounds 173a-b and
174a-b as non-hygroscopic salts.
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Scheme 3.8 Synthetic routes for the preparation of phosphonates 173a-b and
174a-b. Route A starts with D-ribonic lactone and route B starts with D-ribose.
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3.7.2 Preparation of phosphonate 173a-b and 174a-b
At first glance, route A appears to offer the shorter synthetic route, since the
involvement of a protection/deprotection step of the 5-hydroxyl group is not required.
Accordingly, route A was explored at the outset.
3.7.2.1 The D-ribonic--lactone route-Route A.
The synthetic route (Route A Scheme 3.9) started with the protection of D-ribonic--
lactone 176 as its acetonide to generate 2,3-isopropylidene 184.21 Fluorination of the
free 5-hydroxyl group of 184 was accomplished directly with Deoxo-fluor™ to afford
5-deoxy-5-fluoro-2,3-isopropylidene-D-ribonic--lactone (185) in good yield.
Subsequent reduction of lactone 185 with NaBH4 resulted in the generation of
(2S,3R,4S)-5-fluoro-2,3-(O-isopropylidenedioxy)-pentan-1,4-diol (186). Diol 186 has
previously been synthesised,22 however this route appears to offer a more efficient
preparation. Reduction of 185 with limiting NaBH4 (0.5 eq.) was found to be
incomplete with only about 60% of the lactone 185 converted to the desired product,
along with the diol 186, in a ratio of 1:5 as determined by 19F NMR (Figure 3.4).
Reduction of 185 with DIBAL-H at -78 ˚C and at -40 ˚C failed to give the desired 
product,23 and only starting material were recovered in each case. However at the
elevated temperature (40 ˚C), DIBAL-H24 smoothly reduced the lactone 185 to 5-
fluoro-ribofuranoside 177, in good yield.
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Scheme 3.9 Synthetic route A. Reagent and conditions: i) Acetone, cH2SO4 (cat.),
6h, 86%; ii) Deoxo-fluor™, DCM, 40˚C, 30 min, 84%; iii) NaBH4, ethanol, 0˚C, 2 h, 
65%; iv) DIBAL-H, toluene, 40˚C, 64%; v) CH2[P(O)(OMe)2]2, DCM, 50%
aq.NaOH, 60%.
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Figure 3.4 19F NMR of the product obtained when lactone 185 was treated with
NaBH4 (0.5 eq.) at 40 °C.
The next step involved a Wadsworth-Emmons reaction of 177 with tetramethyl
methylenediphosphonate (187) in DCM/50% aq.NaOH .25 This gave a clean reaction
to yield the 5-fluoro-phosphonate 178 which had an : ratio of 4:1 as determined by
19F and 31P NMR (Figure 3.5). The reaction is believed to generate an intermediate
olefin 188, which subsequently undergoes a Michael-type addition to give the cyclic
methylenephosphonates 178a-b (Scheme 3.10). Unfortunately, the diastereoisomers
were inseparable by conventional chromatography.
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Scheme 3.10 Formation of an anomeric mixture of phosphonates 178a and 178b via
a Wadsworth-Emmons reaction.
Figure 3.5 A) 19F and B) 31P NMR of the phosphonate 178 showing the α:β ratio 
as 4.1.
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3.7.2.2 The D-ribose route – Route B
Due to the inability to separate α-178 from β-178, Route B (Scheme 3.11) was
explored as an alternative. Following the previously described protocol by Meyer
et.al,25 the free hydroxyl group at C5 of 2,3-isopropylidine-D-ribose (189) was now
protected as a trityl group after treating 189 with trityl chloride and DMAP. This gave
180 with an epimer ratio (:) of 1:2.5 as determined by 1H NMR spectroscopy. In a
similar manner to Route A, the dimethyl methylenephosphonate ester moiety was
installed by a Wadsworth-Emmons protocol to obtain 5-O-trityl-phosphonates 181a
and 181b as individual epimers, after chromatographic separation of the initial
product mixture (: of 4:1, Figure 3.6). Apparently, the bulky 5-OTr group
influences the anomeric ratio of 181 favouring the α-epimer over the β-epimer, as 
previously shown by Ohrui et al.26
Scheme 3.11 Preparation of phosphonates 181a-b via a Wadsworth-Emmons
reaction. Reagents and conditions: i) Acetone, cH2SO4 (cat.), 4 h, 90%; ii) TrCl,
pyridine, DMAP, rt, 16h, 94%; iii) CH2[P(O)(OMe)2]2, 50% aq.NaOH; DCM, 64%;
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Figure 3.6 31P NMR of 181a/181b product mixture indication an : ratio of 4:1.
The 1H NMR of the α-181 and β-181 epimers was assigned based on a NOSEY
experiment (Figure 3.7 and 3.8). Selective irradiation of H-3 of 181a resulted in an
enhancement of the H-2 signals (Figure 3.7), corresponding to the α-epimer whereas 
irradiation of the H-3 proton of 181b resulted in an enhancement of the H-1 signals
(Figure 3.8). These results are consistent with literature.25
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Figure 3.7 1H NMR NOE experiment showing the correlation between H-2 and
H-3 in 181a.
Figure 3.8 1H NMR NOE experiment showing the correlation between H-1 and
H-3 in 181b.
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For the next step, selective deprotection of the 5-OTr was explored (Schemes 3.12
and 3.13). Detritylation of 181a-b with formic acid is reported to efficiently remove
the trityl group from C5 of some similarly protected carbohydrates and nucleic
acids.27 However, this proved to be ineffective in this case. However, deprotection
was achieved by treatment of 181 with ZnCl228 to generate the 5-hydroxy
phosphonates 182a and 182b in a good yield. The free alcohol of both epimers was
then directly fluorinated by using tosylfluoride and TBAF under refluxing THF.29, 30
Finally phosphonate esters, 182a-b, and the 5-deoxy-5-fluoro 183a-b were
sequentially deprotected with TMSBr and then TFA/H2O to yield the free phosphonic
acids. These phosphonic acids were dissolved in water and the pH of the solution was
adjusted to ~11 with cyclohexylamine.31 After removal of water, the non-hygroscopic
salts 173a-b and 174a-b were obtained by precipitation from MeOH/acetone.
Recrystallisation of the amine salts 173a-b and 174a-b from MeOH/acetone was
explored. Fortunately, a sample of colourless needles was obtained for phosphonate
174a. This allowed X-Ray structure analysis to be carried out (Figure 3.9). The
resultant crystal structure of 174a confirmed its structure and its stereochemical
relationship to the intermediate ribose-1-phosphate metabolite 47. Phosphonate 174a
formed a 1:1 salt with the amine in the crystal structure.
Figure 3.9 X-ray Crystal structure of cyclohexylammonium salt of phosphonate
174a.
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Scheme 3.12 Preparation of 173a and 174a; Reagents and conditions: i) ZnCl2,
DCM, rt, 2h, 78-81%; ii) TsF, TBAF, THF, reflux, 16h, 83-92%; iii) a) TMSBr,
DCM, rt; b) TFA:H2O (1:1), c) cyclohexylamine, pH~11, 84-87%;
Scheme 3.13 Preparation of 173b and 174b; Reagents and conditions: i) ZnCl2,
DCM, rt, 2h, 78-81%; ii) TsF, TBAF, THF, reflux, 16h, 83-92%; iii) a) TMSBr,
DCM, rt; b) TFA:H2O (1:1), c) cyclohexylamine, pH~11, 84-87%;
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Figure 3.10 1H NMR of the amine salt 174a.
Figure 3.11 A) 19F NMR and B) 31P NMR of the amine salt 174a.
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3.7.2.3 Preparation of phostones 175a and 175b
In order to prepare the phostonic acids 175a, phosphonate 182a was treated with
TMSBr, followed by TFA:H2O to give the phosphonic acid 190a (Scheme 3.14). The
phosphonic acid was then treated with acetic anhydride in dry pyridine to afford the
cyclic phostone 175a.32 The conversion from phosphonic acid to a 5-membered ring
phostonic acid could be conveniently followed by a change in the 31P-NMR resonance
from 27 ppm (phosphonate) to 44 ppm (Figure 3.12), characteristic of a 5-membered
ring phostone.31, 33, 34 The product was also confirmed by HRMS. Purification by
chromatography allowed the recovery of phostone 175a as a white amorphous solid in
moderate yield. By treating the 5-fluoro phosphonate 183a in a similar manner, the 5-
fluoro phostone 175b was similarly obtained as a white amorphous solid. Attempts to
recrystallise 175a and 175b from acetone/MeOH or EtOAc/MeOH were
unfortunately unsuccessful. With these compounds in hand inhibition assay was
conducted with the 5-FDRP isomerase enzyme.
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Scheme 3.14 Preparation of phostone 175a-b; Reagents and conditions: i) TMSBr,
DCM, rt; ii) TFA:H2O (1:1), iii) Ac2O, pyridine, 16h, 40-47%.
Figure 3.12 31P NMR of phosphonic acid (190a) and cyclic phosphonic (phostone,
175a).
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3.7.3 Bioassay results
Incubation with 5-FDRP isomerase
Incubation assays of the phosphonate salt 173a-b and 174a-b with the S. cattleya 5-
FDRP isomerase from S. cattleya were performed in our research group by Dr. S.
Cross. In each assay, the S. cattleya isomerase was incubated with its natural substrate
5-FDR-1-P (47) and then the appropriate phosphonate was added. The reaction was
conveniently monitored by 19F NMR. 5-FDR-1-P (47) shows a signal at -231.4 ppm
whereas the product 5-FDRulP (48) exhibits a signal at -231.8 ppm. In the event,
incubation with the phosphonate salts 173a-b and 174a-b did not show any inhibitory
effect on the isomerisation reactions (Figure 3.13) even at 4 mM concentrations. In all
cases, the conversions of 47 to 48 were similar to that of the control experiment.
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Figure 3.13 Incubation of 5-FDRP isomerase with 5-FDRP (47) and the synthetic
phosphonates: a) Control; b) with 173a; c) with 173b; d) with 174a; e) with 174b.
There was no apparent inhibitory effect with any of the phosphonates.
Phostones 175a and 175b are currently being employed to explore crystal structures
of the S. cattleya 5-FDRP isomerase by co-crystallisation. Also the phosphonates
173a-b and 174a-b will be used to co-crystallise with the 5-FDRP isomerase in an
attempt to explore their binding and interactions to the surface of the enzyme in the
University of St Andrews.
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3.8 Conclusions
Synthetic phosphonate analogues of D-ribose-1-phosphate phosphonate 173a-b and
174a-b have been successfully synthesised. Incubations of the phosphonates 173a-b
and 174a-b with the 5-FDRP isomerase have shown that these phosphonates were not
inhibitors of the isomerase at 4mM concentration. However, these analogues are
currently being used to explore co-crystallisation studies with the enzyme to try to
obtain a structure with a cyclic substrate.
The photones 175a-b were designed based on a putative phosphate migration
mechanism for the isomerisation of 5-FDRP (47) to 5-FDRulP (48). These photones
were considered as potential inhibitors for the 5-FRRP isomerase enzyme with
potential utility as tools to explore the mechanism of this biosynthetic enzyme. Their
co-crystallisation is on going.
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4.1 Introduction
Isoprenoids are one of the most abundant, diverse and important families of naturally
occurring compounds found in nature. They contribute to biological functions
including electron transport in respiration and photosynthesis (ubiquinone (191),
plastoquinone (192), the phytol residue (193) of chlorophyll and carotenoids), and
growth and development regulation (vitamin A, D, E (194), K; steroid hormone;
phytohormone; abscisic acid (195), insect juvenile hormones). In addition,
isoprenoids constitute a structural component of cell membranes (hopanoid (196) in
prokaryote and cholesterol (39) in eukaryotes).1, 2 The fundamental precursors of
isoprenoids are C-5 units derived from isopentenyl pyrophosphate (IPP, 197) and
dimethylallyl pyrophosphate (DMAPP, 198). These precursors originate from two
different biosynthetic pathways, the mevalonic acid (MVA) and methylerythritol
phosphate (MEP) pathways. The classic mammalian pathway to the steroids proceeds
via mevalonic acid as a key intermediate, the so-called the MVA pathway. This
pathway had been known since the 1950s and for many years it was assumed to be the
sole pathway used for isoprenoid biosynthesis in all organisms.3
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Figure 4.1 Example of isoprenoids; ubiquinone (191), plastoquinone (192), phytol
(193), vitamin E (194), cholesterol (39), abscisic (195), and hopane (196) and the
biosynthetic precursors IPP (197) and DMAPP (198)
In the early 1990’s an alternative biosynthetic pathway was discovered.4 This novel
pathway proceeds via the key intermediate methylerythritol phosphate, the so-called
MEP pathway (or DOXP, the first substrate of the pathway). It was found to operate
in eubacteria, all photosynthetic organisms such as higher plants, and algae, as well as
in cyanobacteria and diatoms.5-8 In addition, the MEP pathway is also found operating
in Plasmodium falciparum,9 the malaria parasite, and it is utilised by Mycobacterium
tuberculosis. However the MEP pathway is not functional in humans, animals and
archaebacteria.3
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4.2 Biosynthesis of the isoprenoid precursors IPP and DMAPP
4.2.1 The mevalonic acid pathway (MVA pathway)1
The biosynthesis of IPP and DMAPP via the MVA pathway (Scheme 4.1) starts with
a Claisen condensation between two molecules of acetyl-CoA (75e) to generate
acetoacetyl-CoA (91b). A third molecule of acetyl-CoA condenses via an aldol
addition to form the branched chain ester, β-hydroxy-β-methylglutaryl-CoA (HMG-
CoA, 199). Reduction of HMG-CoA generates mevalonic acid (200), a transformation
catalysed by HMG-CoA reductase. This step is the rate determining step of the MVA
pathway. The last two steps involve sequential phosphorylation where two ATP
molecules generate a diphosphate (202), which is then combined with a third ATP,
followed by decarboxylation to generate IPP (197). The resulting IPP is then
isomerised to DMAPP (198) by the action of an IPP isomerase enzyme.
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Scheme 4.1 The biosynthesis of IPP (197) and DMAPP (198) via the MVA
pathway, showing the enzymes involved; i) acetoacetyl CoA thiolase; ii) HMG-CoA
synthase; iii) HMG-CoA reductase; iv) mevalonate kinase; v) phosphomevalonate
kinase; vi) mevalonate 5-phosphate decarboxylase; vii) IPP isomerase.
4.2.2 The 2-C-methyl-D-erythritol 4-phosphate pathway or 1-deoxy-D-xylulose
5-phosphate pathway (the MEP or DOXP pathway).
The biosynthesis of isoprenoids via the alternative non-mevalonate pathway
comprises seven enzymatic reaction steps which are catalysed by eight enzymes
(Scheme 4.2). The initial step is the formation of 1-deoxy-D-xylulose 5-phosphate
(DXP, 49) by condensation of pyruvate (203) and glyceraldehyde 3-phosphate (204).
This step is catalyzed by the thiamine-dependent enzyme, DXP synthase (DXS, EC
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2.2.1.7).10 11 The DXP also serves as a biosynthetic precursor of vitamins B1
(thiamine) and B6 (pyridoxal).12 The second biosynthetic step involves the conversion
of 49 to the branched chain polyol, 2-C-methyl-D-erythritol 4-phosphate (MEP, 50).
A pinacol-like rearrangement of 49 generates a transient intermediate 2-C-methyl-D-
erythrose 4-phosphate (205) which is then converted to MEP by delivery of the pro-S
hydrogen of NADPH to the re face of aldehyde intermediate 205. This
biotransformation step is a reversible process13, 14 and is mediated by the enzyme DXP
reducto-isomerase (DXR, EC 1.1.1.267).15 In the third step, 4-diphosphocytidyl-2-C-
methyl-D-erythritol (CDP-MEP, 206)16, 17 is formed from the reaction of MEP with
CTP, which is catalyzed by the ATP-dependent enzyme, 2-C-methyl-D-erythritol-4-
phosphate cytidyltransferase (MCT, EC 2.7.7.60). The CDP-MEP (206) is then
converted to 4-diphosphocytidyl-2-C-methylerythritol 2-phosphate (207)18, 19 by an
ATP-dependent enzyme, 4-(cytidine5-diphospho)-2-C-methyl-erythritol kinase
(CMK, EC 2.7.1.148). In the fifth step intermediate 207 is converted to MECP (208),
20, 21 catalysed by 2-C-methyl-D-erythritol-2,4-cyclodiphosphate synthase (MDS, EC
4.6.1.12). In the last two steps, the cyclic diphosphate 208 undergoes consecutive
reduction and then elimination to form 1-hydroxy-2-methyl-2-(E)-butenyl 4-
diphosphate (HMBPP, 209).22 NADPH dependent 2-methyl-2-(E)-butenyl
diphosphate reductase (HDR, EC 1.17.1.2) then converts intermediate 209 to IPP and
DMAPP.23, 24 Most of these enzymes have now had their X-ray structures solved.25
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Scheme 4.2 Summary of the biosynthesis of DMAPP (197) and IPP (198) via the
MEP pathway.
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4.3 The rearrangement of DXP to MEP
4.3.1 The proposed mechanism of the rearrangement of DXP to MEP7, 13, 26
4.3.1.1  α-Ketol rearrangement 
The conversion of DXP to MEP, the first step of the MEP pathway, involves an
intramolecular rearrangement process. This α-ketol rearrangement (Scheme 4.3) is 
initiated by deprotonation of the hydroxyl group at C3 of DXP (49), followed by a
migration of the C4-C5 phosphate-bearing subunit to C2, generating the transient
intermediate methylerythrose phosphate (205). Subsequent reduction of 205 by
NADPH then delivers MEP (50). It is noteworthy that C3 of 49 is rehybridised from
sp3 to sp2 in its conversion from 205 whilst C4 remains sp3 hybridised. The α-ketol 
rearrangement has an analogy with the biosynthesis of the amino acids valine and
leucine,27 where α-ketol rearrangements are also involved (Scheme 4.4).    
Scheme 4.3 Proposed α-ketol rearrangement mechanism of DXP (49) to MEP
(50).26
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Scheme 4.4 The α-ketol rearrangement reported for acetoxy acid isomeroreductase.27
4.3.1.2 The reto-aldol/aldol rearrangement
The alternative retro-aldol/aldol rearrangement mechanism involves deprotonation of
the hydroxyl group at C4 of 49, followed by cleavage of C3-C4 bond to generate the
enolate of hydroxyacetone (210) and glycoaldehyde phosphate (211). Recombination
of fragments 210 and 211 via an aldol reaction generates 205 with a new C-C bond
derived from C-2 and C-4 of 49. In this event, the C3 and C4 carbon atoms are both
rehybridised from sp3 to sp2 in 205. Such a reaction has been reported for the
epimerization of L-ribulose 5-phosphate (L-Ru5P, 212) and D-xylulose-5-phosphate
(D-Xu5P, 213) which is catalysed by the enzyme L-ribulose-5-phosphate 4-
epimerase.28
Scheme 4.5 Proposed retro-aldol/aldol rearrangement mechanism of DXP to MEP.
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Scheme 4.6 Epimerization between L-ribulose-5-phosphate (L-Ru5P, 212) and D-
xylulose-5-phosphate (D-Xu5P, 213) via a retro-aldol/aldol mechanism.28
4.3.1.3 Hydride/methyl shift
The third mechanistic hypothesis for this rearrangement involves a 1,2-hydride shift
from C3 to C2 to form 214, followed by a 1,2-methyl shift. However, the results from
labelling studies7, 13 are inconsistent with this mechanism, so the hydride/methyl
migration mechanism is ruled out. Either α-ketol and retro-aldol/aldol mechanisms 
remain candidates for the rearrangement of DXP to MEP.
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Scheme 4.7 Hydride shift mechanism for the rearrangement of DXP to MEP
catalysed by DXR. However this mechanism is not supported by isotope labelling
studies.
4.3.2 α-Ketol rearrangement or retro-aldol/aldol rearrangement 
mechanism
In order to differentiate the mechanisms between the α-ketol and retro-aldol/aldol 
rearrangement mechanisms for the DXP to MEP isomerisation, 3-deoxy and 4-deoxy
MEP (215, 216) were explored as inhibitors of DXR.13, 29 They were partial
inhibitors,13 and Proteau found that they were non-competitive inhibitors.29 For the
retro-aldol/aldol reaction, the putative fragments, hydroxyacetone (217) and
glycoaldehyde phosphate (218), were incubated with DXR. Neither 217 nor 218
inhibited enzyme catalysis.13
Figure 4.2 The 3-deoxy and 4-deoxy MEP (215, 216) are partial inhibitors of DXR,
whereas hydroxyacetone (217) and glycoaldehyde phosphate (218) are not inhibitors.
Fluorinated analogues of MEP have been analysed as inhibitors of DXR. Both 219
and 220 proved to be inhibitors. Fluorinated analogues with one, two and three
fluorines at C1 were also tested with DXR. Interestingly, 221 and 222 were poor
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substrates whereas 219 was a good substrate for DXR.30 Incubation of 219 with (4S)-
[2H]NADPH and DXP showed a normal KIE compared to that of the natural substrate
case.31
Figure 4.3 Fluorinated analogues of DXP which have been explored as substrates
for DXR.
Recently, two independent studies have shown evidence for a retro-aldol/aldol
mechanism, as deduced by kinetic isotope labelling studies.32, 33 Incubations of [3-2H]
DXP (49a) and [4-2H]DXP (49b) allowed the observation of a secondary KIE on the
intramolecular rearrangement process. During the retro-aldol/aldol reaction, both C3
and C4 are rehybridised from sp3 to sp2 thus a secondary KIE should be observed for
both of these isotopically labelled substrates. On the other hand, only C3 is
rehybridised from sp3 to sp2 if a α-ketol rearrangement is occurring, so a secondary 
KIE would be observed only for 49a.
Figure 4.4 Labelling probes to measure the KIE of the rearrangement of DXP to
MEP.
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Interestingly, both substrates exhibited similar KIEs during incubations with DXR.
These results supported the retro-aldol/aldol reaction mechanism. However, in a
separate study an inverse (0.92, 0.86 for 49a and 49b)32 and normal secondary KIE
(1.04, 1.11 for 49a and 49b)33 was reported. The different KIE observations between
these two studies may arise from the purity of the substrates. In the first study, the
synthetic route to prepare labelled substrates 49a and 49b gave only 74-84%ee. An
inverse KIE would be observed if the unlabelled DXP had a lower ee% than that of
isotopically labelled substates.29, 33
4.4 The structure of the DXR enzyme
Four crystal structures of DXR from E. coli have been reported. These are the apo-
enzyme,34 a binary complex with NADPH,35 a complex with fosmidomycin (224) and
manganese,36 and a complex with a biphosphonate inhibitor and manganese.37 In
addition, a ternary complex of DXR, fosmidomycin and NADPH has also been
reported. 38Also the crystal structure of DXR from Zmomonas mobilis has recently
been reported as has the apoenzyme and a binary complex with NADPH.39
The first reported structure of DXR was the E. coli apoenzyme without a bound
substrate.34 The structure revealed that the enzyme is present as a homodimer. Each
monomer (42-45 kDa) displays a V-like shape (Figure 4.5). This monomer composes
three distinct domains: an amino-terminal dinucleotide NADPH binding domain, a
central connective domain, and a carboxyl-terminal four helix bundle domain. The
connective domain is responsible for dimerisation and harbors most of the active site.
A remarkable feature of DXR is its intrinsic flexibility suggesting the necessity to
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undergo induced fit upon substrate binding. Residues 186-216 function as a “lid” over
the active site, shielding the reactants from the solvent environment.
Figure 4.5 A ribbon representation of the DXR; monomer with the NADPH co-
substrate modelled into the structure (upper) and the DXR dimer (lower).34
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The crystal structure of the ternary complex of DXR, NADPH, and fosmidomycin has
been reported.38 This revealed Asp 150, Glu152, Glu231, Glu234, His209 and His257
as conserved active site residues. Residues 206-216 link the connective and C-
terminal domains and act as the lid. The substrate binding cavity at the active site
consists of three regions: a positively charged pocket, which binds the phosphate
moiety of fosmidomycin (Figure 4.6), a hydrophobic region around the carbon
backbone, and an amphipathic region, which binds the hydroxamic acid group.
Interestingly, fosmidomycin does not form hydrogen bonds with His209, which
appears to play an important role in binding the substrate in the correct orientation for
catalysis. This is rationalised by the presence of the mono-anionic phosphonate of
fosmidomycin resulting from crystallization at pH 5.0.
Figure 4.6 Representation of fosmidomycin contacts on binding of the inhibitor to
DXR (distances are given in Å).38
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A ternary complex of DXR, NADPH, and DXP has been reported.28 The phosphate
moiety of the substrate forms hydrogen bonds to Ser186, Asn227, Lys228 and with
the catalytically essential His209 (Figure 4.7). The substrate backbone interacts with
the β-indole of Trp212 and the carbonyl group of C2 is hydrogen bonded to Glu152 
and the backbone NH of Ser151. The hydroxyl group of C3 is involved in hydrogen
bonds with Lys125 and Glu231, while the C4 hydroxyl group is hydrogen bonded to
Glu152, Asn227 and Lys228. The C3 hydroxyl group of the alternative
diastereoisomer is not involved in any hydrogen bonding interactions. The
nicotinamide ring of NADPH adopts an orientation that allows the transfer of hydride
from the pro-S hydrogen at C4 of the nicotinamide ring to C2 of the proposed
intermediate, 2-C-methylerythrose 4-phosphate 50.
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Figure 4.7 Representation of the DXP substrate binding to DXR as deduced from
the X-ray structure of the DXR, NADPH, DXP ternary complex (distances are given
in Å) .38
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4.5 Inhibitors of DXR
For some microbial pathogens such as the malaria parasite and the micro-organism
responsible for tuberculosis, Plasmodium falciparum and Mycobacterium
tuberculosis, the MEP pathway is the exclusive source of IPP and DMAPP. The
pathway is not found in humans. Therefore, each enzyme of the MEP pathway
represents an attractive target for the development of new antibacterial, antimalarial,
anti-TB agents, and herbicides.40, 41 Extensive studies have focused on the
biotransformation of DXP to MEP, the reaction mediated by the enzyme DXP
reductoisomerase. Fosmidomycin (224),42 which is a natural antibacterial, displayed a
potent inhibitory effect on E. coli DXR with an IC50 of 8.2 nM and it also showed
strong inhibition of the growth of P. falciparum cells. The potent inhibitory effect of
this compound may derive from its structural similarity to the hypothetical
intermediate 205. The analogue of fosmidomycin, FR900098 (225) showed twice the
antimalarial activity in vitro and also cures malaria infected-mice.43 To date, the most
powerful inhibitor of DXR is the fosmidomycin analogue 226 which shows a 12-fold
increase in activity over the parent compound and almost a 4-fold increase over
FR900098 in antimalarial activity.44 The combination of fosmidomycin with
clindamycin is currently being employed in clinical studies against malaria in Gabon
and Thailand. Several analogs of DXP, (3S)-hydroxypentan-2-one-5-phosphate (215,
216, and 227) have also shown inhibitory effects but at lower activity than
fosmidomycin and its derivatives.
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Figure 4.8 Inhibitors of DXR fosmidomycin (224), FR900098 (225) and DXP
analogues.
4.6 Aims of the project
The aim of this study was to prepare 5-hydroxy-3,4-dioxohexylphosphonate (228).
This phosphonate mimic is close in structure and geometry to the putative
intermediates 210 and 211 involved in the retro-aldol/aldol mechanism (Scheme 4.5).
The cleavage of the bond between C3-C4 of DXP (Scheme 4.9) converts these sp3
carbons into sp2 in the resultant glycoaldehyde phosphate (211) and hydroxy acetone
(210) fragments. These two fragments then undergo an aldol condensation to form a
bond between C2 and C4 to generate the transient aldehyde (205) intermediate. The
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tautomeric forms of 5-hydroxy-3,4-dioxo-hexyl-phosphonate (228) have similar
structures to hydroxyacetone (210) and glycoaldehyde phosphate (211) and therefore
228 represents a possible transition state inhibitor of DXP.
The study aimed to explore if 228 would form tautomeric structures in solution. These
tautomers may also be relevant as transition state analogues/inhibitors of DXR. To
clarify the ground state content in the product mixtures, a synthesis of [5-13C]-228a
was also designed. By enriching the carbonyl at C-5 with the 13C-isotope, tautomeric
mixtures in the crude product could potentially be identified by 13C-NMR.
It was also an objective to assess the bioactivity of 228 by incubation with the E. coli
DXR. A particular tautomer may bind the active site if it approximates the transition
state geometry. The study may also reveal details of the enzyme mechanism.
Scheme 4.8 Target molecules, 228 and [5-13C]-228a. Their tautomer (229) mimics
the transition state of the retro-aldol/aldol mechanism.
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4.7 Previous study on synthesis of potential DXR inhibitors.32
As a potential transition state inhibitor of the retroaldol/aldol mechanism, 5-hydroxy-
3,4-dioxohexylphosphonate (228) was synthesised in our laboratory by Dr C. D.
Cadicamo. Two different synthetic routes to 228 are shown in Schemes 4.9 and 4.10.
The first involved the protection of the hydroxyl group as a triisopropylsilyl ether and
the second as an acetyl ester. In both cases the target compound showed complex 1H
NMR spectra. A preliminary biological assay suggested that a crude product
preparation of 228 was a modest inhibitor of the E. coli DXR enzyme. At 1.0 mM it
showed about 80% inhibition with a tentative Ki of 0.5 mM. Although not a very
potent inhibitor it had a similar affinity to the enzyme as the natural substrate (~0.34
mM). The assay was carried out in the laboratory of Prof. R. J. Cox at the University
of Bristol. A definitive conclusion on its inhibition potential was confused as the
compound was clearly a complex mixture by 1H-NMR analysis.
Scheme 4.9 Preparation of 228; i. 1) BuLi, THF; 2) acetaldehyde, 40-60%; ii.
TIPS-triflate, DCM, 2,6-lutidine, ~100; iii. 1) Diethyl methylphosphonate, BuLi,
THF; 2) (5-bromopent-3-yn-2-yloxy)triisopropylsilane, 40%; iv. 1) O3, MeOH; 2)
PPh3, diethyl ether, 70%. v. TMS-Br, DCM; ii H2O; vi. 0.2 M NaOH until pH ~7.
Synthesis carried out by Dr. C. D. Cadicamo (2006).
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Scheme 4.10 Preparation of 228; i. acetic anhydride, DCM/Pyr/DMAP, 60%; ii. 1)
Dimethyl methylphosphonate, BuLi, THF; 2) 5-bromopent-3-yn-2-yl acetate, 40%;
iii. 1) O3, CCl4/acetic acid (4:1); 2) PPh3, diethyl ether, 70%. V. 1). TMS-Br, DCM;
2) H2O; 3) NaOH (3 eq.) or lipase, phosphate buffer. Synthesis carried out by Dr. C.
D. Cadicamo (2006).
The objective of this study was to modify the synthesis of 228 to prepare a purer
product, and also to prepare [5-13C]-228a, for a more in-depth assessment of the
tautomers of this compound by 13C-NMR.
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4.8 Results
4.8.1 Synthesis
4.8.1.1 Preparation of 5-hydroxy-3,4-dioxohexylphosphonate (228)
The preparation of 5-hydroxy-3,4-dioxohexylphosphonate (228) was previously
described by C. D. Cadicamo. In this project, the synthesis essentially followed that
route, however, with a slight modification during installation of the α-diketone 
(Scheme 4.11). Propargyl bromide was treated with LDA and then acetaldehyde for a
condensation reaction to give 231. The resultant alcohol was then protected as a TIPS
ether (232). Dimethyl phosphonate was treated with n-BuLi to form the lithium
phosphonate, which was then reacted with 232 to give the acetylene 233 in moderate
yield. In order to install the α-diketone moiety, treatment of the acetylenic 
phosphonate 233 with NaIO4/cat.RuO2 in CHCl3:ACN:H2O (1:1:1.5) was employed.45
The active species RuO4 is generated in situ from RuO2 by the action of NaIO4. Such
reaction with acetylenes has previously been shown to give an α-diketone.45, 46 A
bright yellow oil was obtained in good yield after chromatography and the resultant
1H and 13C-NMR spectra of the ethyl phosphonate 234 are shown in Figures 4.9A and
B. It was envisaged that the ethyl phosphonate esters could be hydrolysed by
treatment with TMSBr, however the acidic conditions generated by TMSBr may also
hydrolyse the TIPS ether. Therefore, 234 was treated with an excess TMSBr and then
with water until a homogeneous solution was obtained. Then the solution was
neutralised with 0.2 M NaOH. The product 228 was analysed by 1H NMR in D2O.
The 1H NMR spectrum (Figure 4.10) now was extremely complex, unlike that of 234,
indicating that the deprotected product was a complex mixture of isomers.
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Scheme 4.11 Summary of synthetic route to 5-hydroxy-3,4-dioxohexylphosphonate
(228). Reagents and conditions: i. 1) LDA, THF; 2) acetaldehyde, 60%; ii. TIPS-
triflate, CH2Cl2, 2,6-lutidine (quantitative); iii. 1) diethyl methylphosphonate, BuLi,
THF; 2) 232, 40%; iv. RuO2, NaIO4, H2O:CH3CN:CHCl3 (1.5:1:1), 60%; v. TMS-Br,
DCM; vi. 1) H2O; 2) 0.2 M NaOH.
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Figure 4.9 A) 1H-NMR (CDCl3) spectrum of α-diketone 234; B) 13C-NMR of
α-diketone 234.
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Figure 4.10 Complex 1H-NMR (D2O) of 228 obtained after treatment of 234 with
TMSBr, H2O, and neutralised with 0.2 M NaOH. This shows a clear contrast to the
relatively clean NMR spectra of the immediate precursor 234 (Figure 4.9 A and B).
4.8.1.2 Preparation of [5-13C]-5-hydroxy-3,4-dioxohexylphosphonate
(228a)
In order to gain a clearer insight into understanding the complexity of this mixture, it
was decided to incorporate a 13C isotope as a probe to explore the extent of the
isomerisation. The strategy taken (Scheme 4.12) involved installing 13C at C5 of
228a. A synthetic route was envisaged that involved treating [1-13C]-acetaldehyde
(240) with propagyl bromide (230). Further synthetic steps then followed the previous
synthesis of 228 as illustrated in Scheme 4.12.
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Scheme 4.12 Synthetic route to [5-13C]-228a. Reagents and conditions: i. n-
Bu3SnH/Pd(0)(PPh3)4, toluene, 30 °C; ii. 1) LDA, THF; 2) propargyl bromide
(38.1%); iii. TIPS-triflate, CH2Cl2, 2,6-lutidine (96.7%); iv. 1) diethyl methyl
phosphonate, BuLi, THF; 2) 232a (56.9%); v. RuO2, NaIO4, H2O:CH3CN:CHCl3
(1.5:1:1) (64.6%); vi. 1)TMS-Br, DCM; 1) H2O.
4.8.1.3 Preparation of [4-13C]-1-bromo-4-hydroxypent-2-yne (231a).
In order to generate a sample of [1-13C]-acetaldehyde (240), [1-13C]-acetylchloride
(239a), was treated with Pd(0)(Ph3)4 and n-Bu3SnH in toluene at 30°C.47 The product
was flushed from the reaction mixture by evaporation on a flow of nitrogen gas, and
was trapped by condensation in a round bottom flask which contained dry THF at
-89°C. The flask was warmed to ambient temperature and the mixture was then
transferred via a cannular into a round bottom flask containing propagyl bromide
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(230) which had previously been treated with LDA. The resultant [4-13C]-231a
alcohol was obtained in moderate yield (38%) after chromatography.
The consensus mechanism for the catalytic reduction is shown in Scheme 4.13.48 The
key acylhydridopalladium (242) intermediate may be derived from two possible
pathways. Firstly, an oxidative addition of acyl chloride with Pd(PPh3)2 to form an
acylchloropalladium(II) complex (241), followed by a metathesis reaction with n-
Bu3SnH. A second possible pathway involves the oxidative addition of n-Bu3SnH
with Pd(PPh3)2 to generate adduct (243), followed by oxidative addition of the acyl
chloride to form the acylhydridopalladium (242) intermediate. Reductive elimination
of 242 would then give the aldehyde and regenerate the catalyst.
Scheme 4.13 Proposed catalytic reduction of acyl chloride to acetaldehyde by
Pd(0)(PPh3)4/n-Bu3SnH.48
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4.8.1.4 Preparation [5-13C]-α-diketone 234a. 
Following the method for the previous synthesis of 228, alcohol 231a was then
protected as a TIPS ether, which then underwent a condensation with the ethyl
methylphosphonate moiety to give 233a. Treatment of the acetylene 233a with
NaIO4/cat.RuO2 gave the α-diketone [5-13C]-234a in good yield. The 1H NMR of [5-
13C]-234a (Figure 4.11) shows a dq multiplicity at 5.03 ppm (1JCH 144.3 and 3JHH 6.8
Hz) corresponding to the methylene proton directly attached to the carbon-13 isotope.
The 13C-NMR shows a clear predominant signal at 70.7 ppm, indicating isotope
enrichment of the C-5 carbon. These spectra again indicate a relatively clean synthetic
phosphonate ester precursor, prior to final deprotection.
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Figure 4.11 1H-NMR (A) and 13C-NMR (B) spectra of α-diketone 234a.
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4.8.1.5 Preparation of [5-13C]-α-diketone phosphonate 228a. 
Compound [5-13C]-234a was now treated with an excess TMSBr in DCM, followed
by addition of water until a homogeneous solution was obtained, and the solvents
were then remove in vacuo to give 228a. The 1H and 13C NMR spectra of the resultant
228a are shown in Figure 4.12, and they are clearly complex, representing a mixture
of tautomers of 228a.
Scheme 4.14 Deprotection of [5-13C]-234a gave a mixture of isomers of 228a.
Reagents and conditions: i) TMSBr, DCM; ii) H2O; iii) 0.2 M NaOH.
The 1H NMR (Figure 4.12) of 228a shows two methylene groups multiplets at 1.53-
1.68 ppm and 2.34-2.64 ppm. Methyl groups attached directly to an isotopically
enriched carbonyl are identified as two sets of doublets at 1.80 ppm and 1.81 ppm.
The 13C NMR spectrum (Figure 4.12) revealed that there were at least four different
13C-enriched environments in the product indicating a significant level of
tautomerisation. Two carbonyl environments were clearly obvious as indicated by the
two 13C signals at 207.0 ppm and 207.5 ppm. Also signals consistent with carbinols
(H13COH) appear at 69.8 ppm and 72.5 ppm. This combination of signals suggested
that the product contains at least two isomers bearing C5 carbonyls (244) and two
isomers containing 13C-5 enriched carbinol motifs (245, Scheme 4.15).
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Figure 4.12 A) 1H-NMR (D2O) and B) 13C-NMR (D2O) of 228a obtained after
treatment [5-13C]-234a with an excess TMSBr/H2O.
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Scheme 4.15 Possible isomer motifs contained in the product after treatment of
[5-13C]-234a with TMSBr.
4.8.1.3 Influence of pH on tautomerism of 228a.
In order to explore tautomerism in the isotopically labelled sample of 228a, a series of
13C-NMR studies were carried out at different pH’s in D2O. Accordingly, the solution
of 228a was adjusted the pH’s to 3.5, 7.0, 10.5, and 12.5 with 0.2 M NaOH. The
13C-NMR spectrum was recorded in D2O at each pH point to observe the influence of
pH on the nature of the carbon-13 signals in product mixture. The 13C NMR for this
series of experiments is shown in Figure 4.13 and all possible tautomeric motifs of the
isotopically labelled C-5 are shown in Figure 4.14.
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Figure 4.13 13C NMR of 228a recorded in D2O at pH’s 3.5, 7.0, 10.5, and 12.5.
The 13C NMR of 228a adjusted pH to 3.5 showed only one obvious enriched carbonyl
signal at 207.8 ppm, a predominant carbinol signal at 70.0 ppm, and a minor signal of
a hydrate at 95.7 ppm. These signals are perhaps consistent with the motifs 244, 245,
and 246, respectively. Therefore, at this pH there were at least three isotopically
enriched C-5 environments. Neutralised 228a (pH 7.0) exhibited two additional
signals relative to pH 3.5. A new carbonyl signal emerged perhaps consistent with an
enol motif (247), at 182.3 ppm. It was envisaged that 247 may tautomerise to an enol
248, however there was no apparent 13C signal consistent with this enol motif. The
signal for a secondary carbinol also appeared at 69.1 ppm. Under basic conditions (pH
10.5), the carbonyl signal at 207.8 ppm and the carbinol at 70.0 ppm disappered.
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However, two predominant signals consistent with structural motifs 245 and 247
remained. These signals also persisted at pH 12.5. These results clearly demonstrate
pH dependent tautomerisation with different tautomers present under acidic and basic
conditions.
Figure 4.14 Molecular fragments contained in solution of [5-13C]-228a at different
pH’s. In an acidic environment, the product contained both 13C-enriched C5 carbonyl
(244) and carbinol (245) moieties. At neutral pH, 247 emerged along with 244 and
245. Under basic conditions, the predominant labelled moiety was 245.
4.8.2 Incubation of 229a with E. coli DXR
Samples of phosphonate salt 228a for enzyme assays were obtained by adjusting the
pH to 7.0 with 0.2 M NaOH. All incubations with DXR were carried out in
collaboration with Prof. M. Rohmer at the University of Strasbourg. Assays were
carried out by Denis Tritsch. DXR (2 µL, stock concentration 2.7 µg/µL) was first
preincubated with NADPH (0.25 mM final concentration) and the solutions of 228a at
37°C for 2 min. The enzymatic reaction was then initiated by the addition of DXP
(0.5 mM final concentration). The reaction was followed at 340 nm in a UV
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spectrometer. The concentrations of inhibitor varied from 10 to 800 µM, however no
apparent decrease of the enzymatic rate was observed over this concentration range.
Phosphonate 228a did not appear to inhibit DXR. The compound (400 µM) was also
incubated with NADPH and DXR as a potential substrate. However there was no
decrease in the absorbance at 340 nm. It is concluded that 228a is not a substrate or an
inhibitor of DXR.
The earlier Bristol assay had been carried out on a small amount of material, and we
must conclude that the assay carried out in Strasburg was more rigorous.
4.9 Discussion and conclusion
Based on the retroaldol/aldol mechanism for the rearrangement of DXP to MEP, the
phosphonate analogue 228 was designed as a potential transition state mimic. A
synthesis of 228 has previously been demonstrated by Dr. Cadicamo in St Andrews,
however at that time the nature of the product was not clear. Molecules containing a
1,2-diketone-3-hydroxyl motif (250) are anticipated to tautomerise, and are also
susceptible to hydration, and therefore assignment by NMR is complicated. For
instance, the natural compound 4,5g-dihydroxy-pentane-2,3-dione (DPD, 251) has
never been isolated as a pure compound.49-51 It was shown to equilibrate as a mixture
of cyclic anomers (252, 252a) and hydrated anomeric forms (253, 253a).49, 50
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OH
O
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250
Scheme 4.16 The 1,2-diketone-3-hydroxyl motif (250) and the equilibrium of 4,5-
dihydroxy-pentane-2,3-dione (253).49, 50
Although the precursor to 228 and 228a could be relatively easily characterised by 1H
NMR, deprotection to the phosphonate salt led to a complex mixture of isomers. It
was anticipated that this complex mixture was actually an equilibrium between a
number of tautomeric forms, and also with hydrates. A selectively labelled 13C
analogue was synthesised to investigate if this carbon could equilibrate between
carbonyls and carbinols and hydrates. Isotopic labelling at C-5 was selected. Under an
acidic environment (pH < 3.5), the labelled carbon of 228a was substantially carbonyl
(244) in nature along with a minor carbinol component (245). However, the
equilibrium favored 13C-5 carbinol isomers when the pH of the solution was adjusted
to 3.5. At neutral pH, an additional 13C-5 carbonyl emerged, suggesting that C-3 and
C-4 were perhaps in an enol form (247). Thus, there were at least four 13C-5 enriched
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environments present at pH 7. Under basic conditions (pH 10.5 and 12.5), tautomeric
forms 244 disappeared and a 13C-5 carbinol isomer predominated.
It was envisaged that the tautomeric enol 248 could mimic the putative transition state
of the isomerisation of DXP to MEP (Scheme 4.8). The geometry of this tautomer
would fit the catalysis reaction of the DXR enzyme. A study of the influence of pH on
the tautomerisation of 228a (Section 4.8.1.3) has revealed that at a neutral pH all
tautomeric motifs, 244 and 245 were present in the solution, particularly an enol 247.
This enol can tautomerise to enol 248 in solution. However, there was no obvious
signal indicating the presence of the tautomer 248 at all varying pH states.
O HO
+
244 isomers
major
245 isomers
minor
pH < 3.5
O HO
+
244 isomers
minor
245 isomers
major
O HO
+
244 isomers 245 isomers
O
247
OH
OH
+
O
247
minor
OH
OH
HO
244 isomers
major
pH 7.0
pH > 10.0
+
pH 3.5
HO OH
HO
248
OH
O
246 isomers
+
Scheme 4.17 Fate of the 13C-5 enriched carbon of 228a with pH variation.
Previous enzyme assays of 228 with the E. coli DXR were carried out in Dr. R. Cox’s
laboratory at the Bristol University in 2006 and suggested some inhibition activity. In
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this study, an enzyme assay evaluating the inhibitory effect of 228a on the production
of MEP was carried out in Prof. M. Rohmer’s laboratory at the University of
Strasbourg. However, triethanolamine buffer (254) was employed instead of Tris
buffer (Bristol), since Tris buffer (255) is able to react with carbonyl compounds.
Incubation of the tautomeric forms of 228a with DXR, and NADPH showed no
decrease of absorbance at 340 nm. This result suggested that 228a was not a substrate
for the enzyme. Incubation of the tautomeric forms of 228a with DXR, DXP, and
NADPH suggested also that 228a was not an inhibitor of DXR even at concentrations
up to 8 mM.
Inconsistent bioassay results were somewhat confusing, but the assay carried out in
Strasburg during this research suggests that 228 is not an inhibitor.
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5.1 General methods
Air and moisture sensitive reactions were carried out under a nitrogen atmosphere
using oven-dried glassware (140 ˚C). All reagents of synthetic grade were used as 
supplied. If further purification was required the procedures are detailed in Armarego
and Perrin, “Purification of laboratory chemicals” 4th Ed. Dry ether, THF, DCM, and
toluene were collected directly from a MBRAUN solvent purification system MB
SPS-800. Ambient temperature refers to 20-25 ˚C. Reaction temperatures of -78 ˚C to 
-10 ˚C were obtained using solid carbon dioxide pellets and acetone or isopropyl 
alcohol or by using a bath cooling LP technology RP-100-CD. Temperatures of
-10 ˚C to +4 ˚C were obtained in an ice/water/NaCl bath. Reactions requiring reflux 
or heating were carried out using an oil bath equipped with a contact thermometer.
Nuclear magnetic resonance (NMR) spectra were obtained using Bruker Av-300 and
Varian Unity Plus 300 machines operating at 300 MHz for 1H, 75 MHz for 13C, 282
MHz for 19F, and 121 MHz for 31P. A Bruker Advance II 400 machine operating at
400 MHz for 1H, 100 MHz for 13C, 376 MHz for 19F, and 162 MHz for 31P. All
chemical shifts (δ) are reported in parts per million (ppm) and are quoted relative to 
the residual peak of CDCl3, CFCl3, D2O, or CD3OH or to the internal standard for
(CH3)4Si. Coupling constants (J) are given in Hertz (Hz). 13C-NMR spectra were 1H
decoupled. 19F-NMR and 31P-NMR spectra were 1H coupled. Complete assignment
based on 1D and 2D NMR (COSY, NOESY, HSQC, and HMBC). Thin layer
chromatography (TLC) was performed using Merck, Kieselgel 60 plates. Compounds
were detected by either UV or by the use of a molybdenum based staining agents.
Column chromatography was performed using Merck Kieselgel 60 silica gel (230-400
nm mesh). Cation exchange procedures were carried out using Dowex 50W (X8) resin
with 50-100 mesh particles. Melting points were determined in Pyrex capillaries using
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a Gallenkamp Griffin MPA350.BM2.5 melting point apparatus. All infra red (IR)
spectra were recorded in the range 4000-440 cm-1 on a Nicolet Avatar 360 FT-IR as a
thin film on NaCl plates or on PTFE plates. High-mass resolution spectrometry
(HRMS) and low resolution mass spectrometry (LRMS) were performed using a
Micromass LCT (Manchester, UK) mass spectrometer with electrospray ionization
(ESI) operating in both positive and negative mode. Optical rotations were measured
on Perkin-Elmer model 341 polarimeter. Single X-ray diffraction analyses were
carried out by Prof. Alex M. Z. Slawin at the University of St Andrews.
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5.2 Synthetic experiment for Chapter 2
5.2.1 (RS)-o-Fluorophenyllactic acid 103k
Conc. HCl (6.9 ml, 3 equiv.) was added to a solution of (RS)-o-fluorophenylalanine
(4.98 g, 27.2 mmol) in water (260 ml) and the reaction mixture was stirred until
homogenous. The solution was then cooled to 0 ˚C and NaNO2 (3.90 g, 2 equiv.) was
added portionwise over 4 h maintaining a temperature of 0 ˚C. The reaction was
warmed to ambient temperature and left to stir for a further 48 h. The solution was
concentrated under reduced pressure and organic compounds were extracted into ether
(3150 ml). The organic extracts were combined, dried over MgSO4, and filtered.
After removal of solvents under reduced pressure, a crude yellow oil was obtained.
Recrystallisation of the crude product from chloroform gave (RS)-o-
fluorophenyllactic acid 103k as a white crystalline solid (1.62 g, 32.2%). Mp. 80-81
˚C (lit.1 80-81 ˚C); H (300 MHz, MeOH-d4) 3.04 (dd, 1H, 3JHH = 7.7, 2JHH = 14.2, H-
3), 3.28 (dd, 1H, 3JHH = 4.7, 2JHH = 14.2, H-3), 4.54 (dd, 1H, 3JHH = 4.7, 3JHH = 7.7, H-
2), 7.03-7.14 (m, 2H, Ar-H), 7.22-7.31 (m, 2H, Ar-H). C (75 MHz, CDCl3) 33.8 (C-
3), 70.1 (C-2), 115.4 (d, 2JCF = 22.3, C-3), 124.1 (d, 4JCF = 3.5, C-5), 123.0 (d, 2JCF =
15.5, C-1), 128.9 (d, 3JCF = 8.2, C-4 or C-6), 131.9 (d, 3JCF = 4.6, C-6 or C-4),
161.3 (d, 1JCF = 245.5, C-2), 177.9 (C-1). F (283 MHz, CDCl3,) -117.9 (m, 1F, Ar-
F). max (KBr): 3416, 2950, 1703, 1604, 1507, 1450, 1418, 1362, 1230 cm-1.
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5.2.2 (RS)-m-Fluorophenyllactic acid 103l
(RS)-m-Fluorophenyllactic acid 103l was prepared as procedure described in 5.2.1 to
obtain a white crystalline solid (1.25 g, 26.0%). Mp. 106-107 ˚C (lit.1 106-107 ˚C); H
(300 MHz, MeOH-d4) 2.81 (dd, 3JHH = 8.0, 2JHH = 14.0, 1H, H-3), 3.01 (dd, 1H, 3JHH
= 4.3, 2JHH = 14.0, H-3), 4.23 (dd, 1H, 3JHH = 4.3, 3JHH = 8.0, H-2), 6.82 (ddt, 4JHH =
0.8, 4JHH = 2.6, 3JHF, HH = 9.0, 1H, H-4), 6.91 (td, 1H, 4JHH = 2.4, 3JHF = 10.2, H-2),
6.97 (d, 1H, 3JHH = 7.6, H-6), 7.14 (dt, 1H, 4JHF = 6.1, 3JHH = 7.9, H-5). C (75 MHz,
CDCl3) 41.1 (C-3), 72.4 (C-2), 114.2 (d, 2JCF = 21.5, C-4), 117.3 (d, 2JCF = 21.5, C-
2), 126.4 (d, 4JCF = 2.8, C-6), 130.8 (d, 3JCF = 8.3, C-5), 141.7 (d, 3JCF = 7.6, C-1),
164.1 (d, 1JCF = 243.2, C-3), 176.8 (C-1). F (283 MHz, CDCl3,) -116.7 (ddd, 4JHF =
6.2, 3JHF = 9.3, 3JHF = 9.3, 1F, Ar-F). max (KBr) 3428, 2940, 1722, 1585, 1486, 1450,
1429, 1324, 1240 cm-1.
5.2.3 (RS)-p-Fluorophenyllactic acid 103m
(RS)-p-Fluorophenyllactic acid 103m was prepared as procedure described in 5.2.1 to
obtain a white crystalline solid (1.01 g, 20.5%). Mp. 99-100 ˚C (lit.1 100-101 ˚C); H
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(300 MHz, MeOH-d4) 2.78 (dd, 1H, 3JHH = 7.9, 2JHH = 14.0, H-3), 2.98 (dd, 1H, 3JHH
= 4.3, 2JHH = 14.0, H-3), 4.20 (dd, 1H, 3JHH = 4.3, 3JHH = 7.9, H-2), 6.89 (dd, 2H, 3JHF
= 8.9, 3JHH = 8.9, H-3, H-5), 7.17 (dd, 2H, 4JHF = 5.6, 3JHH = 8.6, H-2, H-6). C (75
MHz, MeOH-d4) 43.2 (C-3), 75.1 (C-2), 118.3 (d, 2JCF = 21.5, C-3, C-5), 134.8 (d,
3JCF = 7.9, C-2, C-6), 137.3 (d, 4JCF = 3.0, C-1), 165.7 (d, 1JCF = 243.0, C-4), 179.5
(C-1). F (283 MHz, MeOH-d4) -116.1 (dddd, 4JHF = 5.4, 4JHF = 5.4, 3JHF = 8.7, 3JHF =
8.7, 1F, Ar-F). max (KBr) 3417, 2950, 1702, 1600, 1507, 1445,1363, 1228 cm-1.
5.2.4 (rac)-o-Fluorolittorine ((RS)-o-fluorophenyllactoyltropine, 45e)1
OH
O
OF
Me
N
1
2
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3"
4"
5" 45e
Dry (RS)-o-fluorophenyllactic acid 103k (0.32 g, 1.71 mmol) and tropine (0.24 g,
1.71 mmol) were mixed intimately under nitrogen in the solid phase. The mixture was
heated to 130 ˚C and a current of dry HCl gas was passed periodically over the 
reaction for 4 h and the reaction was allowed to cool to ambient temperature. The
product was dissolved as completely as possible in 50 mM H2SO4 (10 ml), the
insoluble material was filtered off. The filtrate was then treated with 10% aqueous
ammonium hydroxide until it was basic, and then the organics were extracted into
chloroform (3  15 ml). The combined organic phases were dried over MgSO4, and
the solvents were evaporated under reduced pressure to give a pale yellow oil. The
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product was purified over silica gel column eluting with EtOH:CHCl3:35%NH3
(7:7:0.2) to afford 45e as a colourless viscous oil (0.11 g, 21.0%). δH (300 MHz,
CDCl3) 1.58 (d, 1H, 2JHH = 15.3, H-4a), 1.65 (d, 1H, 2JHH = 15.3, H-2a), 1.74-1.79 (m,
2H, H-6a, H-7a), 1.87-1.98 (m, 2H, H-6e, H-7e), 2.04-2.15 (m, 2H, H-2e, H-4e), 2.22 (s,
3H, NMe), 2.93 (dd, 1H, 3JHH = 7.6, 2JHH = 14.0, H-3), 3.05-3.06 (br, 2H, H-1, H-5),
3.12 (dd, 1H, 3JHH = 5.1, 2JHH = 14.0, H-3), 4.33 (dd, 3JHH = 5.1, 3JHH = 7.6, 1H, H-
2), 5.01 (t, 3JHH = 5.3, 1H, H-3e), 6.93-7.05 (m, 2H, Ar-H), 7.13-7.24 (m, 2H, Ar-H).
δC (CDCl3) 25.3 (C-6 or C-7), 25.5 (C-6 or C-7), 34.0 (C3), 36.3 (C-2 or C-4), 36.6
(C-2 or C-4), 40.4 (NCH3), 59.6 (C-1, C-5), 69.4 (C-3 ), 70.4 (C-2), 115.2 (d, 2JHF =
22.1, C-3), 123.6 (d, 2JHF = 15.6, C-1), 124.0 (d, 4JHF = 3.5, C-5), 128.7 (d, 3JHF =
8.1, C-4), 131.9 (d, 3JHF = 4.5, C-6), 162.7 (d, 1JHF = 245.23, C-2), 173.2 (C-1). δF
(282 MHz, CDCl3) -118.20 (m, 1F, Ar-F). νmax (neat) 2923, 1739, 1587, 1493,
1461,1377, 1260 cm-1. m/z (ES+): Calcd. for C17H23NFO3 [M+H]+: 308.1662, found
308.1328 100%)
5.2.5 (rac)-m-Fluorolittorine ((RS)-m-fluorophenyllactoyltropine, 45f)1
OH
O
O
Me
N
45f
F
The procedure described in 5.2.4 was repeated with (RS)-m-fluorophenyllactic acid
(103m, 0.37 g, 1.90 mmol) and tropine (0.27 g, 1.90 mmol) to afford 45f as colorless
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viscous oil (0.12 g, 20%). δH (300 MHz, CDCl3) 1.57 (d, 2JHH = 15.0, 2H, H-4a), 1.60
(d, 2JHH = 15.0, 2H, H-2a), 1.66-1.73 (m, 2H, H-6a, H-7a), 1.92-1.96 (m, 2H, H-6e, H-
7e), 2.02-2.12 (m, 2H, H-2e, H-4e), 2.19 (s, 3H, NMe), 2.89 (dd, 3JHH = 7.1, 2JHH =
14.0, 1H, H-3), 3.00-3.05 (br, 2H, H-1, H-5), 3.06 (dd, 3JHH = 4.7, 2JHH = 14.0, 1H,
H-3), 4.31 (dd, 3JHH = 4.7, 3JHH = 7.1, 1H, H-2), 5.00 (t, 3JHH = 4.8, 1H, H-3e), 6.84-
6.92 (m, 2H, H-4, H-5), 6.94 (d, 3JHF = 7.8, 1H, H-6), 7.16-7.23 (m, 1H, H-2). δC
(75 MHz, CDCl3) 25.4 (C-7 or C-6), 25.5 (C-6 or C-7), 36.3 (C-2 or C-4), 36.6 (C-4
or C-2), 40.4 (C-3, NMe), 59.6 (C-1, C-5), 69.4 (C-3), 70.4 (C-2), 115.3 (d, 2JCF =
22.0, C-4), 123.5 (d, 3JCF = 15.5, C-1), 124.0 (d, 4JCF = 3.4, C-6), 128.7 (d, 3JCF =
8.1, C-2), 131.9 (d, 3JCF = 4.5, C-5), 161.2 (d, 1JCF = 245.5, C-3), 173.5 (C-1). F
(282 MHz, CDCl3) -113.8 (ddd, 4JHF = 6.2, 3JHF = 9.3, 3JHF = 9.3, 1F, Ar-F). νmax
2948, 1740, 1620, 1592, 1492, 1452, 1254 cm-1. m/z (ES+): Calcd. for C17H22NFO3
[M]+: 307.1584, found 307.8809.
5.2.6 (rac)-p-Fluorolittorine ((RS)-p-fluorophenyllactoyltropine, 45g)1
OH
O
O
Me
N
F
45g
The procedure described in 5.2.4 was repeated with (RS)-o-fluorophenyllactic acid
(103m, 0.39 g, 2.1 mmol) and tropine (0.29 g, 2.1 mmol) to afford 45g a colourless
viscous oil (0.48 g, 48.1%). δH (300 MHz, CDCl3) 1.65 (d, 1H, 2JHH = 15.2, H-4a),
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1.68 (d, 1H, 2JHH = 15.2, H-2a), 1.74-1.83 (m, 2H, H-6a, H-7a), 1.96-2.09 (m, 2H, H-
6e, H-7e), 2.11-2.23 (m, 2H, H-2e, H-4e), 2.38 (s, 3H, -NMe), 2.94 (dd, 1H, 3JHH = 6.9,
2JHH = 14.0, H-3), 3.12 (dd, 1H, 3JHH = 4.7, 2JHH = 14.0, H-3), 3.07-3.16 (m, 3H, H-1,
H-5, H-3), 4.36 (dd, 1H, 3JHH = 4.7, 3JHH = 6.9, H-2), 5.07 (t, 1H, 3JHH = 5.3, H-3e),
6.99 (t, 2H, 3JHF, HH = 8.8, H-3, H-5), 7.21 (dd, 2H, 4JHF = 5.4, 3JHH = 8.7, H-2, H-
6). δC (75 MHz, CDCl3) 25.3 (C-6, C-7), 25.4 (C-6, C-7), 36.1 (C-4 or C-2), 36.2 (C-
2 or C-4), 39.7 (C-3), 40.1 (NMe), 59.7 (C-2, C-5), 68.9 (C-3), 71.4 (C-2), 115.2 (d,
2JCF = 21.4, C-3, C-5), 130.9 (d, 3JCF = 7.8, C-2, C-6), 132.2 (d, 4JCF = 3.2, C-1),
162.7 (d, 1JCF = 244.9, C-4), 173.2 (C-1). δF (CDCl3, 283 MHz) -116.6 (dddd, 4JHF =
5.4, 4JHF = 5.4, 3JHF = 8.7, 3JHF = 8.7, 1F, Ar-F). νmax (KBr) 2944, 1730, 1601, 1508,
1448, 1418, 1218 cm-1. m/z (ES+): Calcd. for C17H22NFO3 [M]+: 307.1584, found
307.8727.
5.2.7 Methyl-(RS)-p-fluorophenyllactate 124a
Conc. HCl (0.1 ml, 1.20 mmol) was added to a solution of (RS)-p-fluorophenyllactic
acid 103m (50 mg, 0.27 mmol) in toluene (5 ml) and MeOH (10 ml) and the reaction
mixture was brought to reflux. After 4 h the reaction mixture was neutralised with 5%
NaHCO3 and the mixture was extracted into DCM (310 ml). The combined organic
phases were washed with water, brine, dried over MgSO4, and filtered. The solvents
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were removed under reduced pressure to yield 124a as white solid (50 mg, 93.4%).
Mp 53-54 ˚C. H (300 MHz, CDCl3) 2.95 (dd, 3JHH = 6.6, 2JHH = 14.0, 1H, H-3), 3.12
(dd, 1H, 3JHH = 4.5, 2JHH = 14.0, H-3), 3.79 (s, 3H, -OMe), 4.44 (dd, 1H, 3JHH = 4.5,
3JHH = 6.6, H-2), 7.00 (dd, 2H, 3JHF = 8.7, 3JHH = 8.7, H-3, H-5), 7.19 (dd, 2H, 4JHF =
5.6, 3JHH = 8.6, H-2, H-6). C (75 MHz, CDCl3) 39.9 (C-3), 52.9 (-OMe), 71.6 (C-2),
115.63 (d, 2JCF = 21.2, C-3, C-5), 131.4 (d, 3JCF = 7.7, C-2, C-6), 132.6 (d, 4JCF =
3.2, C-1), 162.3 (d, 1JCF = 244.8, C-4), 174.9 (C-1). F (283 MHz, CDCl3) -116.6
(dddd, 4JHF = 5.5, 4JHF = 5.5, 3JHF = 8.8, 3JHF = 8.8, 1F, Ar-F). max (KBr) 3176, 1748,
1508, 1218, 1154, 503 cm-1.
5.2.8 (-)-Menthyl-(RS)-m-fluorophenyllactate 1312
The mixture of (RS)-m-fluorophenyllactic acid 103l (0.10 g, 0.5 mmol) and (-)-
menthol (0.12 g, 0.75 mmol) was heated at 120 ˚C under a periodically stream of dry 
HCl gas. After 6 h the reaction was cooled to ambient temperature, dissolved in ether
(20 ml), and washed with aq. Na2CO3 (5 ml). The ethereal phase was washed with
water (10 ml), brine, dried over MgSO4, filtered, and evaporated under reduced
pressure. The crude product was purified over silica gel eluting with
ether:cyclohexane (3:2) to afford a mixture of 1:1 diastereomers 131 as a white solid
(0.118 g, 73.2 %). H (300 MHz, MeOH-d4) 0.65 (d, 3H, 3JHH = 7.0, CH3CHCH3),
0.66 (d, 3H, 3JHH = 7.0, CH3CHCH3), 0.81 (d, 3H, 3JHH = 6.5, CH3CHCH3), 0.82 (d,
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3H, 3JHH = 6.5, CH3CHCH3), 0.84 (d, 3H, 3JHH = 7.0, -CHCH3), 0.85 (d, 3H, 3JHH =
7.0, -CHCH3), 0.80-0.95 (m, 6H, H-3a, H-4a, H-6a), 1.27-1.48 (m, 4H, H-2a, H-
5a), 1.57-1.76 (m, 6H, (CH3)2CH, H-3e, H-4e), 1.79-1.97 (m, 2H, H-26e), 2.83 (dd,
1H, 3JHH = 7.4, 2JHH = 14.1, H-3), 2.87 (dd, 1H, 3JHH = 7.0, 2JHH = 14.0, H-3), 3.05
(dd, 1H, 3JHH = 4.5, 2JHH = 14.0, H-3), 3.08 (dd, 1H, 3JHH = 4.3, 2JHH = 14.1, H-3),
4.30-4.37 (m, 2H, H-2), 4.68 (dt, 2H, 3JHH = 4.7, 3JHH = 10.9, H-1), 6.84 (dd, 2H,
4JHH = 2.6, 3JHF, HH = 8.6, H-4), 6.91 (dd, 2H, 4JHH = 2.3, 3JHF = 9.6, H-2), 6.96 (d,
2H, 3JHH = 7.6, H-6), 7.18 (dt, 2H, 4JHF = 2.7, 3JHH = 8.6, H-5). C (75 MHz, CDCl3)
15.8, 16.9, (CH3CHCH3), 20.7, 20.8 (CH3CHCH3), 21.9 (CH3CH-), 22.9, 23.3 (C-3),
25.9, 26.2 (CH3CHCH3), 31.4 (C-5), 34.0 (C-4), 40.0, 40.1 (C-3), 40.6, 40.8 (C-6),
46.8, 46.9 (C-2), 70.7 (C-2), 71.2 (C-2), 76.3 (C-1), 76.5 (C-1), 113.7 (d, 2JCF =
21.3, C-4), 116.3 (d, 2JCF = 16.9, C-2), 116.6 (d, 2JCF = 16.9, C-2), 125.1 (d, 4JCF =
2.9, C-6), 125.3 (d, 4JCF = 2.9, C-6), 129.6 (d, 3JCF = 7.9, C-5), 129.7 (d, 3JCF = 7.9,
C-5), 141.7 (d, 3JCF = 7.6, C-1), 164.1 (d, 1JCF = 243.2, C-3), 173.6 (C-1), 173.7 (C-
1). F (283 MHz, CDCl3) -113.9 (ddd, 4JHF = 6.2, 3JHF = 9.5, 3JHF = 9.5, 1F, Ar-F), -
114.2 (ddd, 4JHF = 6.2, 3JHF = 9.5, 3JHF = 9.5, 1F, Ar-F). max (KBr) 3478, 2955, 1724,
1616, 1588, 1209, 1152 cm-1. m/z (ES+) 345.14 [M+Na]+ (100%).
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5.2.9 α-Acetyl-(-)-menthyl–(RS)-m-fluorophenyllactate 131a
Acetic anhydride (0.2 ml, 0.21 mmol) was added to a solution of (-)-menthyl-(RS)-m-
fluorophenyllactate 131 (50 mg, 0.15 mmol) in dry pyridine (0.5 ml, mmol) at 0 ˚C. 
The reaction mixture was then warmed to ambient temperature. After being left
overnight, MeOH (3 ml) was added the reaction mixture and was evaporated under
reduced pressure. The residue was dissolved in 1 M HCl (5 ml) and the mixture was
extracted into DCM (310 ml). The combined organic phases were washed with
water, brine, dried over MgSO4, and filtered. The solvents were removed under
reduced pressure to afford a mixture of diastereomers 131a as colourless oil (50 mg,
88.5%). H (300 MHz, CDCl3) 0.62 (d, 3H, 3J = 7.0, CH3CHCH3), 0.66 (d, 3H, 3J =
7.0, CH3CHCH3), 0.78 (d, 3H, 3J = 7.0, CH3CHCH3), 0.79 (d, 3H, 3J = 7.0,
CH3CHCH3), 0.82 (d, 3H, 3J = 6.5, -CHCH3), 0.83 (d, 3H, 3J = 6.5, -CHCH3), 0.86-
1.04 (m, 6H, H-3a, H-4a, H-6a), 1.23-1.46 (m, 4H, H-2a,H-5a), 1.54-1.65 (m, 4H,
H-3e, H-4e), 1.67-1.75 (m, 2H, (CH3)2CH), 1.76-1.94 (m, 2H, H-6e), 2.01 (s, 3H,
COCH3), 2.02 (s, 3H, COCH3), 2.96-3.12 (m, 4H, H-3), 4.59 (dd, 1H, 3JHH = 4.4, 3JHH
= 6.9, H-2), 4.66 (dd, 1H, 3JHH = 4.4, 3JHH = 6.9, H-2), 5.09 (m, 2H, H-1), 6.83-6.93
(m, 4H, H-2, H-4), 6.95 (d, 2H, 3JHH = 7.8, H-6), 7.18 (m, 2H, H-5). C (75 MHz,
CDCl3) 15.8, 16.3 (CH3CHCH3), 20.5, 20.6 (O=CCH3), 20.6, 20.8 (CH3CHCH3), 21.9
(CH3CH-), 23.2, 23.4 (C-3), 25.9, 26.1 (CH3CHCH3), 31.3, 31.4 (C-5), 34.1 (C-4),
36.9 (C-3), 40.4, 40.5 (C-6), 46.8, 46.9 (C-2), 72.7, 72.9 (C-2), 77.0, 77.5 (C-1),
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113.9 (d, 2JCF = 20.9, C-4), 116.3, 116.4 (d, 2JCF = 21.5, C-2), 125.0, 125.1 (d, 4JCF =
2.8, C-6), 129.8, 129.9 (d, 3JCF = 8.3, C-5), 138.4, 138.5 (d, 3JCF = 2.0, C-1), 162.7
(d, 1JCF = 245.7, C-3), 162.8 (d, 1JCF = 246.1, C-3), 169.0, 169.1 (C-1), 170.2, 170.3
(C-1). F (283 MHz, CDCl3) -113.7 (ddd, 4JHF = 6.0, 3JHF = 9.3, 3JHF = 9.3, 1F, Ar-F),
-113.9 (ddd, 4JHF = 6.2, 3JHF = 9.3, 3JHF = 9.3, 1F, Ar-F). max (KBr) 2956, 1746,
1590, 1452, 1371, 1213 cm-1. m/z (ES+) 428.25 [M+Na+ACN] (100%); m/z (ES-)
225.03 (M-menthyl) (100%)
5.2.10 (S)-Camphanoyl-methyl-(RS)-p-fluorophenyllactate 133
O
O
F
O
O
O
O
133
2'
3'
4'
1
2
3
1"
2"
3"4"5"
6"
7"
9"
10"
11"
8"
A solution of (RS)-methyl-p-fluorophenyllactate 124a (0.1g, 0.5 mmol) in dry
pyridine (0.32 ml, 4 mmol) was slowly added to a solution of (S)-(-)-camphanoyl
chloride (0.11 g, 0.5 mmol) in dry DCM (10 ml) at 0 ˚C. The progress of the reaction 
was monitored by TLC. After completion, the reaction mixture was diluted with DCM
(10 ml), washed successively with 1 M HCl, then washed with water and sat.
NaHCO3. The organic phase was dried over MgSO4, filtered, and evaporated under
reduced pressure. The crude product was purified over silica gel eluting with
EtOAc:hexane (1:4) to afford a mixture of diastereoisomers 133 as colourless oil
(0.17g, 90.2%). H (300 MHz, CDCl3) 0.86 (s, 3H, H-10 or H-11), 0.92 (s, 6H, H-
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10or H-11), 1.03 (s, 3H, H-10or H-11), 1.09 (s, 6H, H-9), 1.66 (m, 2H, H-5e),
1.84-2.02 (m, 4H, H-4a, H-5a), 2.43-2.27 (m, 2H, H-4e), 3.10 (dd, 3JHH = 4.2, 2JHH
= 14.4, 1H, H-3), 3.13 (dd, 3JHH = 4.0, 2JHH = 14.4, 1H, H-3), 3.24 (dd, 3JHH = 3.5,
2JHH = 14.4, 1H, H-3), 3.73 (s, 3H, OCH3), 3.74 (s, 3H, OCH3), 5.32 (m, 2H, H-2),
6.97 (t, 3JHF = 8.6, 3JHH = 8.6, 2H, H-3, H-5), 7.19 (ddd, 4JHF = 5.5, 3JHH = 8.6, 2H,
H-2, H-6). C (75 MHz, CDCl3) 10.0, 10.1, (C-9), 16.5, 16.8, 16.9, (C-10, C-11),
29.1, 29.4, (C-5), 30.8, 30.9 (C-4), 36.6, 36.7 (C-3), 52.8, 52.9 (OCH3), 54.8, 54.9
(C-7), 55.2, 55.4 (C-6), 73.8, 73.9 (C-2), 91.1, 91.2 (C-3), 115.8 (d, 2JCF = 21.4, C-
3, C-5), 131.4 (d, 3JCF = 8.1, C-2, C-6), 162.5 (d, 1JCF = 245.4, C-4), 167.0, 167.4,
(C-8), 169.3, 169.4 (C-1), 178.6, 178.3 (C-1). F (283 MHz, CDCl3) -115.9 (dddd,
4JHF = 5.3, 4JHF = 5.3, 3JHF = 8.7, 3JHF = 8.7, 1F, Ar-F), -115.8 (dddd, 4JHF = 5.5, 4JHF =
5.5, 3JHF = 8.7, 3JHF = 8.7, 1F, Ar-F). max (KBr) 2967, 1789, 1752, 1603, 1510,1222
and 1159 cm-1. m/z (ESI+) 401.08 [M+Na] (100%).
5.2.11 α-Acetyl-methyl-D-phenylalanyl-(RS)-p-fluorophenyllactamide 146
D-phenylalanine methyl ester hydrochloride (45 mg, 0.21 mmol), which was
neutralised with NMM (27 l) was added a solution of (RS)-α-acetyl-p-
fluorophenyllactic acid 103n (47 mg, 0.21 mmol) in DMF (2 ml). HOBt (71 mg, 0.53
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mmol) was then added and the reaction mixture was cooled to 0 ˚C. To this mixture, a 
solution of EDC (0.13 g, 0.69 mmol) in chloroform (3 ml) was slowly added. The
reaction mixture was warmed to ambient temperature. After being left stir overnight,
water (5 ml) was added and the mixtures were extracted into EtOAc (310 ml). The
combined organic phases were washed with 1 M HCl (210 ml), sat.NaHCO3 (210
ml), and brine. After drying over MgSO4 and filtered off, the solvents were
evaporated under reduced pressure. The residue was purified over silica gel eluting
with EtOAc:hexane (2:3) to give a mixture of diastereoisomers of 146 as colourless
viscous oil (61 mg, 74.8%); H (CDCl3, 300 MHz) 1.95 (s, 3H, O=CCH3), 1.96 (s,
3H, O=CCH3), 2.86-3.12 (m, 8H, H-3, H-3), 3.61 (s, 3H, OCH3), 3.64 (s, 3H,
OCH3), 4.74 (dd, 1H, 3J = 5.7, 3JHH = 8.0, H-2), 4.77 (dd, 1H, 3JHH = 5.7, 3JHH = 8.0,
H-2), 5.25 (dd, 1H, 3JHH = 4.8, 3JHH = 6.5, H-2), 5.27 (dd, 1H, 3JHH = 4.7, 3JHH = 7.2,
H-2), 6.29 (d, 1H, 3JHH = 8.0, NH), 6.37 (d, 1H, 3JHH = 8.0, NH), 6.79-7.19 (m, 18H,
Ar-H). C (CDCl3, 75 MHz) 20.6, 20.7 (O=CCH3), 36.6, 36.9 (C-3), 37.6, 38.0 (C-3),
52.3, 52.4 (OCH3), 52.5, 52.6 (C-2), 73.9, 74.0 (C-2), 115.2 (d, 2JCF = 21.2, C-3, C-
5), 127.2, 127.3 (C-4), 128.5, 128.6 (C-2, C-6), 129.2, 129.3 (C-3, C-5), 131.2,
131.9 (d, 3JCF = 7.9, C-2, C-6), 131.5, 131.4 (d, 3JCF = 3.3, C-1), 135.3 (C-1),
161.9, 162.0 (d, 1JCF = 245.1, C-4), 168.3, 168.6 (C=O), 169.2 (C=O), 171.4, 171.3
(C-1). F (CDCl3, 283 MHz) -116.4 (dddd, 4JHF = 5.4, 4JHF = 5.4, 3JHF = 8.6, 3JHF =
8.6, 1F, Ar-F), -116.2 (dddd, 4JHF = 5.3, 4JHF = 5.3, 3JHF = 8.6, 3JHF = 8.6, 1F, Ar-F).
max (neat): 3422, 3322, 1744, 1678, 1603, 1509, 1371, 1221, 702, 503 cm-1. HRMS
(ES+): Calcd. for C21H22FNO5Na+ [M+Na]+: 410.1380, found: 410.1369
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5.2.12 (S)-3-(2-Fluorophenyl)-2-hydroxyl-N-((S)-1-phenylethyl)
propanamide (S,S)-147 and (R)-3-(2-fluorophenyl)-2-hydroxyl-N-((S)-1-
phenylethyl)propanamide (R,S)-147
(S)-Phenylethylamine (0.72 ml, 5.3 mmol) and HOBt (1.8 g, 13.3 mmol) were added
to a solution of (RS)-o-fluorophenyllactic acid (0.98 g, 5.32 mmol) in DMF (3 ml) and
the reaction mixture was cooled to 0 ˚C. A solution of EDC (3.4 g, 17.7 mmol) in 
CHCl3 (5 ml) was slowly added. The reaction mixture was warmed to ambient
temperature and left stirring overnight. Water (10 ml) was added and the mixture was
extracted into EtOAc (3 20). The combined organic phases were washed with 1 M
HCl (210 ml), sat. aq. NaHCO3 (210 ml), brine, and dried over MgSO4. After
filtration, the solvents were removed under reduced pressure. The crude product was
purified over silica gel eluting with EtOAc:hexane (1:3) to afford (S,S)-147 as
colourless needles (0.67g, 44.3%) and (R,S)-147 as a white solid (0.61g, 39.7%).
(S,S)-147: Mp 71-72 C; [α]D20: -74.0˚ (c = 1.010-3, CHCl3); H (CDCl3, 300 MHz)
1.36 (d, 3JHH = 7.0, 3H, H-1), 2.92 (dd, 1H, 3JHH = 7.8, 2JHH = 14.2, H-3), 3.23 (dd,
1H, 3JHH = 4.4, 2JHH = 14.2, H-3), 4.29 (dd, 1H, 3JHH = 4.29, 3JHH = 7.8, H-3), 5.04
(quint, 1H, 3JHH = 7.0, H-2), 6.65 (d, 1H, 3JHH = 6.7, NH), 6.93-7.03 (m, 2H, Ar-H),
7.12-7.28 (m, 7H, Ar-H); C (CDCl3, 75 MHz) 21.7 (C-2), 34.3 (C-3), 48.5 (C-1),
72.0 (C-2), 115.8 (d, 3JCF = 22.2, C-3), 123.9 (d, 2JCF = 15.8, C-1), 124.3 (d, 3JCF =
8.1, C-4 or C-6), 126.2 (C-2, C-6), 127.4 (C-4), 128.6 (C-3, C-5), 128.7 (d,
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3JCF = 8.1, C-4 or C-6), 132.0 (d, 3JCF = 4.6, C-4 or C-6), 142.8 (C-1), 161.7 (d,
1JCF = 244.2, C-2), 171.4 (C-1); F (CDCl3, 283 MHz) -117.3 (ddd, 4JHF = 6.5, 4JHF =
6.5, 3JHF = 9.8, 1F, Ar-F); max (KBr): 3335, 2972, 1647, 1583, 1451, 1229, 1075, 758
cm-1. HRMS (ES+): Calcd. for: C17H18FNO2Na [M+Na]+: 310.1219, found 310.1222.
(R,S)-147: Mp 76-77 C; [α]D20: +14.0˚ (c = 2.010-3, CHCl3); H (CDCl3, 300 MHz)
1.36 (d, 3H, 3JHH = 7.0, H-1), 2.92 (dd, 1H, 3JHH = 7.8, 2JHH = 14.0, H-3), 3.23 (dd,
1H, 3JHH = 4.4, 2JHH = 14.2, H-3), 4.31 (t, 1H, 3JHH = 5.4, 3JHH = 7.8, H-3), 5.02
(quint, 1H, 3JHH = 7.1, H-2), 6.52 (d, 1H, 3JHH = 7.4, NH), 6.49-6.99 (m, 2H, Ar-H),
7.10-7.25 (m, 7H, Ar-H); C (CDCl3, 75 MHz) 21.8 (C-2), 34.3 (C-3), 48.5 (C-1),
72.1 (C-2), 115.4 (d, 3JCF = 22.2, C-3), 123.7 (d, 2JCF = 15.6, C-1), 124.4 (d, 3JCF =
3.3, C-5), 126.1 (C-2, C-6), 127.3 (C-4), 128.7 (C-3, C-5), 128.8 (d, 3JCF =
8.9, C-4 or C-6), 132.1 (d, 3JCF = 4.6, C-4 or C-6), 142.8 (C-1), 161.4 (d, 1JCF =
244.7, C-2), 171.4 (C-1). F (CDCl3, 283 MHz) -117.9 (ddd, 4JHF = 6.8, 4JHF = 6.8,
3JHF = 10.6, 1F, Ar-F). max (KBr): 3330, 2969, 1646, 1580, 1450, 1230, 1067, 755
cm-1. HRMS (ES+): Calcd. for C17H18FNO2Na [M+Na]+: 310.1219, found 310.1221.
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5.2.13 (S)-3-(3-Fluorophenyl)-2-hydroxyl-N-((S)-1-phenylethyl)
propanamide (S,S)-148 and (R)-3-(3-fluorophenyl)-2-hydroxyl-N-((S)-1-
phenylethyl)propanamide (R,S)-148
The same procedure as described in 5.2.12 was repeated with (RS)-m-
fluorophenyllactic acid 103l to yield (S,S)-148 as viscous oil (46.8%) and (R,S)-148 as
white solid (44.1%).
(S,S)-148: [α]D20: -93.88˚ (c = 4.9010-3, CHCl3); H (CDCl3, 300 MHz) 1.32 (d, 3H,
3JHH = 6.9, H-1), 2.85 (dd, 1H, 3JHH = 7.7, 2JHH = 13.9, H-3), 3.09 (dd, 1H, 3JHH =
4.1, 2JHH = 13.9, H-3), 4.19 (dd, 1H, 3JHH = 4.1, 3JHH = 7.7, H-3), 4.99 (quint, 1H, 3JHH
= 7.0, H-2), 6.66 (d, 1H, 3JHH = 7.9, NH), 6.84-6.93 (m, 3H, Ar-H), 7.14-7.27 (m,
6H, Ar-H). C (CDCl3, 75 MHz) 22.1 (C-2), 40.8 (C-3), 48.9 (C-1), 72.8 (C-2),
114.1 (d, 2JCF = 21.0, C-4), 117.0 (d, 2JCF = 21.3, C-2), 125.7 (d, 4JCF = 2.7, C-6),
126.5 (C-2, C-6), 127.8 (C-4), 129.1 (C-3, C-5), 130.3 (d, 3JCF = 8.2, C-5),
139.8 (d, 3JCF = 7.3, C-1), 143.1 (C-1), 163.2 (d, 1JCF = 246.5, C-4), 172.0 (C-1). F
(CDCl3, 283 MHz) -113.5 (ddd, 4JHF = 6.0, 3JHF = 9.1, 3JHF = 9.1, 1F, Ar-F). max
(KBr): 3393, 3263, 1645, 1586, 1483, 1190, 1080, 765 cm-1. HRMS (ES+): Calcd.
for: C17H18FNO2Na [M+Na]+: 310.1219, found 310.1210.
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(R,S)-148: Mp 110- 111 C. [α]D20 : +16.47˚ (c = 1.0510-3, CHCl3). H (CDCl3, 300
MHz) 1.32 (d, 3H, 3JHH = 6.9, H-1), 2.84 (dd, 1H, 3JHH = 7.6, 2JHH = 14.0, H-3), 3.07
(dd, 3JHH = 4.3, 1H, 2JHH = 14.0, H-3), 4.23 (dd, 3JHH = 4.3, 3JHH = 7.6, 1H, H-3), 5.00
(quint, 1H, 3JHH = 7.0, H-2), 6.68 (d, 1H, 3JHH = 7.4, NH), 6.83-6.90 (m, 3H, Ar-H),
7.08-7.27 (m, 6H, Ar-H). C (CDCl3, 75 MHz) 22.1 (C-2), 40.8 (C-3), 48.9 (C-1),
72.7 (C-2), 114.0 (d, 2JCF = 21.1, C-4), 117.0 (d, 2JCF = 21.2, C-2), 125.6 (d, 4JCF =
2.7, C-6), 126.5 (C-2, C-6), 127.8 (C-4), 129.1 (C-3, C-5), 130.1 (d, 3JCF =
8.1, C-5), 139.8 (d, 3JCF = 7.8, C-1), 143.1 (C-1), 163.2 (d, 1JCF = 246.5, C-4),
172.0 (C-1). F (CDCl3, 283 MHz) -113.3 (ddd, 4JHF = 6.3, 3JHF = 9.1, 3JHF = 9.1, 1F,
Ar-F). max (KBr): 3393, 3263, 1647, 1586, 1487, 1187, 1086, 765 cm-1. HRMS
(ES+): Calcd. for: C17H18FNO2Na [M+Na]+: 310.1219, found 310.1218.
5.2.14 (S)-3-(4-Fluorophenyl)-2-hydroxyl-N-((S)-1-phenylethyl)
propanamide (S,S)-149 and (R)-3-(4-fluorophenyl)-2-hydroxyl-N-((S)-1-
phenylethyl)propanamide (R,S)-149
The same procedure as described in 5.2.12 was repeated with (RS)-p-
fluorophenyllactic acid 103m to yield (S,S)-149 as white solid (48.4%) and (R,S)-149
as white solid (36.6%).
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(S,S)-149: Mp 92.0-93.0 C; [α]D20: -101.6˚ (c = 1.2510-3, CHCl3). H (CDCl3, 300
MHz) 1.40 (d, 3H, 3JHH = 6.9, H-1), 2.92 (dd, 1H, 3JHH = 7.5, 2JHH = 14.0, H-3), 3.14
(dd, 1H, 3JHH = 4.1, 2JHH = 14.0, H-3), 4.24 (dd, 1H, 3JHH = 4.1, 3JHH = 7.5, H-3), 5.08
(quint, 1H, 3JHH = 7.2, H-2), 6.74 (d, 1H, 3JHH = 7.8, NH), 6.95-7.35 (m, 9H, Ar-H);
C (CDCl3, 75 MHz) 22.1 (C-2), 40.5 (C-3), 48.84 (C-1), 73.0 (C-2), 115.8 (d, 3JCF
= 21.2, C-3, C-5), 126.6 (C-2, C-6), 127.9 (C-4), 129.1 (C-3, C-5) 131.5 (d,
3JCF = 7.9, C-2, C-6), 132.7 (d, 4JCF = 3.2, C-1), 143.4 (C-1), 162.4 (d, 1JCF =
244.9, C-4), 171.6 (C-1). F (CDCl3, 283 MHz) -116.3 (dddd, 4JHF = 5.4, 4JHF = 5.4,
3JHF = 8.8, 3JHF = 8.8, 1F, Ar-F). max (KBr): 3392, 3208, 1643, 1535, 1214 cm-1;
HRMS (ES+): Calcd. for: C17H18FNO2Na [M+Na]+: 310.1219, found 310.1221.
(R,S)-149: Mp 116.0-117.5 C; [α]D20 : +11.43˚ (c = 1.0510-3, CHCl3); H (CDCl3,
300 MHz) 1.49 (d, 3H, 3JHH = 6.9, H-1), 2.98 (dd, 1H, 3JHH = 7.3, 2JHH = 14., H-3),
3.15 (dd, 1H, 3JHH = 4.5, 2JHH = 14.1, H-3), 4.34 (dd, 1H, 3JHH = 4.5, 3JHH = 7.3, H-3),
5.12 (quint, 1H, 3JHH = 7.4, H-2), 6.65 (d, 1H, 3JHH = 6.9, NH), 6.92-7.37 (m, 9H,
Ar-H). C (CDCl3, 75 MHz) 22.2 (C-2), 40.3 (C-3), 48.5 (C-1), 73.1 (C-2), 115.9 (d,
3JCF = 21.2, C-3, C-5), 126.5 (C-2, C-6), 127.8 (C-4), 129.1 (C-3, C-5),
131.6 (d, 3JCF = 8.1, C-2, C-6), 132.7 (d, 4JCF = 3.2, C-1), 143.4 (C-1), 162.4 (d,
1JCF = 244.7, C-4), 171.6 (C-1). F (CDCl3, 283 MHz) -116.3 (dddd, 4JHF = 5.4, 4JHF
= 5.4, 3JHF = 8.6, 3JHF = 8.6, 1F, Ar-F). max (KBr): 3390, 3210, 1644, 1535, 1211
cm-1. HRMS (ES+): Calcd. for: C17H18FNO2Na [M+Na]+: 310.1219, found 310.1219.
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5.2.15 (S)-o-Fluorophenyllactic acid (S)-103k
OH
OH
O
(S)-103k
F
A solution of (S)-3-(2-fluorophenyl)-2-hydroxyl-N-((S)-1-phenylethyl)propanamide
147 (0.49 g, 1.71 mmol) in 6 M HCl (20 ml) was refluxed for 24 h. The reaction
mixture was allowed to cool to ambient temperature, and then was extracted into ether
(3  30ml), washed with water (10 ml), brine (10 ml), dried over MgSO4, and filtered.
The solvent was removed under reduced pressure to give a white solid.
Recrystallisation from EtOAc/Hexane gave (S)-103k as a white solid (0.30 g, 93.7%).
Mp 76-77 C; [α]D20: -26.7˚ (c = 1.3010-3, CHCl3); H (400 MHz, MeOH-d4) 2.93
(dd, 1H, 2JHH = 8.5, 2JHH = 13.9, H-3), 3.19 (dd, 1H, 3JHH = 4.5, 2JHH = 13.9, H-3),
4.36 (dd, 1H, 3JHH = 4.5, 3JHH = 8.5, H-2), 7.02-7.13 (m, 2H, Ar-H), 7.21-7.36 (m, 2H,
Ar-H). C (CDCl3, 75 MHz) 34.9 (C-3), 71.6 (C-2), 116.0 (d, 2JCF = 22.4, C-3), 125.0
(d, 3JCF = 3.5, C-5), 125.8 (d, 2JCF = 15.7, C-1), 129.6 (d, 3JCF = 8.1, C-4 or C-6),
133.1 (d, 4JCF = 4.7, C-6 or C-4), 162.8 (d, 1JCF = 243.69, C-2), 176.9 (C-1). F
(CDCl3, 283 MHz) -120.5 (m, 1F, Ar-F). max (KBr): 3427, 2940, 1733, 1578, 1490,
1110, 1068, 760 cm-1. HRMS (ES+): Calcd. for: C9H8FO3 [M-H]+: 183.0457, found
183.0460.
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5.2.16 (R)-o-Fluorophenyllactic acid (R)-103k
The same procedure as described in 5.2.15 was repeated with (R)-3-(2-fluorophenyl)-
2-hydroxyl-N-((S)-1-phenylethyl)propanamide 147 to afford (R)-103k as a white solid
(93.7%). Mp 76-77 C; [α]D20 : +27.0˚ (c = 1.3510-3, CHCl3); H (MeOH-d4, 400
MHz) 2.92 (dd, 1H, 2JH,H = 8.4, 2JH,H = 14.0, H-3), 3.19 (dd, 1H, 3JH,H = 4.6, 2JH,H =
14.0, H-3), 4.36 (dd, 1H, 3JH,H = 4.6, 3JH,H = 8.4, H-2), 7.02-7.13 (m, 2H, Ar-H), 7.21-
7.36 (m, 2H, Ar-H); C (CDCl3, 75 MHz) 34.9 (C-3), 125.0 (d, 3JC,F = 3.6, C-5),
115.9 (d, 2JC,F = 22.6, C-3), 71.6 (C-2), 125.8 (d, 2JC,F = 15.8, C-1), 129.6 (d, 3JC,F =
8.2, C-4 or C-6), 133.1 (d, 4JC,F = 4.45, C-6 or C-4), 163.0 (d, 1JC,F = 243.7, C-2),
176.9 (C-1); F (CDCl3, 283 MHz) -120.5 (m, 1F, Ar-F); max (KBr): 3429, 2934,
1738, 1581, 1491, 1257, 1110, 1070, 760 cm-1; HRMS (ESI+): Calcd. for: C9H8FO3
[M-H]+: 183.0457, found 183.0457.
5.2.17 (S)-m-Fluorophenyllactic acid (S)-103l
The same procedure as described in 5.2.15 was repeated with (S)-3-(3-fluorophenyl)-
2-hydroxyl-N-((S)-1-phenylethyl)propanamide 148 to yield (S)-103l as a white solid
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(96.21%). Mp 89-90 C; [α]D20: -33.0˚ (c = 1.1510-3, CHCl3). H (400 MHz, MeOH-
d4) 2.92 (dd, 1H, 2JHH = 8.0, 2JHH = 13.9, H-3), 3.11 (dd, 1H, 3JHH = 4.3, 2JHH = 13.9,
H-3), 4.34 (dd, 1H, 3JHH = 4.3, 3JHH = 8.0, H-2), 6.93 (ddt, 1H, 4JHH = 0.8, 4JHH = 2.4,
3JHH = 9.16, 3JHF = 9.1, H-4), 7.02 (td, 1H, 4JHH = 2.4, 3JHF = 10.1, H-2), 7.08 (d, 1H,
3JHH = 7.9, H-6), 7.27 (dt, 1H, 4JHF = 6.1, 3JHH = 7.9, H-5). C (CDCl3, 75 MHz) 41.1
(C-3), 72.4 (C-2), 114.2 (d, 2JCF = 21.4, C-4), 117.3 (d, 2JCF = 21.3, C-2), 126.5 (d,
4JCF = 2.3, C-6), 130.8 (d, 3JCF = 8.3, C-5), 141.7 (d, 3JCF = 7.9, C-1), 164.1 (d, 1JCF
= 243.3, C-3), 176.8 (C-1). F (CDCl3, 283 MHz) -116.7 (ddd, 4JHF = 6.4, 3JHF = 9.6,
3JHF = 9.7, 1F, Ar-F). max (KBr): 3450, 2928, 1731, 1587, 1487, 1098, 801 cm-1.
HRMS (ES+): Calcd. for: C9H9FO3Na [M+Na]+: 207.0433, found 207.0432.
5.2.18 (R)-m-Fluorophenyllactic acid (R)-103l
The same procedure as described in 5.2.15 was repeated with (R)-3-(3-fluorophenyl)-
2-hydroxyl-N-((S)-1-phenylethyl)propanamide 148 to afford (R)-103l as white solid
(93.5 %). Mp 89-90 C; [α]D20: +33.0˚ (c = 1.1510-3, CHCl3). H (MeOH-d4, 400
MHz) 2.91 (dd, 1H, 2J(H,H) = 8.0, 2JH,H = 13.9, H-3), 3.11 (dd, 1H, 3JH,H = 4.3, 2JH,H =
13.9, H-3), 4.34 (dd, 1H, 3JH,H = 4.3, 3JH,H = 8.0, H-2), 6.93 (ddt, 1H, 4JH,H = 0.9, 4JH,H
= 2.3, 3JH,F; H,H = 9.0, H-4), 7.02 (td, 1H, 4JH,H = 2.3, 3JH,F = 10.2, H-2), 7.07 (d, 1H,
3JH,H = 7.7, H-6), 7.27 (dt, 1H, 4JH,F = 6.1, 3JH,H = 7.9, H-5); C (CDCl3, 75 MHz)
41.7 (C-3), 72.4 (C-2), 114.1 (d, 2JC,F = 21.5, C-4), 117.3 (d, 2JC,F = 21.4, C-2), 126.4
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(d, 4JC,F = 2.7, C-6), 130.8 (d, 3JC,F = 8.5, C-5), 141.7 (d, 3JC,F = 7.7, C-1), 164.1 (d,
1JC,F = 242.5, C-3), 176.8 (C-1); F (CDCl3, 283 MHz) -116.7 (ddd, 4JH,F = 6.3, 3JH,F
= 9.5, 9.5, 1F, Ar-F); max (KBr): 3445, 2926, 1731, 1587, 1488, 1096, 799 cm-1.
HRMS (ESI+): Calcd. for: C9H9FO3Na [M+Na]+: 207.0433, found 207.0430.
5.2.19 (S)-p-Fluorophenyllactic acid (S)-103m
The same procedure as described in 5.2.15 was repeated with (S)-3-(4-fluorophenyl)-
2-hydroxyl-N-((S)-1-phenylethyl)propanamide 149 to afford (S)-103m as a white
solid (93.60%). Mp 71-72 C; [α]D20: -35.6˚ (c = 1.3510-3, CHCl3). H (MeOH-d4,
400 MHz) 2.98 (dd, 1H, 2JH,H = 7.9 Hz, 2JH,H = 14.0, H-3), 3.08 (dd, 1H, 3JH,H = 4.4 ,
2JH,H = 14.0, H-3), 4.34 (dd, 1H, 3JH,H = 4.4, 3JH,H = 7.9, H-2), 6.99 (t, 2H, 3JH,F = 8.9,
3JH,H = 8.9, H-3, H-5), 7.28 (dd, 2H, 4JH,F = 5.5, 3JH,H = 8.8, H-2, H-6); C (CDCl3,
75 MHz) 42.1 (C-3), 73.0 (C-2), 116.2 (d, 2JC,F = 21.5, C-3, C-5), 135.2 (d, 4JC,F =
3.1, C-1), 132.7 (d, 3JC,F = 7.9, C-2, C-6), 163.6 (d, 1JC,F = 243.1, C-4), 177.4 (C-1);
F (CDCl3, 283 MHz) -116.3 (dddd, 4JH,F = 5.4, 5.4, 3JH,F = 9.0, 9.0, 1F, Ar-F); max
(KBr): 3474, 1737, 1508, 1240 cm-1. HRMS (ES+): Calcd. for: C9H9FO3Na
[M+Na]+: 207.0433, found 207.0437.
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5.2.20 (R)-p-Fluorophenyllactic acid (R)-103m
The same procedure as described in 5.2.15 was repeated with (R)-3-(4-fluorophenyl)-
2-hydroxyl-N-((S)-1-phenylethyl)propanamide 149 to afford (R)-103m as a white
solid (95.04 %). Mp 71-72 C; [α]D20 : +34.8˚ (c = 1.3510-3, CHCl3); H (MeOH-d4,
400 MHz) 7.28 (dd, 2H, 4JH,F = 5.5, 3JH,H = 8.7, H-2, H-6), 6.99 (t, 3JH,F = 8.9, 2H,
3JH,H = 8.9, H-3, H-5), 4.32 (dd, 1H, 3JH,H = 4.3, 3JH,H = 7.9, H-2), 3.08 (dd, 1H, 3JH,H
= 4.3, 2JH,H = 14.0, H-3), 2.90 (dd, 1H, 2JH,H = 7.9, 2JH,H = 14.0, H-3); C (CDCl3, 75
MHz) 40.1 (C-3), 73.0 (C-2), 116.2 (d, 2JC,F = 21.4, C-3, C-5), 132.7 (d, 3JC,F = 8.0,
C-2, C-6), 135.2 (d, 4JC,F = 3.0, C-1), 163.6 (d, 1JC,F = 243.9, C-4), 177.4 (C-1); F
(CDCl3, 283 MHz) -119.7 (dddd, 4JH,F = 5.8, 5.8, 3JH,F = 9.6, 9.6, 1F, Ar-F); max
(KBr): 3473, 1735, 1506, 1240 cm-1; HRMS (ESI+): Calcd. for: C9H9FO3Na
[M+Na]+: 207.0433, found 207.0434.
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5.2.21 (S)-o-Fluorolittorine (S)-45e
OH
O
OF
Me
N
1
2
356
7
1'
2'
3'2"
3"
4"
5"
(S)-45e
Dry (S)-o-fluorophenyllactic acid 103k (0.18 g, 0.98 mmol) and tropine (0.17 g, 1.17
mmol) were mixed intimately under nitrogen in the solid phase. The mixture was
heated to 130˚C and a current of dry HCl gas was passed periodically over the reaction
for 4 h and the reaction was allowed to cool to room temperature. The product was
dissolved in 50 mM H2SO4 as much as possible and filtered. The filtrate was treated
with 10% aqueous ammonium hydroxide until it was basic. The organics were
extracted into chloroform (3 x 15 ml), dried over MgSO4, and evaporated to give pale
yellow oil. The product was purified over silica gel eluting with EtOH:CHCl3:
35%NH3 (7:7:0.2) to afford (S)-45e as a white solid (0.15 g, 49.8 %). Mp 75-76 C;
[α]D
20: -9.39˚ (c = 3.3  10-3, CHCl3); H (CDCl3, 400 MHz) 1.51 (d, 1H, 2JH,H = 15.0,
H-4a), 1.62 (d, 1H, 2JH,H = 15.6, H-2a), 1.68-1.79 (m, 2H, H-6a, H-7a), 1.83-1.95 (m,
2H, H-6e, H-7e), 2.16 (s, 3H, NMe), 1.99-2.10 (m, 2H, H-2e, H-4e), 2.91 (dd, 1H, 3JH,H
= 7.6, 2JH,H = 14.1, H-3), 2.95-3.04 (m, 2H, H-1, H-5), 3.10 (dd, 1H, 3JH,H = 5.2, 2JH,H
= 14.0, H-3), 4.13 (br, OH), 4.30 (dd, 1H, 3JH,H = 5.2, 3JH,H = 7.6, H-2), 4.96 (t, 1H,
3JH,H = 5.3, H-3e), 6.91-7.03 (m, 2H, Ar-H), 7.11-7.23 (m, 2H, Ar-H); C (CDCl3, 75
MHz) 25.3 (C-7 or C-6), 25.5 (C-6 or C-7), 34.1 (C-3), 36.1(C-2 or C-4), 36.4 (C-4
or C-2), 40.7 (NMe), 59.6 (C-1, C-5), 69.1 (C-3), 70.4 (C-2), 115.2 (d, 2JC,F = 22.0,
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C-3), 123.8 (d, 3JC,F = 15.6, C-1), 124.0 (d, 3JC,F = 3.3, C-5), 128.6 (d, 3JC,F = 8.1,
C-6, C-4), 131.9 (d, 3JC,F = 4.4, C-4 or C-6), 161.3 (d, 1JC,F = 245.4, C-2), 173.4
(C-1); F (CDCl3, 282 MHz) -118.3 (m, 1F, Ar-F); max (KBr): 2963, 1734, 1580,
1490, 1110, 1029, 749 cm-1; HRMS (ESI+): Calcd. for: C17H23NFO3 [M+H]+:
308.1662, found 308.1657.
5.2.22 (R)-o-Fluorolittorine (R)-45e
OH
O
OF
Me
N
(R)-45e
The same procedure as described in 5.2.21 was repeated with (R)-o-fluorophenyllactic
acid 103k to obtain (R)-45e as a white solid (51.4 %). Mp 75-76 C; [α]D20: +8.98˚ (c
= 3.4510-3, CHCl3); δH (CDCl3, 400 MHz) 1.53 (d, 1H, 2JH,H = 15.1, H-4a), 1.65 (d,
1H, 2JH,H = 15.8, H-2a), 1.72-1.83 (m, 2H, H-6a, H-7a), 1.87-1.99 (m, 2H, H-6e, H-7e),
2.02-2.13 (m, 2H, H-2e, H-4e), 2.19 (s, 3H, NMe), 2.95 (dd, 1H, 3JH,H = 7.4, 2JH,H =
13.8, H-3), 2.99-3.07 (br, 2H, H-1, H-5), 3.14 (dd, 1H, 3JH,H = 5.2, 2JH,H = 13.8, H-3),
4.27 (br, OH), 4.33 (dd, 1H, 3JH,H = 5.2, 3JH,H = 7.4, H-2), 4.99 (t, 1H, 3JH,H = 4.9, H-
3e), 6.96-7.06 (m, 2H, Ar-H), 7.15-7.24 (m, 2H, Ar-H); δC (CDCl3, 75 MHz) 25.3 (C-
7 or C-6), 25.5 (C-6 or C-7), 34.1 (C-3), 36.1 (C-2 or C-4), 36.4 (C-4 or C-2), 40.2
(NMe), 59.6 (C-1, C-5), 69.0 (C-3), 70.4 (C-2), 115.2 (d, 2JC,F = 22.2, C-3), 123.4
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(d, 3JC,F = 15.8, C-1), 124.0 (d, 3JC,F = 3.6, C-5), 128.6 (d, 3JC,F = 8.1, C-6, C-4),
131.9 (d, 3JC,F = 4.5, C-4 or C-6), 161.2 (d, 1JC,F = 244.7, C-2), 173.4 (C-1); δC
(CDCl3, 283 MHz) -118.3 (m, 1F, Ar-F); max (KBr): 2963, 1734, 1580, 1488, 1113,
1029, 752 cm-1; HRMS (ES+): Calcd. for: C17H23NFO3 [M+H]+: 308.1662, found
308.1655.
5.2.23 (S)-m-Fluorolittorine (S)-45f
OH
O
O
Me
N
(S)-45f
F
The same procedure as described in 5.2.21 was repeated with (S)-m-
fluorophenyllactic acid 103l to obtain (S)-45f as a white solid (42.5%). Mp 83-83 C;
[α]D
20: -16.08˚ (c = 2.3  10-3, CHCl3); H (CDCl3, 300 MHz) 1.57 (d, 2H, 2JH,H =
16.1, H-2a, H-4a), 1.68-1.75 (m, 2H, H-6a, H-7a), 1.86-1.99 (m, 2H, H-6e, H-7e), 2.05-
2.17 (m, 2H, H-2e, H-4e), 2.20 (s, 3H, NMe), 2.88 (dd, 1H, 3JH,H = 7.2, 2JH,H = 14.0,
H-3), 3.03 (dd, 1H, 3JH,H = 4.8, 2JH,H = 14.0, H-3), 3.03-3.108 (br, 2H, H-1, H-5),
4.28 (dd, 1H, 3JH,H = 4.8, 3JH,H = 7.2, H-2), 4.34 (br, OH), 4.97 (t, 1H, 3JH,H = 5.2, H-
3e), 6.28-6.92 (m, 2H, H-2, H-4), 6.94 (d, 1H, 3JH,F = 7.7, H-6), 7.18 (dt, 1H, 4JH,F
= 6.2, 3JH,H = 7.8, H-5); C (CDCl3, 75 MHz) 25.7 (C-7 or C-6), 25.8 (C-6 or C-7),
36.6 (C-2 or C-4), 36.7 (C-4 or C-2), 40.5 (C-3, NMe), 60.0 (C-1, C-5), 69.4 (C-3),
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71.6 (C-2), 114.1 (d, 2JC,F = 21.0, C-4), 116.7 (d, 2JC,F = 21.5, C-2), 125.5 (d, 4JC,F =
2.7, C-6), 130.2 (d, 3JC,F = 8.3, C-5), 139.5 (d, 3JC,F = 7.4, C-1), 163.1 (d, 1JC,F =
245.8, C-2), 173.5 (C-1); F (CDCl3, 283 MHz) -113.8 (ddd, 4JH,F = 6.1, 3JH,F = 9.2,
9.2, 1F, Ar-F); max (KBr): 2929, 1728, 1583, 1485, 1197, 1032, 693 cm-1; HRMS
(ES+): Calcd. for: C17H23NFO3 [M+H]+: 308.1662, found 308.1657.
5.2.24 (R)-m-Fluorolittorine (R)-45f
OH
O
O
Me
N
(R)-45f
F
The same procedure as described in 5.2.21 was repeated with (R)-m-
fluorophenyllactic acid 103l to obtain (R)-45f as a white solid (31.9%). Mp 76-77 C;
[α]D
20: +16.08˚ (c = 2.310-3, CHCl3); δH (CDCl3, 300 MHz) 1.59 (d, 2H, 2JH,H = 16.2,
H-2a, H-4a), 1.70-1.77 (m, 2H, H-6a, H-7a), 1.90-1.99 (m, 2H, H-6e, H-7e), 2.12-2.21
(m, 2H, H-2e, H-4e), 2.23 (s, 3H, NMe), 2.87 (dd, 1H, 3JH,H = 7.2, 2JH,H = 14.0, H-3),
3.04 (dd, 1H, 3JH,H = 4.8, 2JH,H = 14.0, H-3), 3.06-3.13 (br, 2H, H-1, H-5), 4.29 (dd,
1H, 3JH,H = 4.83 Hz, 3JH,H = 7.2, H-2), 4.79 (br, OH), 4.98 (t, 1H, 3JH,H = 5.2, H-3e),
6.83-6.91 (m, 2H, H-2, H-4), 6.94 (d, 1H, 3JH,F = 8.6, H-6), 7.18 (dt, 1H, 4JH,F =
6.2, 3JH,H = 7.9, H-5); δC (CDCl3, 75 MHz) 25.7 (C-7 or C-6), 25.8 (C-6 or C-7), 36.4
(C-2 or C-4), 36.5 (C-4 or C-2), 40.4 (C-3), 40.5 (NMe), 60.1 (C-1, C-5), 69.3 (C-3),
71.6 (C-2), 114.1 (d, 2JC,F = 21.1, C-4), 116.8 (d, 2JC,F = 21.5, C-2), 125.5 (d, 4JC,F =
2.7, C-6), 130.2 (d, 3JC,F = 8.3, C-5), 139.5 (d, 3JC,F = 7.5, C-1), 163.1 (d, 1JC,F =
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245.6, C-2), 173.5 (C-1); δF (CDCl3, 283 MHz) -113.8 (ddd, 4JH,F = 6.2, 3JH,F = 9.3,
9.3, 1F, Ar-F); max (KBr): 2952, 1728, 1586, 1485, 1197, 1029, 693 cm-1; HRMS
(ESI+): Calcd. for: C17H23NFO3 [M+H]+: 308.1662, found 308.1661.
5.2.25 (S)-p-Fluorolittorine (S)-45g
OH
O
O
Me
N
(S)-45g
F
The same procedure as described in 5.2.21 was repeated with (S)-p-fluorophenyllactic
acid 103m to obtain (S)-45g as a white solid (41.7 %). Mp 93-94 C; [α]D20: -15.2˚ (c
= 1.2510-3, CHCl3); δH (CDCl3, 400 MHz) 1.57 (d, 3JH,H = 13.5, 2H, H-2a, H-4a),
1.66-1.76 (m, 2H, H-6a, H-7a), 1.88-1.99 (m, 2H, H-6e, H-7e), 2.04-2.13 (m, 2H, H-2e,
H-4e), 2.19 (s, 3H, NMe), 2.87 (dd, 3JH,H = 7.1, 2JH,H = 14.0, 1H, H-3), 2.99-3.06 (m,
3H, H-1, H-5, H-3), 4.27 (dd, 3JH,H = 4.1, 3JH,H = 7.1, 1H, H-2), 4.97 (t, 3JH,H = 5.3,
1H, H-3e), 6.91 (t, 3JH,F; H,H = 8.7, 2H, H-3, H-5), 7.13 (dd, 4JH,F = 5.5, 3JH,H = 8.5,
2H, H-2, H-6); δC (CDCl3, 75 MHz) 25.9 (C-6, C-7), 36.8 (C-4 or C-2), 36.9 (C-2
or C-4), 40.0 (C-3), 40.7 (NMe), 60.0 (C-2, C-5), 69.7 (C-3), 71.8 (C-2), 115.6 (d,
2JC,F = 21.3, C-3, C-5), 131.3 (d, 3JC,F = 7.9, C-2, C-6), 132.6 (d, 4JC,F = 3.0, C-
1), 162.3 (d, 1JC,F = 244.7, C-4), 173.7 (C-1); δF (CDCl3, 283 MHz) -116.6 (dddd,
4JH,F = 5.7, 5.7, 3JH,F = 8.9, 8.9, 1F, Ar-F); max (KBr): 2946, 1730, 1597, 1508, 1328,
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1197, 1032 cm-1; HRMS (ESI+): Calcd. for: C17H23FO3N [M+H]+: 308.1662, found
308.1660.
5.2.26 (R)-p-Fluorolittorine (R)-45g
OH
O
O
Me
N
(R)-45g
F
The same procedure as described in 5.2.21 was repeated with (R)-m-
fluorophenyllactic acid 103m to obtain (R)-45g as a white solid (43.2 %). Mp 82-84
C; [α]D
20: +15.2˚ (c = 1.2510-3, CHCl3); δH (CDCl3, 400 MHz) 1.57 (d, 2H, 3JH,H =
14.8, H-2a, H-4a), 1.68-1.75 (m, 2H, H-6a, H-7a), 1.86-1.97 (m, 2H, H-6e, H-7e), 2.06-
2.15 (m, 2H, H-2e, H-4e), 2.19 (s, 3H, NMe), 2.86 (dd, 1H, 3JH,H = 7.1, 2JH,H = 14.0,
H-3), 3.01 (dd, 1H, 3JH,H = 4.8, 2JH,H = 14.0, H-3), 3.02-3.08 (m, 2H, H-1, H-5), 4.26
(dd, 1H, 3JH,H = 4.8, 3JH,H = 7.1, H-2), 4.96 (t, 1H, 3JH,H = 5.3, H-3e), 6.91 (t, 2H, 3JH,F;
H,H = 8.7, H-3, H-5), 7.13 (dd, 2H, 4JH,F = 5.5, 3JH,H = 8.6, H-2, H-6); δC (CDCl3,
75 MHz) 25.8 (C-7, C-6), 25.9 (C-6, C-7), 36.7 (C-4 or C-2), 36.8 (C-2 or C-4), 40.1
(C-3), 40.6 (NMe), 60.0 (C-2, C-5), 69.5 (C-3), 71.9 (C-2), 115.6 (d, 2JC,F = 21.2, C-
3, C-5), 131.3 (d, 3JC,F = 7.9, C-2, C-6), 132.8 (d, 4JC,F = 3.2, C-1), 162.3 (d, 1JC,F
= 244.8, C-4), 173.7 (C-1); δF (CDCl3, 283 MHz) -116.6 (dddd, 4JH,F = 5.4, 5.4, 3JH,F
= 8.8, 8.8, 1F, Ar-F); max (KBr): 2950, 1730, 1599, 1328, 1197, 1033 cm-1; HRMS
(ES+): Calcd. for: C17H23FO3N [M+H]+: 308.1662, found 308.1654.
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5.2.27 (2S,2S)-[3,3-2H2]-3-Phenyl-2-hydroxyl-N-(1-phenylethyl)
propanamide (S,S)-154 and (2R,2S)-[3,3-2H2]-3-phenyl-2-hydroxyl-
N-(1-phenylethyl) propanamide (R,S)-154
A solution of phenylpyruvic acid 104 (1 g, 6.09 mmol) in D2O (30 ml) was adjusted
to pH 11 with K2CO3 and left at 4 ˚C for 48 h. After acidification with D2SO4, the
reaction mixture was extracted into ether (330 ml). The combined organic extracts
were dried over MgSO4, filtered and evaporated under reduced pressure to yield
[3,3-2H2]-phenylpyruvic acid. The crude product was then dissolved in MeOD (10 ml)
at 0 ˚C and a solution of NaBH4 (1.73 g, 40.2 mmol) in D2O (15 ml) and 1M KOD
(10 ml) was added dropwise, maintaining temperature below 5 ˚C during the addition. 
The reaction was then allowed to warm to ambient temperature and left to stir
overnight. Methanol was evaporated, the residue dissolved in 10% HCl and the
solution extracted into ether (330 ml). The combined organic extracts were dried
over MgSO4, filtered and evaporated under reduced pressure to yield crude (rac)-[3,3-
2H2]-phenyllactic acid 104a. This product was then coupled with (S)-
phenylethylamine 145 using the same procedure as described for the preparation of
(S,S)-147 in 5.2.12 to give (S,S)-154 as a viscous oil (0.23 g, 13.9%, 3 steps) and
separately (R,S)-154 as a white solid (0.19 g, 12%, 3 steps).
(S,S)-154: [α]D20: -88.9˚ (c = 4.0510-3, CHCl3); δH (CDCl3, 300 MHz) 1.28 (d, 3H,
3JH,H = 6.9, H-1), 4.13 (s, 1H, H-2), 4.96 (quint, 1H, 3JH,H = 7.1, H-2), 6.73 (d, 1H,
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3JH,H = 7.7, NH), 7.10-7.22 (m, 10H, Ar-H); δC (CDCl3, 75 MHz) 22.8 (C-2), 40.1
(m, C-3), 48.5 (C-1), 72.7 (C-2), 126.2, 126.9, 127.4, 128.6, 128.7, 129.7 (Ar-C),
136.8 (C-1 or C-1), 142.8 (C-1 or C-1), 172.1 (C-1); max (KBr): 3397, 3193,
1644, 1538, 1104, 697 cm-1; HRMS (ESI+): Calcd. for: C17H17D2FNO2Na [M+Na]+:
294.1439, found 294.1435.
(R,S)-154: Mp 116.0-117.5 C; [α]D20: +16.4˚ (c = 1.4010-3, CHCl3); δH (CDCl3, 300
MHz) 1.47 (d, 3H, 3JH,H = 7.0, H-1), 3.17-3.28 (br, -OH), 4.30 (s, 1H, H-2), 5.10
(quint, 1H, 3JH,H = 6.9, H-2), 6.83 (d, 1H, 3JH,H = 7.9, NH), 7.18-7.34 (m, 10H, Ar-
H); δC (CDCl3, 75 MHz) 21.8 (C-2), 40.1 (m, C-3), 48.4 (C-1), 72.6 (C-2), 126.1,
126.9, 127.3, 128.6, 128.7, 129.7 (Ar-C), 136.7 (C-1 or C-1), 142.8 (C-1 or C-1),
171.9 (C-1); max (KBr): 3397, 3195, 1644, 1538, 1104, 697 cm-1; HRMS (ESI+):
Calcd. for: C17H17D2FNO2Na [M+Na]+: 294.1439, found 294.1433.
5.2.28 (S)-[3,3-2H2]-Phenyllactic acid (S)-103i
The same procedure as described in 5.2.15 was repeated with (S)-[3,3-2H2]-3-phenyl-
2-hydroxyl-N-((S)-1-phenylethyl))propanamide 154 to afford (S)-103i as colourless
needles (95.5%). Mp 118-119 ˚C; [α]D
20: -39.0˚ (c 1.0510-3, CHCl3); δH (MeOH-d4,
400 MHz) 4.33 (s, 1H, H-2), 7.21 (m, 1H, Ar-H), 7.26-7.29 (m, 4H, Ar-H); δC
(CDCl3, 75 MHz) 39.5 (quint, 1JC,D = 19.1, C -3), 71.3 (C-2), 126.1 127.8, 129.1, (Ar-
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C), 137.4 (C-1), 175.7 (C-1); max (KBr): 3447, 2644, 1731, 1490, 1110, 700 cm-1;
HRMS (ES+): Calcd. for: C9H8D2O3Na [M+Na]+: 191.0653, found 191.0657.
5.2.29 (R)-[3,3-2H2]-Phenyllactic acid (R)-103i
The same procedure as described in 5.2.15 was repeated with (R)-[3,3-2H2]-3-phenyl-
2-hydroxyl-N-((S)-1-phenylethyl))propanamide 154 to afford (R)-103i as colourless
needles (95.5%). Mp 118-119 ˚C. [α]D
20: -39.0˚ (c 1.0510-3, CHCl3). δH (MeOH-d4,
400 MHz) 4.33 (s, 1H, H-2), 7.21 (m, 1H, Ar-H), 7.26-7.29 (m, 4H, Ar-H). δC
(CDCl3, 75 MHz) 39.5 (qt, 1JCD = 19.1, C -3), 71.3 (C-2), 112.6, 127.8, 129.1 (Ar-C),
137.4 (C-1), 175.7 (C-1). max (KBr): 3447, 2644, 1731, 1490, 1110, 700 cm-1.
HRMS (ES+): Calcd. for C9H8D2O3Na+ [M+Na]+: 191.0653, found: 191.0657.
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5.2.30 (S)-[3,3-2H2]-Littorine (S)-45h
OH
O
O
Me
N
D D
(S)-45h
The same procedure as described in 5.2.21 was repeated with (S)-[3,3-2H2]-
phenyllactic acid 103i to obtain (S)-45h as white solid (39.54%). Mp 116-117 C;
[α]D
20: -8.6˚ (c = 2.310-3, CHCl3); δH (CDCl3, 300 MHz) 1.53 (d, 1H, 2JH,H = 15.3,
H-4a), 1.59 (d, 1H, 2JH,H = 15.5, H-2a), 1.68-1.73 (m, 2H, H-6a, H-7a), 1.88-1.94 (m,
2H, H-6e, H-7e), 2.06-2.14 (m, 2H, H-2e, H-4e), 2.20 (s, 3H, NMe), 3.01-3.07 (br, 2H,
H-1, H-5), 4.29 (s, 1H, H-2), 4.97 (t, 1H, 3JH,H = 5.3, H-3e), 7.15-7.18 (m, 3H, Ar-H),
7.20-7.24 (m, 2H, Ar-H); δC (CDCl3, 75 MHz) 25.4 (C-7 or C-6), 25.5 (C-6 or C-7),
36.1 (C-2 or C-4), 36.2 (C-4 or C-2), 40.1 (NMe), 40.1 (C-3), 59.6 (C-1, C-5), 68.9
(C-3), 71.5 (C-2), 126.9, 128.5, 129.4, (Ar-C), 136.4 (C-1), 173.4 (C-1); max
(KBr): 2952, 1731, 1580, 1172, 738 cm-1. HRMS (ES+): Calcd. for: C17H22D2NO3
[M+H]+: 292.1882, found 292.1880.
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5.2.31 (R)-[3,3-2H2]-Littorine (R)-45h
OH
O
O
Me
N
D D
(R)-45h
The same procedure as described in 5.2.21 was repeated with (R)-[3,3-2H2]-
phenyllactic acid 103i to obtain (R)-45h as white solid (41.2%). Mp 116.0-117.5 C;
[α]D
20: +8.60˚ (c = 2.310-3, CHCl3); δH (CDCl3, 300 MHz) 1.53 (d, 2JH,H = 15.2, 1H,
H-4a), 1.59 (d, 2JH,H = 15.3, 1H, H-2a), 1.68-1.73 (m, 2H, H-6a, H-7a), 1.88-1.94 (m,
2H, H-6e, H-7e), 2.06-2.14 (m, 2H, H-2e, H-4e), 2.20 (s, 3H, NMe), 3.02-3.07 (br, 2H,
H-1, H-5), 4.29 (s, 1H, H-2), 4.97 (t, 3JH,H = 5.3, 1H, H-3e), 7.14-7.18 (m, 3H, Ar-H),
7.20-7.24 (m, 2H, Ar-H); δC (CDCl3, 75 MHz) 25.3 (C-7 or C-6), 25.4 (C-6 or C-7),
36.1 (C-2 or C-4), 36.2 (C-4 or C-2), 40.1 (NMe), 40.1 (C-3), 59.8 (C-1, C-5), 68.9
(C-3), 71.5 (C-2), 126.9, 128.5, 129.5 (Ar-C), 136.3 (C-1), 173.4 (C-1); max (KBr):
2952, 1728, 1583, 1172, 735 cm-1. HRMS (ES+): Calcd. for: C17H22D2NO3 [M+H]+:
292.1882, found 292.1881.
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5.2.32 Enzymatic resolution of fluorophenyllactic acids3
To a 250 ml Erlenmeyer flasks was added (RS)-α-acetyl-m-fluorophenyllactic acid
103o (0.1 g, 0.44 mmol), acetone (20 ml), and phosphate buffer (pH 7.5, 35 ml, 50
mmol). Porcine pancreatic lipase (EC 3.1.1.3, Sigma type II, crude) was then added
and the flask was shaken at 30 ˚C and 150 rpm and the progress of the reaction was 
monitored every 6 h by TLC (50% EtOAc/hexane) and 1H NMR. After 24 h, the
content of the flask then transferred to a centrifuge tube. After centrifugation, the
solvent was removed under reduced pressure and the residue was acidified with 3 M
HCl to pH 1-2. The reaction mixture was extracted into DCM (220 ml). The
combined organic phases were dried over MgSO4, filtered, and the solvents were
removed under reduced pressure. The product was purified over silica gel eluting with
a gradient of 0-10% MeOH/DCM to afford (R)-α-acetyl-m-fluorophenyllactic acid
(R)-103o as oil (34.5%) and (S)-m-fluorophenyllactic acid 103l as colourless needles
(28.9%).
(R)-103o: [α]D20: +10.0˚ (c = 11 10-3, CHCl3). H 2.02 (s, 3H, CH3CO), 3.04 (dd, 1H,
2JHH = 8.8, 2JHH = 14.4, H-3), 3.16 (dd, 1H, 3JHH = 4.29, 2JHH = 14.4, H-3), 5.17 (dd,
1H, 3JHH = 4.3, 3JHH = 8.8, H-2), 6.84-6.92 (m, 2H, H-2, H-4), 6.95 (d, 1H, 3JHH =
7.9, H-6),7.17-7.24 (m, 1H, H-5); C (CDCl3, 75 MHz) 20.5 (CH3C=O), 36.7 (C-3),
72.1 (C-2), 114.2 (d, 2JCF = 21.0, C-4), 116.3 (d, 2JCF = 21.3, C-2), 124.9 (d, 4JCF =
2.7, C-6), 130.1 (d, 3JCF = 8.4, C-5), 138.1 (d, 3JCF = 7.5, C-1), 162.8 (d, 1JCF =
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246.2, C-3), 170.3 (C-1), 174.8 (CH3C=O); F (CDCl3, 283 MHz) -113.6 (ddd, 4JHF =
6.1, 3JHF = 9.0, 3JHF = 9.0, 1F, Ar-F). max (KBr): 2921, 1735, 1588, 1214, 1152 cm-1.
HRMS (ES+): Calcd. for: C9H9FO3Na+ [M+Na]+: 207.0433, found: 207.0432.
(S)-103l: Mp 101-102 C. [α]D20: -40.0˚ (c = 1.3510-3, CHCl3). H (CDCl3, 300 MHz)
3.01 (dd, 1H, 2JHH = 7.0, 2JHH = 14.1, H-3). 3.21 (dd, 1H, 3JHH = 4.3, 2JHH = 14.1, H-
3), 4.54 (dd, 1H, 3JHH = 4.3, 3JHH = 7.0, H-2), 6.94-7.02 (m, 2H, H-2, H-4)7.04 (d,
1H, 3JHH = 7.7, H-6), 7.25-7.32 (m, 1H, H-5); C (CDCl3, 75 MHz) 40.2 (C-3), 71.9
(C-2), 114.5 (d, 2JCF = 21.1, C-4), 116.9 (d, 2JCF = 21.3, C-2), 125.6 (d, 4JCF = 2.9, C-
6), 130.4 (d, 3JCF = 8.3, C-5), 141.5 (d, 3JCF = 7.9, C-1), 164.1 (d, 1JCF = 243.7, C-
3), 177.5 (C-1); F (CDCl3, 283 MHz) -113.5 (ddd, 4JHF = 6.1, 3JHF = 9.4, 3JHF = 9.4,
1F, Ar-F). max (KBr): 3457, 2926, 1732, 1587, 1487, 1098, 801 cm-1. HRMS (ES+):
Calcd. for: C9H9FO3Na+ [M+Na]+: 207.0433, found: 207.0432.
5.2.33 (R)-2-Acetoxy-3-(3-fluorophenyl)-2-hydroxyl-N-((S)-1-
phenylethyl)propanamide (R,S)-148a
The procedure described in Section 5.2.12 was repeated with (R)-2-acetoxy-m-
fluorophenyllactic acid ((R)-103o) (29.6 mg, 0.13 mmol) to obtain (R,S)-148a as
colourless needles (39.8 mg, 90.7%). [α]D
20: +16.5˚ (c = 1.0510-3, CHCl3). H
(CDCl3, 300 MHz) 1.35 (d, 3H, 3J = 6.9, H-1), 2.02 (s, 3H, CH3C=O), 3.10 (d, 2H,
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3JHH = 5.6, H-3), 5.02 (qt, 1H, 3JHH = 7.4, H-2), 5.32 (t, 1H, 3JHH = 5.6, H-2), 6.05 (d,
1H, 3JHH = 7.79, NH), 6.75-6.89 (m, 3H, Ar-H),7.01-7.27 (m, 6H, Ar-H); C (CDCl3,
75 MHz) 21.4 (CH3C=O), 21.8 (C-1), 37.6 (C-3), 48.9 (C-2), 74.4 (C-2), 114.3 (d,
2JCF = 20.8, C-4), 117.0 (d, 2JCF = 21.3, C-2), 125.8 (d, 4JCF = 2.8, C-6), 126.5 (C-
2, C-6), 127.8 (C-4), 129.1 (C-3, C-5), 130.3 (d, 3JCF = 8.3, C-5), 138.6 (d,
3JCF = 7.7, C-1), 142.7 (C-1), 163.1 (d, 1JCF = 245.7, C-4), 168.0 (CH3C=O),169.8
(C-1); F (CDCl3, 283 MHz) -113.7 (ddd, 4JHF = 6.0, 3JHF = 9.1, 3JHF = 9.1, 1F, Ar-F).
max (KBr): 3393, 3263, 1647, 1586, 1487, 1187, 1086, 765 cm-1. HRMS (ES+):
Calcd. for: C17H18FNO2Na+ [M+Na]+: 310.1219, found: 310.1218.
223
5.3 Synthetic experiments for Chapter 3
5.3.1 2,3-O-Isopropylidene-D-ribono-1,4-lactone 1844
A catalytic amount of concentrated sulfuric acid was added to a suspension of
D-ribono--1,4-lactone 176 (2.92 g, 19.75 mmol) in acetone (100 ml) at 0 ˚C. After 
warming to ambient temperature the reaction was stirred for further 4 h. NH3 was
slowly added until the solution was neutralised, and the precipitate resultant was then
filtered off. Recrystallisation of the prodcut from benzene yielded 184 as colourless
needles (3.19 g, 86%); Mp: 136-137 ˚C. (lit.4 138-139 ˚C), [α]D
20: -62.3º (c 0.05,
acetone) (lit.1 [α]20D: -84.2 (c 0.9, acetone); δH (Acetone-d6, 400 MHz) 1.35 (s, 3H,
CH3), 1.39 (s, 3H, CH3), 3.83 (m, 2H, H-5), 4.59 (t, 1H, 3JHH = 2.3, H -4), 4.77 (d, 1H,
3JHH = 5.6, H-3), 4.85 (d, 1H, 3JHH = 5.6, H-2). δC (100 MHz; Acetone-D6) 25.5
(CH3), 27.1 (CH3), 62.1 (C-5), 79.3 (C-4), 83.1 (C-2), 76.4 (C-3), 112.9 (C(CH3)2),
206.3 (C-1). max (KBr): 3460, 1771, 1201, 1088, 968 cm-1. m/z (ES+) 210.99
[M+Na] (100%).
224
5.3.2 5-Deoxy-5-fluoro-2,3-O-isopropylidene-D-ribono-1,4-lactone 1855
O
F
O
O O
185
Deoxo-Fluor (3.06 ml, 16.58 mmol) was slowly added to a stirred solution of 2,3-O-
isopropylidene-D-ribono-1,4-lactone 184 (1.04 g, 5.53 mmol) in DCM (10 ml) at
ambient temperature. After stirring at 40 ˚C for 30 min, the reaction mixture was
cooled down to ambient temperature and silica gel (0.5 g) was carefully added. After
removal of the solvent, the silica gel was applied to a silica gel eluting with
EtOAc:hexane (1:3) to afford 185 as white solid (0.88 g, 84%); Mp: 60-62 ˚C; [α] D20:
-82.8˚ (c 5.010-3, CHCl3). δH (CDCl3, 400 MHz) 1.39 (s, 3H, CH3), 1.48 (s, 3H,
CH3), 4.67 (ddd, 1H, 3JHH = 1.9, 2JHH = 11.0, 2JHF = 46.1, H-5), 4.72 (dddd, 1H, 3JHH =
1.7, 3JHH = 1.7, 3JHH = 1.7, 3JHF = 34.57, H-4), 4.74 (ddd, 1H, 3JHH = 1.8, 2JHH = 11.0,
2JHF = 48.1, H-5), 4.81 (dd, 1H, 3JHH = 3.3, 3JHH = 5.6, H-3), 4.85 (d, 1H, 3JHH = 5.7,
H-2); δC (CDCl3, 100 MHz;) 25.5 (CH3), 26.8 (CH3), 75.1 (d, 4JCF = 3.9, C-2), 77.2
(d, 3JCF = 5.1, C-3), 80.3 (d, 2JCF = 19.2, C-4), 82.2 (d, 1JCF = 171.3, C-5), 113.9
(C(CH3)2), 173.6 (C-1); δF (282 MHz, CDCl3) -236.0 (ddd, 3JHF = 3.3, 2JHF = 34.8,
2JHF = 46.3). max (KBr): 3563, 2993, 1804, 1455, 1384, 1272, 1054, 849, 610, 513.
HRMS (ES+): Calcd. for: C8H11FO4Na+ [M+Na]+: 213.0539, found: 231.0537.
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5.3.3 5-Deoxy-5-fluoro-2,3-O-isopropylidene-D-ribofuranose 177 and
(2S,3S,4S)-5-fluoro-2,3-(O-isopropylidenedioxy)pentan-1,4-diol 186
5.3.3.1 Synthesis with NaBH4
NaBH4 (11.18 mg, 0.3 mmol) was added to a vigorously stirred solution of 5-fluoro-
2,3-O-isopropylidene-D-ribono-1,4-lactone 185 (22.5 mg, 0.12 mmol) in absolute
ethanol (3 ml) at 0 ˚C. After stirring for 2 h, excess AcOH was added, and the 
volatiles were evaporated under reduced pressure. The residue was dissolved in
EtOAc (20 ml), the solution was washed with H2O, dried over Mg2SO4, After removal
of solvent, the residue was purified over silica gel eluting with EtOAc:cyclohexane
(1:4) to afford 186 as colourless oil (14.97 mg, 65.3%). [α] D20: +19.6˚ (c 4.5510-3,
CHCl3). δH (CDCl3, 400 MHz;) 1.35 (s, 3H, CH3), 1.41 (s, 3H, CH3), 3.73 (dd, 1H,
3JHH = 4.7, 2JHH = 11.6, H-1), 3.81 (dd, 1H, 3JHH = 3.8, 2JHH = 11.6, H-1), 3.96 (dddd,
3JHH = 2.3, 3JHH = 5.5, 3JHH = 9.7, 3JHF = 21.7, H-4), 4.07 (dd, 3JHH = 5.8, 3JHH = 9.7,
H-3), 4.29 (dddd, 1H, 3JHH = 5.3, 3JHH = 5.3, 3JHH = 7.6, 3JHH = 9.7, H-2), 4.48 (ddd,
1H, 3JHH = 5.5, 2JHH = 9.7, 2JHF = 47.5, H-5), 4.60 (ddd, 1H, 3JHH = 2.3, 2JHH = 9.7,
2JHF = 49.8, H-5); δC (100 MHz; CDCl3) 25.5 (CH3), 26.8 (CH3), 61.1 (C-1), 69.2 (d,
2JCF = 17.7, C-4), 75.8 (d, 3JCF = 6.7, C-3), 77.5 (C-2), 85.5 (d, 1JCF = 163.8, C-5),
109.5 (C(CH3)2); δF (282 MHz; CDCl3) -236.5 (ddd, 3JHF = 22.1, 2JHF = 47.4, 2JHF =
47.4). max (neat): 3384, 2988, 1373, 1043, 874, 507. HRMS (ES+): Calcd. for:
C8H15FO4Na+ [M+Na]+: 217.0852, found: 217.0848.
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5.3.3.2 Synthesis with DIBAL-H6
A solution of DIBAL-H (1 M in hexane, 2.20 ml, 2.18 mmol) was carefully added to
a solution of 5-deoxy-5-fluoro-2,3-O-isopropylidene-D-ribono-1,4-lactone 185 (0.42
g, 2.18 mmol) in dry toluene (10 ml) at 40 ˚C and the reaction was monitored by 19F
NMR. After completion, MeOH (2 ml) was added. The slurry gel was broken by
adding sat. aq. solution of sodium potassium tartrate (1 ml). After extracted into ether
(310 ml), the combined organic phases were washed with brine and dried over
MgSO4. After removal of solvent under reduced pressure the residue was purified
over silica gel eluting with 60% EtOAc/hexane to afford 177 as colourless oil (0.26 g,
/;7.6/1, 63.6%) and 186 (25.4 mg, 6.0%) .
177: δH (CDCl3, 300 MHz), -anomer: 1.27 (s, CH3), 1.43 (s, CH3), 3.27 (t, 3JHH =
5.17, -OH), 4.31-4.41 (m, 2H, H-4, H-5, (overlap with , H-4, H-5)), 4.44-4.61 (m,
2H, H-3, H-5 (overlap with , H-3, H-5)), 4.71 (d, 3JHH = 5.9, H-2), 5.38 (dd, 1H, 3JHH
= 2.5, 3JHH = 5.3, H-1); δC (CDCl3, 75 MHz) 24.9 (CH3), 26.5 (CH3), 81.2 (d, 3JCF =
5.5, C-4), 82.2 (d, 1JCF = 171.3, C-5), 84.8 (C-3 or C-2), 86.1 (C-2 or C-3), 103.3 (C-
1), 112.7 (C(CH3)2). δF (CDCl3, 282 MHz) -230.8 (dddd, 4JHF = 3.3, 3JHF = 37.5, 2JHF
= 47.3, 2JHF = 47.3, 1F).
- anomer: 1.50 (s, CH3), 1.33 (s, CH3), 3.93 (d, 3JHH = 10.9, -OH), 4.31-4.41 (m, 2H,
H-4, H-5, (overlap with , H-4, H-5)), 4.44-4.61 (m, 2H, H-3, H-5 (overlap with ,
H-3, H-5)), 4.74 (ddd, 1H, 3JHH = 0.8, 3JHH = 1.5, 3JHH = 6.4, H-4), 5.33 (ddd, 1H, 3JHH
= 3.7, 3JHH = 3.7, 3JHH = 10.9, H-1); δC (CDCl3, 75 MHz) 24.7 (CH3), 26.1 (CH3), 79.5
(C-2), 79.6 (d, 2JCF = 17.8, C-4), 80.7 (d, 3JCF = 6.7, C-3), 85.1 (d, 1J = 170.5, C-5),
97.7 (C-1), 114.2 (C(CH3)2). δF (CDCl3, 283 MHz) -225.4 (dddd, 4JHF = 3.2, 3JHF =
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23.1, 2JHF = 46.5, 2JHF = 46.5, 1F). max (neat): 3426, 2944, 1376, 1211, 1072, 868,
504. HRMS (ES+): Calcd. for: C8H13FO4Na+ [M+Na]+: 215.0696, found: 215.0691.
5.3.4 5-Deoxy-5-fluoro-1-deoxy-2,3-O-isopropylidene-1-(dimethoxyphosphinyl)-
D-ribofuranose 1787
A 50% aq.NaOH solution (3 ml) was slowly added to a vigorously stirring mixture of
5-deoxy-5-fluoro-2,3-O-isopropylidene-D-ribofuranose 177 (0.125 g, 0.63 mmol) and
tetramethyl methylenediphosphonate (0.16 g, 0.69 mmol) in DCM (3 ml) at ambient
temperature. After 18 h, the reaction mixture was diluted with DCM (10 ml) and the
aq. phase was extracted with DCM (210 ml). The combined organic phases were
dried over MgSO4, and filtered. After removal of solvent, the residue was purified
over silica gel eluting with 5% MeOH:DCM to afford a mixture of epimers 7 as
colourless oil (0.11 g, /; 3.2/1, 58.5%).
δH (CDCl3, 400 MHz) 1.19 (C(CH3)2), 1.33 (C(CH3)2), 1.95-2.20 (m, 2H, H-1), 3.58-
3.63 (m, POCH3), 3.95-4.69 (m, 6H); δP (CDCl3, 162 MHz) 30.3-31.1 (m, P), 31.7-
32.4 (m, P); δF (CDCl3, 283 MHz) -231.1 (ddd, 3J = 28.90, 2J = 47.32, 2J = 47.32,
1F), -229.3 (dddd, 4J = 2.26, 3J = 32.94, 2J = 47.29, 2J = 47.29, 1F). max(neat):
3466, 2955, 1644, 1459, 1374, 1213, 1023, 822, 537 HRMS (ES+): Calcd. for:
C11H20O4FPNa [M+Na]+: 321.0879, found: 321.0874.
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5.3.5 2,3-O-Isopropylidene-D-ribofuranose 189
Catalytic amount of concentrated sulfuric acid was added to a suspension of
D-ribonolactone 179 (2.92 g, 19.75 mmol) in acetone (100 ml) at 0 ºC. After warming
to ambient temperature the reaction was stirred for a further 4 h. 35% NH3 was then
slowly added until the solution was neutralised. The resultant precipitate was then
filtered off. Recrystallisation of the solid from toluene yielded 189 as colourless
needle (3.19 g, 86%); Mp: 136-137 °C. (lit.1 138-139 °C), [α]D20: -62.3° (c 0.05,
acetone) (lit.1 [α]20D -84.2° (c 0.9, acetone); δH (Acetone-d6, 400 MHz) 1.35 (s, 3H,
CH3), 1.39 (s, 3 H, CH3), 3.83 (d, 2H, 3JHH = 2.1, H-5), 4.59 (t, 1H, 3JHH = 2.3, H-4),
4.77 (d, 1 H, 3JHH = 5.6, H-3), 4.85 (d, 1H, 3JHH = 5.6, H-2); δC (Acetone-d6, 100
MHz) 25.5 (CH3), 27.1 (CH3), 62.1 (C-5), 76.4 (C-3), 79.3 (C-4), 83.1 (C-2), 112.9
(CMe2), 206.3 (C-1). max 3445, 2986, 1372, 1212, m/z (ES+) 322.12 [M+H] (40%).
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5.3.6 2,3-O-Isopropylidene-5-O-trityl-D-ribofuranose 180
O
O
OH
O O
180
Trityl chloride (3.67 g, 13.14 mmol) was added portionwise to a solution of 2,3-O-
isopropylidene-D-ribofuranose 189 (2.50 g, 13.14 mmol) in triethylamine (3.67 ml,
26.28 mmol). A catalytic amount of DMAP was then added. After stirring overnight,
water (20 ml) was added and the mixture was extracted with EtOAc (3  20 ml). The
combined organic extracts were washed with water and brine and then dried over
MgSO4. After removal of the solvent, the residue was purified over silica gel eluting
with EtOAc:hexane (1:4) to afford 180 as viscous oil (5.30g, 93.6%, /; 1/4.3).
-anomer: δH (CDCl3, 300 MHz) 1.29 (s, CH3),1.48 (s, CH3), 2.94 (dd,1H, 3JHH =
2.8, 2JHH = 10.2, H-5), 3.38 (dd, 1H, 3JHH = 3.1, 2JHH = 10.2, H-5), 3.93 (d, 1H, 3JHH =
11.3, -OH), 4.12 (t, 1H, 3JHH = 2.6, H-4), 4.51 (dd, 1H, 3JHH = 0.9, 3JHH = 6.3, H-3),
4.67 (dd, 1H, 3JHH = 4.1, 3JHH = 6.3, H-2), 5.67 (dd, 1H, 3JHH = 4.1, 3JHH = 11.3, H-1),
7.17-7.35 (m, 15H, Ar-H, overlap with -anomer); C (CDCl3, 75 MHz) 25.2 (CH3),
26.6 (CH3), 65.8 (C-5), 79.9 (C-3), 82.6 (C-4), 86.5 (C-2), 98.5 (C-1), 113.5
(C(CH3)2), 127.6 (Ar-C), 128.4 (Ar-C), 129.0 (Ar-C), 143.9 (Ar-Cquat).
-anomer: δH (CDCl3, 300 MHz) 1.28 (s, CH3), 1.41 (s, CH3), 3.27 (dd, 1H, 3JHH =
3.8, 2JHH = 10.4, H-5), 3.35 (dd, 1H, 3JHH = 3.5, 2JHH = 10.4, H-5), 3.86 (d, 1H, 3JHH =
9.1, -OH), 4.28 (t, 1H, 3JHH = 3.5, H-4), 4.59 (d, 1H, 3JHH = 5.9, H-3), 4.71 (dd, 1H,
3JHH = 0.6, 3JHH = 5.9, H-2), 5.26 (d, 1H, 3JHH = 9.1, H-1), 7.17-7.35 (m, 15H, Ar-H,
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overlap with -anomer); C (CDCl3, 75 MHz) 25.5 (CH3), 26.9 (CH3), 65.5 (C-5),
80.5 (C-3), 82.4 (C-4), 87.5 (C-2), 103.9 (C-1), 112.7 (C(CH3)2), 127.9 (Ar-C), 128.5
(Ar-C), 129.1 (Ar-C), 143.2 (Ar-Cquat). max(neat): 3439, 3058, 2339, 1569, 1491,
1448, 1374, 1212, 1072, 870, 705, 648. m/z (ES+) 455.06 [M+Na] (40%); 243.03
[Ph3C] (100%).
5.3.7 2,5-Anhydro-1-deoxy-2,3-O-isopropylidene-1-(dimethoxyphosphinyl)-5-O-
trityl-D-altritol 181a and D-allitol 181b7
The same procedure as described for preparation of 7 was repeated with 2,3-O-
isopropylidene-5-O-trityl-D-ribofuranose 180 (2.1g, 5 mmol). After chromatographic
separation, 181a (1.36g, 50.64%) and 181b (0.32 g, 13.39%) were obtained as viscous
colourless oil.
181a: [α]D20: +2.9˚ (c = 11.4510-3, CHCl3), δH (CDCl3, 300 MHz) 1.35 (s, 3H, CH3),
1.51 (s, 3H, CH3), 2.26 (ddd, 1H, 3JHH = 7.0, 2JHH = 15.5, 2JHP = 17.6, H-1), 2.36 (ddd,
1H, 3JHH = 6.2, 2JHH = 15.5, 2JHP = 18.5, H-1), 3.15 (dd, 1H, 3JHH = 4.8, 2JHH = 10.1,
H-6), 3.28 (dd, 1H, 3JHH = 4.2, 2JHH = 10.1, H-6), 3.75 (d, 3H, 3JHP = 3.8, POCH3),
3.79 (d, 3H, 3JHP = 3.8, POCH3), 4.23 (t, 1H, 3JHH = 4.4, H-5), 4.57 (dddd, 1H, 3JHH =
3.8, 3JHH = 6.4, 3JHH = 6.4, 3JHP = 10.1, H-2), 4.69 (d, 3JHH = 6.0, 1H, H-4), 4.76 (dd,
3JHH = 3.9, 3JHH = 6.0, 1H, H-3), 7.23-7.28 (m, 3H, Ar-H), 7.30-7.36 (m, 6H, Ar-H),
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7.41-7.46 (m, 6H, Ar-H); δC (CDCl3, 75 MHz) 25.6 (CH3), 26.1 (d, 1JPC = 141.2, C-
1), 27.0 (CH3), 52.6 (d, 2JCP = 6.3, OCH3), 53.2 (d, 2JCP = 6.3, OCH3), 64.8 (C-6) 77.1
(C-3)), 82.4 (d, 2JCP = 8.3, C-2), 83.7 (C-4), 83.8 (C-5), 112.8 (C(CH3)2), 127.5 (Ar-
C), 128.3 (Ar-C), 129.0 (Ar-C), 143.9 (Ar-C); δP (CDCl3, 121 MHz) 32.3-33.0 (m, P).
max(neat): 2949, 1489, 1447, 1371, 1209, 1029, 705, 503. HRMS (ES+): Calcd. for:
C30H35O7PNa+ [M+Na]+: 561.2018, found: 561.2021.
181b: [α]D20: -8.3˚ (c = 12.8510-3, CHCl3), δH (CDCl3, 300 MHz) 1.35 (s, 3H, CH3),
1.55 (s, 3H, CH3), 2.16 (ddd, 1H, 3JHH = 7.7, 2JHH = 15.3, 2JHP = 17.8, H-1), 2.24 (ddd,
1H, 3JHH = 5.6, 2JHH = 15.3, 2JHP = 19.1, H-1), 3.19 (dd, 1H, 3JHH = 4.8, 2JHH = 11.1,
H-6), 3.33 (dd, 1H, 3JHH = 3.7, 2JHH = 11.0, H-6) 3.74 (d, 3H, 3JHP = 11.0, POCH3),
3.78 (d, 3H, 3JHP = 11.0, POCH3), 4.20 (dd, 1H, 3JHH = 3.4, 3JHH = 8.3, H-5), 4.26
(dddd, 1H, 3JHH = 5.3, 3JHH = 5.3, 3JHH = 7.7, 3JHP = 10.3, H-2), 4.54 (dd, 1H, 3JHH =
5.1, 3JHH = 6.6, H-3), 4.62 (dd, 3JHH = 3.5, 3JHH = 6.6, 1H, H-4), 7.22-7.28 (m, 3H, Ar-
H), 7.28-7.35 (m, 6H, Ar-H), 7.44-7.48 (m, 6H, Ar-H); δC (CDCl3, 75 MHz) 26.1
(CH3), 27.1 (CH3), 30.4 (d, 1JCP = 141.1, C-1), 52.7 (d, 2JCP = 6.4, OCH3), 53.1 (d, 2JCP
= 6.4, OCH3), 64.7 (C-6), 79.9 (d, 2JCP = 3.6, C-3), 82.7 (C-4), 83.9 (C-5), 85.7 (d,
2JCP = 12.6, C-2), 114.9 (C(CH3)2), 127.5 (Ar-C), 128.3 (Ar-C), 129.1 (Ar-C), 144.1
(Ar-C); δP (CDCl3, 121 MHz) 30.6-31.7 (m, P). max(neat): 2955, 1486, 1442, 1374,
1211, 1032, 711, 513. HRMS (ES+): Calcd. for: C30H35O7PNa+ [M+Na]+: 561.2018,
found: 561.2018.
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5.3.8 2,5-Anhydro-1-deoxy-2,3-O-isopropylidene-1-(dimethoxyphosphinyl)-5-
O-D-altrohexitol 182a.8
Anhydrous ZnCl2 (3.1g, 22.6 mmol) was added portionwise to a solution of 181a
(1.22 g, 2.26 mmol) in DCM (40 ml) over 1 h. The reaction was monitored by TLC
until the starting material was consumed. After completion of the reaction, sat. NH4Cl
(10 ml) was added and the reaction mixture was extracted into DCM (310 ml). The
combined organic phases were washed with water and brine, and died over MgSO4.
After removal of solvent, the residue was purified over silica gel eluting with
MeOH:DCM (1:20) to afford 182a as viscous oil (0.53 g, 78.2%).
[α]D
20: +1.7˚ (c = 10.8510-3, CHCl3), δH (CDCl3, 400 MHz) 1.27 (s, 3H, CH3), 1.42
(s, 3H, CH3), 2.14 (ddd, 1H, 3JHH = 7.3, 2JHH = 15.5, 2JHP = 17.7, H-1), 2.18 (ddd, 1H,
3JHH = 6.2, 2JHH = 15.3, 2JHP = 18.5, H-1), 3.56 (d, 2H, 3JHH = 5.5, H-6), 3.68 (d, 3H,
3JHP = 10.9, POCH3), 3.70 (d, 3H, 3JHP = 10.9, POCH3), 4.06 (t, 1H, 3JHH = 5.2, H-5),
4.25 (dddd, 1H, 3JHH = 3.8, 3JHH = 6.5, 3JHH = 6.5, 3JHP = 10.1, H-2), 4.61 (dd, 3JHH =
3.7, 3JHH = 6.2, 1H, H-3), 4.65 (d, 3JHH = 6.2, 1H, H-4); δC (CDCl3, 100 MHz) 25.0
(CH3), 26.3 (d, 1JCP = 141.8, C-1), 26.4 (CH3), 52.2 (d, 2JPC = 6.5, OCH3), 52.9 (d, 2JPC
= 6.1, OCH3), 62.1 (C-6), 75.8 (C-2), 81.8 (d, 2JPC = 9.3, C-3), 82.7 (C-4), 84.7 (C-5),
112.5 (C(CH3)2); δP (CDCl3, 162 MHz) 31.5-32.1.0 (m, P). max(neat): 3385, 2954,
1373, 1212, 1032, 826, 537. HRMS (ES+): Calcd. for: C11H21O7PNa+ [M+Na]+:
319.0923, found: 319.0927.
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5.3.9 2,5-Anhydro-1-deoxy-2,3-O-isopropylidene-1-(dimethoxyphosphinyl)-5-
O-D-allohexitol 182b.
The same procedure as described in 5.3.8 was repeated with 181b (0.29 g, 0.54 mmol)
to afford 182b as a viscous colourless oil (0.13 g, 80.6 %).
[α]D
20: -21.5˚ (c = 9.7510-3, CHCl3), δH (CDCl3, 400 MHz) 1.27 (s, 3H, CH3), 1.46
(s, 3H, CH3), 2.12 (ddd, 1H, 3JHH = 6.4, 2JHH = 15.5, 2JHP = 18.1, H-1), 2.19 (ddd, 1H,
3JHH = 5.6, 2JHH = 15.5, 2JHP = 18.9, H-1), 3.56 (dd, 1H, 3JHH = 2.8, 2JHH = 12.5, H-6),
3.67 (d, 3H, 3JHP = 11.0, POCH3), 3.71 (d, 3H, 3JHP = 11.0, POCH3), 3.72 (dd, 1H,
3JHH = 2.9, 2JHH = 12.2, H-6), 4.08 (dd, 1H, 3JHH = 3.1, 3JHH = 6.2, H-5), 4.17 (dddd,
1H, 3JHH = 5.7, 3JHH = 5.7, 3JHH = 5.7, 3JHP = 19.3, H-2), 4.53 (dd, 1H, 3JHH = 4.7, 3JHH
= 6.4, H-3), 4.71 (dd, 3JHH = 2.9, 3JHH = 6.4, 1H, H-4); δC (CDCl3, 100 MHz) 25.4
(CH3), 27.3 (CH3), 29.1 (d, 2JPC = 141.9, C-1), 52.1 (d, 2JPC = 6.3, POCH3), 52.9 (d,
2JPC = 6.3, POCH3), 62.7 (C-6), 79.3 (d, 2JPC = 6.5, C-2), 81.7 (C-4), 84.9 ( d, 3JPC =
10.4, C-3), 85.4 (C-5), 113.8 (CCH3)2); δP (CDCl3, 162 MHz) 30.80-31.43 (m,
P).max: 3386, 2936, 1381, 1031, 826. HRMS (ES+): Calcd. for: C11H21O7PNa+
[M+Na]+: 319.0923, found: 319.0925.
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5.3.10 2,5-Anhydro-1-deoxy-5-fluoro-2,3-O-isopropylidene-1-
(dimethoxyphosphinyl)-D-altrohexitol 183a.9, 10
A solution of TBAF (1 M in THF, 2.16 ml, 2.16 mmol) was added to a mixture of
182a (0.16 g, 0.54 mmol) and TsF (0.28g, 1.62 mmol) in THF (15 ml) and then the
reaction mixture was brought to reflux. After refluxing for 18h, the reaction was
cooled to ambient temperature and the product filtered through a short pad of silica
gel washing with EtOAc. After removal of solvent the residue was purified over silica
gel eluting with MeOH:DCM (1:20) to afford 183a as colourless oil (0.148g, 92.3%).
[α]D
20: -16.4˚ (c = 2.2510-3, CHCl3). δH (CDCl3, 300 MHz) 1.28 (s, 3H, C(CH3)2).
1.42 (s, 3H, C(CH3)2), 2.13 (ddd, 1H, 3JHH = 6.7, 2JHH = 15.4, 2JHP = 18.1, H-1), 2.23
(ddd, 1H, 3JHH = 6.6, 2JHH = 15.4, 2JHP = 18.4, H-1), 3.68 (d, 3H, 3JHH = 3.9, POCH3),
3.70 (d, 3H, 3JHH = 3.9, POCH3), 4.12 (ddd, 1H, 3JHH = 2.9, 3JHH = 2.9, 3JHF = 33.1, H-
5), 4.26 (dddd, 1H, 3JHH = 3.2, 3JHH = 6.6, 3JHH = 6.6, 3JHP = 10.3, H-2), 4.44 (ddd,
1H, 3JHH = 3.4, 2JHH = 10.2, 2JHF = 46.8, H-5), 4.48 (ddd, 1H, 3JHH = 3.2, 2JHH = 10.2,
2JHF = 47.6, H-5), 4.65 (dd, 3JHH = 3.9, 3JHH = 6.0, 1H, H-3), 4.77 (d, 3JHH = 6.0, 1H,
H-4); δC (CDCl3, 75 MHz) 24.9 (CH3), 25.5 (d, 2JPC = 141.9, C-1), 26.2 (CH3), 52.3
(d, 2JPC = 6.4, POCH3), 52.6 (d, 2JPC = 6.2, POCH3), 76.9 (d, 2JCF = 1.9, C-2), 81.7 (d,
2JPC = 7.5, C-3), 82.1 (d, 2JCF = 6.4, C-4), 82.5 (d, 2JCF = 17.8, C-5), 84.8 (d, 1JCF =
172.4, C-6), 112.7 (C(CH3)2); δP (CDCl3, 121 MHz) 31.65-32.38 (m, P); δF (CDCl3,
282 MHz) -229.3 (ddd, 3JHF = 2.2, 3JHF = 33.2, 2JHF = 33.2, 2JHF = 47.1, 1F). max
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(neat): 2954, 1372, 1209, 1025, 819, 503. HRMS (ES+): Calcd. for: C11H20O4FPNa+
[M+Na]+: 321.0879, found: 321.0879.
5.3.11 2,5-Anhydro-1-deoxy-5-fluoro-2,3-O-isopropylidene-1-
(dimethoxyphosphinyl)-D-allohexitol 183b.9, 10
The same procedure as described for 183a was repeated with 182b (70 mg, 0.23
mmol) to afford 183b as a colourless oil (60 mg, 83.1%).
[α]D
20: -18.8˚ (c = 2.4510-3, CHCl3). δH (CDCl3, 300 MHz) 1.28 (s, 3H, C(CH3)2),
1.47 (s, 3H, C(CH3)2), 2.13 (dd, 1H, 3JHH = 0.9, 2JHP = 18.4, H-1), 2.09 (d, 1H, 2JHP =
18.4, H-1), 3.67 (d, 3H, 3JHH = 2.3, POCH3), 3.71 (d, 3H, 3JHH = 2.2, POCH3), 4.09
(ddd, 1H, 3JHH = 3.4, 3JHH = 3.4, 2JHF = 28.3, H-5),) 4.23 (dddd, 1H, 3JHH = 4.2, 3JHH =
6.7 , 3JHH = 6.7, 3JHP = 11.1, H-2),4.45 (ddd, 1H, 3JHH = 3.5, 2JHH = 10.8, 2JHF = 47.0,
H-6), 4.48 (dd, 1H, 3JHH = 4.3, 3JHH = 6.6, H-3),4.49 (ddd, 1H, 3JHH = 2.8, 2JHH = 10.4,
2JHF = 47.6, H-6), 4.64 (dd, 3JHH = 3.9, 3JHH = 6.6, 1H, H-4); δC (CDCl3, 75 MHz)
25.9 (CH3), 27.7 (CH3), 30.1 (d, 2JCP = 141.1, C-1), 52.7 (d, 2JCP = 6.5, OCH3), 52.9
(d, 2JCP = 6.5, OCH3), 80.5 (d, 2JCF = 3.4, C-2), 81.2 (d, 3JCF = 7.4, C-4), 83.2 (d, 2JCF
= 172.7, C-6), 83.5 (d, 2JCF = 18.3, C-5), 85.7 (d, 4JCF = 11.3, C-3), 114.9 (C(CH3)2);
δP (CDCl3, 162 MHz) 30.33-31.09 (m, P); δF (CDCl3, 282 MHz) -231.0 (ddd, 3JHF =
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28.8, 2JHF = 47.3, 2JHF = 47.3, 1F,). max (neat): 3464, 2956, 1383, 1214, 1030, 822,
513. HRMS (ES+): Calcd. for: C11H20O4FPNa [M+Na]+: 321.0879, found: 321.0875.
5.3.12 2,5-Anhydro-1-deoxy-1-phophono-D-altritol
cyclohexylammonium salt 173a 7, 11
TMSBr (0.08 ml, 0.64 mmol) was added to a solution of 182a (44.8 mg, 0.16 mmol)
in DCM (5 ml). The progress of the reaction was monitored by 31P NMR. On
completion, a solution of TFA:H2O (1:1, 1 ml) was added to the reaction mixture.
After 30 min, water (5 ml) was added, the solvent was removed under reduced
pressure. Water (5 ml) was added and was removed under reduced pressure a process
that was repeated until all traces of TFA were gone. To this residue water (5 ml) was
added and adjusted pH to 11 with cyclohexylamine. After removal of solvent, the
residue was dissolved in EtOH and about 0.5 volume of acetone was added. The
precipitate was filtered off to afford 173a as a white solid (43.8 mg, 83.7%). [α]D20:
+4.4˚ (c = 5.0510-3, MeOH). δH (MeOH-d4, 400 MHz) 1.18-1.27 (m, 1H,
cyclohexyl), 1.31-1.44 (m, 4H, cyclohexyl), 1.71 (br d, 1H, 2JHH = 12.6, cyclohexyl),
1.80-2.07 (m, 6H, 2H-1 overlap with 4H-cyclohexyl), 3.06 (br, s, 1H, cyclohexyl),
3.54 (dd, 1H, 3JHH = 5.0, 2JHH = 11.9, H-5), 3.68 (dd, 1H, 3JHH = 3.5, 2JHH = 11.9, H-5),
3.78-3.82 (m, 2H, H-3 and H-5), 4.01 (t, 1H, 3JHH = 5.0, H-4), 4.06 (quintet, 1H, 3JHH
= 6.9, H-2); δC (MeOH-d4, 75 MHz) 25.7 (2  C), 25.4 (C), 32.4 (2  C), 51.8 (C-
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1cyclohexyl), 35.4 (d, 1JCP = 130.8, C-1), 64.0 (C-6), 73.5 (C-4), 77.9 (d, 2JCP = 6.5,
C-2), 80.7 (C-3), 86.3 (C-5); δP (MeOH-d4, 162 MHz) 19.4 (ddd, 3JHP = 6.9, 2JHP =
17.5, 2JHP = 17.5). max(KBr): 2938, 2013, 1638, 1389, 1123, 1050, 906. HRMS
(ES+): Calcd. for: C12H27NO7P [M+H]+: 328.1525, found: 328.1522.
5.3.13 2,5-Anhydro-1-deoxy-1-phophon-D-allitol cyclohexylammonium salt 173b
The same procedure as described for preparation of 173a was repeated for 182b (83.2
mg, 0.3 mmol) to afford 173b (84.1 mg, 85.6%). [α]D20: +1.6˚ (c = 5.6510-3, MeOH),
δH (MeOH-d4, 400 MHz) 1.07-1.15 (m, 1H, cyclohexyl), 1.21-1.32 (m, 4H,
cyclohexyl), 1.59 (br d, 1H, 2JHH = 12.5, cyclohexyl), 1.68-1.98 (m, 6H, 2H-1 overlap
with 4H-cyclohexyl), 2.95 (br s, 1H, cyclohexyl), 3.45 (dd, 1H, 3JHH = 5.3, 2JHH =
11.9, H-5), 3.59 (dd, 1H, 3JHH = 3.5, 2JHH = 11.9, H-5), 3.67-3.72 (m, 2H, H-4 and H-
5), 3.09 (t, 1H, 3JHH = 4.9, H-3), 3.96 (quintet, 1H, 3JHH = 6.8, H-2); δC (MeOH-d4, 75
MHz) 25.5 (2  C), 25.9 (1C), 32.0 (2  C), 35.1 (d, 1JCP = 129.9, C-1), 51.3 (C-1-
cyclohex), 63.7 (C-6), 73.0 (C-4), 77.6 (d, 2JCP = 7.1, C-2), 80.4 (C-3), 85.6 (C-5); δP
(MeOH-d4, 162 MHz) 19.4 (ddd, 3JHP = 6.9, 2JHP = 17.5, 2JHP = 17.5). max: 3200,
2938, 2060, 2021, 1596, 1492, 1389, 1018. HRMS (ES+): Calcd. for: C12H27NO7P
[M+H]+: 328.1525, found: 328.1515.
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5.3.14 2,5-Anhydro-1-deoxy-5-fluoro-1-phophono-D-alltritol
cyclohexylammonium salt 174a1
The same procedure as described for preparation of 173a was repeated for 183a (94.8
mg, 0.34 mmol) to afford 174a as colourless needles (97.6 mg, 87.2%). Mp. 168-170
˚C, [α]D
20: +18.7˚ (c = 1.5010-3, MeOH). δH (MeOH-d4, 400 MHz) 1.07-1.16 (m,
1H, cyclohexyl), 1.19-1.34 (m, 4H, cyclohexyl), 1.57-1.64 (m, 1H, cyclohexyl), 1.70-
1.79 (m, 2H, cyclohexyl), 1.88-1.94 (m, 2H, cyclohexyl), 1.87 (ddd, 1H, 3JHH = 4.9,
2JHH = 10.1, 2JHP = 19.1, H-1), 2.04 (ddd, 1H, 3JHH = 10.1, 2JHH = 14.2, 2JHP = 17.1, H-
1), 2.91-2.98 (m, 1H, H-1, cyclohexyl), 3.83 (dddd, 1H, 3JHH = 2.0, 3JHH = 4.6, 3JHH =
8.7, 3JHF = 25.5, H-5), 4.01 (dd, 1H, 3JHH = 4.6, 3JHH = 8.7, H-4), 4.10-4.14 (br, 1H,
H-3), 4.17 (dddd, 1H, 3JHH = 2.9, 3JHH = 4.5, 3JHH = 4.5, 3JHP = 9.7, H-2), 4.34 (ddd,
1H, 3JHH = 4.7, 2JHH = 10.3, 2JHF = 47.7, H-6), 4.56 (ddd, 1H, 3JHH = 2.1, 2JHH = 10.3,
2JHF = 48.4, H-6); δC (MeOH-d4, 100 MHz) 25.4 (2  C, cyclohexyl), 25.9 (C,
cyclohexyl), 31.2 (d, 1JCP = 129.5, C-1), 31.9 (2  C, cyclohexyl), 51.5 (C-1,
cyclohexyl), 72.9 (d, 3JCF = 7.9, C-4), 73.4 (C-3), 79.7 (d, 2JCP = 2.7, C-2), 81.0 (d,
2JCF = 17.6, C-5), 84.3 (d, 1JCF = 170.9, C-6); δP (MeOH-d4, 162 MHz) 18.7 (ddd, 3JHP
= 2.9, 2JHP = 18.1, 2JHP = 18.1 ); δF (MeOH-d4, 376 MHz) -232.4 (ddd, 3JHF = 25.5,
2JHF = 47.4, 2JHF = 47.4, 1F) .max (KBr): 3199, 2939, 2720, 2012, 1597, 1429, 1389,
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1121, 1018, 925. HRMS (ES+): Calcd. for: C12H26NO6FP [M+H]+: 330.1482, found:
330.1492.
5.3.15 2,5-Anhydro-1-deoxy-5-fluoro-1-phophon-D-allitol
cyclohexylammonium salt 174b1
The same procedure as described for preparation of 173a was repeated with 183b
(53.1 mg, 0.19 mmol) to afford 174b as a white solid (52.1 mg, 83.3%). Mp. 146-148
˚C, [α]D
20: +3.1˚ (c = 3.5510-3, MeOH). δH (MeOH-d4, 400 MHz) 1.05-1.32 (m, 5H,
cyclohexyl), 1.54-1.74 (m, 5H, 1H-1 overlap with 4H-cyclohexyl), 1.87-.90 (m, 2H,
cyclohexyl), 1.99 (ddd, 1H, 3JHH = 3.7, 2JHH = 14.1, 2JHP = 18.8, H-1), 2.83-2.91 (m,
1H, H-1, cyclohexyl), 3.96 (t, 3JHH = 6.3, H-3), 3.83 (dddd, 1H, 3JHH = 3.7, 3JHH = 3.7,
3JHH = 3.7, 3JHF = 25.9, H-5), 3.97 (dd, 1H, 3JHH = 3.9, 3JHH = 5.5, H-4), 3.95-4.01 (m,
1H, H-2), 4.31 (ddd, 1H, 3JHH = 4.1, 2JHH = 10.2, 2JHF = 47.4, H-6), 4.36 (ddd, 1H,
3JHH = 3.2, 2JHH = 10.2, 2JHF = 47.9, H-6); δC (MeOH-d4, 100 MHz) 25.5 (2  C,
clohexyl), 26.1 (C, cyclohexyl), 32.8 (2  C, clohexyl), 35.9 (d, 1JCP = 127.0, C-1),
51.4 (C-1, cyclohexyl), 73.1 (d, 3JCF = 5.1, C-4), 77.4 (C-3), 80.7 (d, 2JCP = 2.6, C-2),
84.1 (d, 2JCF = 18.5, C-5), 84.3 (d, 1JCF = 170.5, C-6); δP (MeOH-d4, 162 MHz) 17.9
(ddd, 3JHP = 3.9, 2JHP = 17.8, 2JHP = 17.8 ); δF (MeOH-d4, 376 MHz) -231.6 (ddd, 1F,
3JHF = 25.6, 2JHF = 47.7, 2JHF = 47.7). max (KBr): 3436, 2937, 2561, 2012, 1618,
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1454, 1389, 1051, 974. HRMS (ES+): Calcd. for: C12H26NO6FP [M+H]+: 330.1482,
found: 330.1485.
5.3.16 Phostonic acid 175a12
Deprotection as described in 5.3.12 was repeated for 182a (50 mg, 0.17 mmol) in
DCM (5 ml). The residue was dissolved in dry pyridine (1 ml) and acetic anhydride
(0.027 ml, 0.28 mmol) was then added. An emergence of a 31P-NMR signal at 45 ppm
and a disappearance of the signal at 27 ppm indicated that the reaction had gone to
completion. After removal of the solvent under reduced pressure, the product was
purified over silica gel eluting with MeOH:DCM (3:2) to afford 175a as white solid
(16 mg, 47.1%). Mp. 168-170 ˚C. [α]D
20: +10.5˚ (c = 2.0510-3, MeOH), δH (MeOH-
d4, 300 MHz) 1.84 (ddd, 1H, 3JHH = 2.1, 2JHP = 12.5, 2JHH = 15.2, H-1), 1.98 (ddd, 1H,
3JHH = 6.9, 2JHP = 13.7, 2JHH = 15.2, H-1), 3.58 (dd, 1H, 3JHH = 4.5, 2JHH = 12.1, H-6),
3.75 (dd, 1H, 3JHH = 2.3, 2JHH = 12.1, H-6), 3.95 (ddd, 1H, 3JHH = 2.5, 3JHH = 4.4, 3JHP
= 8.6, H-5), 4.05 (ddd, 1H, 3JHH = 1.8, 3JHH = 4.4, 3JHP = 8.5, H-4), 4.51 (ddd, 1H,
3JHH = 2.8, 3JHH = 4.2, 3JHH = 4.2, H-3), 4.77 (dddd, 1H, 3JHH = 2.1, 3JHH = 4.1, 3JHH =
6.4, 3JHP = 22.9, H-2); δC (MeOH-d4, 75 MHz) 30.5 (d, 1JCP = 119.1, C-1), 62.9 (C-6),
74.1 (d, 4JCP = 6.9, C-4), 80.6 (d, 3JCP = 3.3, C-3), 80.7 (d, 2JCP = 14.9, C-2), 83.2 (C-
5); δP (MeOH-d4, 162 MHz) 43.1-44.5 (br, m). max (PTFE): 3570, 1736, 1215, 1154,
503. HRMS (ES-): Calcd. for C6H10O6P [M]: 209.0215, found: 209.0211.
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5.3.17 5-fluorophostonic acid 175b
The same procedure as described in 5.3.16 was repeated for 183a to obtain 175b as an
amorphous white solid. Mp. 180-182 ˚C. [α]D
20: +103.0˚ (c = 1.010-3, MeOH). δH
(MeOH-d4, 300 MHz) 1.73-1.98 (m, 2H, H-1), 4.25 (dddd, 1H, 3JHH = 2.10, 3JHH =
3.90, 3JHH = 8.30, 3JHF = 26.32, H-1, H-5), 4.36 (ddd, 1H, 3JHH = 3.90, 2JHH = 10.63,
2JHF = 47.18, H-6), 4.48 (ddd, 1H, 3JHH = 2.10, 2JHH = 10.63, 2JHF = 48.14, H-6), 4.67-
4.71 (m, 1H, H-3), 4.72-4.82 (m, 1H, H-2), 4.88 (ddd, 1H, 3JHH = 1.91, 3JHH = 4.61,
3JHP = 8.34, H-4); δC (MeOH-d4, 75 MHz) 29.6 (d, 1JCP = 119.5, C-1), 74.4 (d, 4JCF =
7.15, C-4), 77.8 (d, 4JCF = 8.8, C-3), 79.5 (d, 3JCF = 18.36, C-5), 81.2 (d, 2JCP = 4.0, C-
2), 83.2 (d, 1JCF = 172.1, C-6); δF (MeOH-d4, 282 MHz) -234.3 (ddd, 1F, 3JHF = 26.4,
2JHF = 47.4, 2JHF = 47.7); δP (MeOH-d4, 162 MHz) 41.9-42.6 (br, m). max (PTFE):
3419, 1214, 1154, 799, 503. HRMS (ES-): Calcd. for: C6H9FO5P [M-H]: 211.0172,
found: 211.0166
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5.4 Synthetic experiments for Chapter 4
5.4.1 5-Bromo-3-pentyn-2-ol 23113
A solution of LDA (2.0 M in THF/n-heptane, 9.5 ml, 19.0 mmol) was added to a THF
(30 ml) solution of propargyl bromide (2.4 g 19.0 mmol) in toluene (2.11 ml), at
–78 °C, and the mixture was stirred for 5 min. Acetaldehyde (1.2 ml, 20.4 mmol) was
then added, and the reaction mixture was warmed to 0 °C and stirred for 2 h. A sat.
NH4Cl solution (25 ml) was then added and the mixture was extracted into EtOAc (2
x 50 ml). The organic layer was dried over MgSO4, evaporated and the organic
residue purified over silica gel, eluting with hexane:EtOAc (80:20) to afford 231 as
dark yellow oil (1.64 g, 60%); δH (CDCl3, 300 MHz) 1.44 (d, 3H, 3JHH = 6.6,
CHCH3), 3.93 (d, 2H, 5JHH = 1.8, CH2Br), 4.58 (q, 1H, 3JHH = 6.5, CHCH3); δC
(CDCl3, 75 MHz) 14.4 (CH2), 24.0 (CH3), 58.2 (CH), 79.1 (C≡CCH2), 90.1
(C≡CCHOH). νmax (neat): 3345, 2983, 2252, 1079 cm-1. m/z (ES+) 184.93 (79Br, 90%)
and 186.93 (81Br, 100%) [M + Na]+.
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5.4.2 4-(Triisopropylsilanoyloxy)-1-bromopent-2-yne 232
TIPS-triflate (1.12 ml, 3.65 mmol) was added dropwise to a solution of 5-bromopent-
3-yn-2-ol 231 (0.54 g, 3.32 mmol) in DCM (10 ml) and 2,6-lutidine (1.16 ml, 9.96
mmol), at 0 °C. The mixture was left to warm to ambient temperature. After 45 min
water (2 ml) was added, and the solvent was evaporated. The residue was dissolved in
EtOAc (20 ml) and was washed with water (20 ml). The organic layer was then dried
over MgSO4, evaporated and the organic residue purified over silica gel eluting with
EtOAc:hexane (2:98) to give 232 as colourless oil (~100%). δH (CDCl3, 300 MHz)
0.99-1.01 (m, 21H, 3 × CH(CH3)2), 1.37 (d, 3H, 3JHH = 6.5, CHCH3), 3.86 (d, 2H,
5JHH = 1.9, CH2Br), 4.58 (qt, 1H, 3JHH = 6.5, 5JHH =1.9, CHCH3); δC (CDCl3, 75 MHz)
12.5 (3 × CH(CH3)2), 15.0 (CH2Br), 18.3 and 18.4 (3 × CH(CH3)2], 26.6 (CHCH3),
59.4 (CHCH3), 78.4 (C≡CCH2), 90.1 (C≡CCHOTIPS). νmax (neat): 2944, 2235, 1464,
1104, 1029, 761, 682 cm-1. m/z (ES+): 341.0924 [M+Na] C14H2779BrOSiNa (55%)
and 343.0901 [M+Na]. C14H2781BrOSiNa (52%).
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5.4.3 Diethyl 5-(triisopropylsilanoyloxy)-hex-3-ynylphosphonate 233
A solution of n-BuLi (2.5 M in hexane, 0.40 ml, 1.0 mmol) was added to a THF (20
ml) solution of diethyl methylphosphonate (0.152 g, 1.0 mmol) at -78 °C, and the
mixture was stirred for 15 min. A solution of 4-(triisopropylsilanoyloxy)-1-
bromopent-2-yne 232 (0.319 g, 1.0 mmol) in THF was then added, and the reaction
mixture was warmed to ambient temperature and stirred for 2 h. A sat.aq.NH4Cl
solution (25 ml) was then added and the mixture was extracted into EtOAc (2 × 50
ml). The organic layer was then dried over MgSO4, evaporated and the organic
residue purified over silica gel eluting with EtOAc:hexane (80:20) to afford 233 as
colourless oil (0.156 g, 40%). δH (CDCl3, 300 MHz) 1.04-1.10 (m, 21H, 3 ×
CH(CH3)2), 1.33 (t, 6H, J 7.1, 2 x CH2CH3), 1.40 (d, 3H, 3JHH = 6.4, CHCH3), 1.87-
2.05 (m, 2H, CH2P), 2.43-2.52 (m, 2H, C≡CCH2), 4.02-4.16 (m, 4H, 2 × CH2CH3),
4.56 (tq, 1H, 5JHH = 1.8, 3JHH = 6.4, CHCH3); δC (CDCl3, 75 MHz) 12.5 (3 ×
CH(CH3)2), 13.1 (d, 3JCP = 3.1, CH2CH2P), 16.8 (d, 3JCP = 6.0, 2 × POCH2CH3], 18.3,
18.4 (3 × CH(CH3)2), 25.3 (d, 1JCP = 140.7, CH2P), 26.1 (CHCH3), 59.4 (CHCH3),
62.1 (d, 2JCP = 6.4, 2 × POCH2CH3), 81.9 (d, 3JCP = 23.0, C≡CCH2CH2P), 84.1
(C≡CCHOH); δP (CDCl3, 121.5 MHz) 30.6 (m). νmax (neat): 2941, 2229, 1463, 1247,
1099, 1029 cm-1. HRMS (ES+): Calcd. For C19H39O4PSiNa [M+Na]+: 413.2253,
found: 413.2247.
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5.4.4 Diethyl 5-(triisopropylsilanoyloxy)-3,4-dioxohexyl-phosphonate 234
To a solution of 233 (0.31 g, 0.79 mmol) in CHCl3/CH3CN/H2O (1:1:1.5) was added
NaIO4 (4.1 equiv.). The mixture was stirred vigorously at room temperature and then
RuO2 (0.022 equiv.) was added. Two clear phases partitioned.34 The reaction mixture
turned from black to bright yellow and a white precipitate formed. The mixture was
poured into a separatory funnel, and water (10 ml) was added. The aq. phase was
extracted into CH2Cl2 (3 x 20 ml) and the combined organic phases were dried over
MgSO4, and filtrated through a column of Celite (6 cm high, Ø 2 cm). The solvents
were evaporated under reduced pressure and the residue was purified over silica gel
(EtOAc:hexane, 30:70) to afford 234 as yellow oil (0.19 g, 60%); δH (CDCl3, 300
MHz) 1.00-1.10 (m, 21H, 3 × CH(CH3)2), 1.32 (t, 6H, 3JHH = 7.1, 2 × CH2CH3), 1.41
(d, 3H, 3JHH = 6.9, CHCH3), 1.96-2.08 (m, 2H, CH2P), 2.93-3.18 (m, 2H, O=CCH2),
4.04-4.19 (m, 4H, 2 × POCH2CH3), 5.01 (q, 1H, 3JHH = 6.8, OCHCH3); δC (75 MHz;
CDCl3) 12.6 [3 x CH(CH3)2], 16.8 (d, 3JCP = 6.0, 2 × POCH2CH3), 18.2, 18.3 (3 ×
CH(CH3)2), 19.0 (d, 1JCP = 146.0, CH2P), 20.5 (CHCH3), 37.3 (d, 2JCP = 3.5,
CH2CH2P), 62.2 (d, 2JCP = 6.0, 2 × POCH2CH3), 70.7 (CHCH3), 200.0 (d, 3JCP = 15.4,
COCH2CH2P), 200.2 (C=O); δP (121.5 MHz; CDCl3) 31.5; νmax (neat): 2943, 1719,
1218, 1507, 1026 cm-1. HRMS (ES+): Calcd. For C19H39O6PSiNa [M+Na]+:
445.2151, found: 445.2160.
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5.4.5 Deprotection of diethyl-5-(triisopropylsilanoyloxy)-3,4-
dioxohexyl phosphonate 23437
TMS-bromide (0.26ml, 1.96 mmol) was added to a solution of diethyl 5-
(triisopropylsilanoyloxy)-3,4-dioxohexyl-phosphonate 234 (0.21 g, 0.49 mmol) in
DCM (2 ml) at ambient temperature and under an inert atmosphere. After 6 h the
solvent was removed and the residue was dried under reduced pressure. Water (5 ml)
was then added and the mixture was stirred for 20 min until the solid completely
dissolved. The solution was then neutralized with 0.2 M NaOH until pH ~7 and the
solvent was finally removed to afford 228 as crude product as white amorphous solid.
H1 and 13C NMR are shown in Figure 4.9. δP (D2O, 121.5 MHz;) 25.6; m/z (ES+)
432.72 (100%).
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5.4.6 [1-13C]-acetaldehyde 24014, 15
Pd(0)P(Ph3)4 (0.15g, 0.13 mmol) was added to a 2-necked flask equipped with
condenser and a receiving flask containing dry THF (3 ml) cooling at -89 °C under
N2. Dry toluene (5 ml) was then added. [1-13C]acetyl chloride (1g, 6.24 mmol) was
slowly added and the reaction was stirred for 5 min and then a solution of n-Bu4SnH
(4.40 ml, 1.29 mmol) was added dropwise. After 10 min, N2 was bubbled through the
reaction mixture and this was continued for 45 min after the addition of n-Bu4SnH
was finished. [1-13C]-acetaldehyde was used immediately in Section 5.4.7.
5.4.7 [2-13C]-5-Bromo-3-pentyn-2-ol 231a14, 15
Propagyl bromide (80% solution in toluene, 1.05 ml, 11.8 mmol) in THF was treated
with LDA (2.0 M in THF/n-heptane, 5.70 ml, 11.4 mmol) at -78 °C. A solution of
[1-13C]-acetaldehyde in THF was then added to the reaction via a cannular. After
stirring at 78 °C for 15 min, the reaction mixture was warmed to 0 °C and stirred for a
further 2 h. A sat. NH4Cl solution (25 ml) was added and the mixture was extracted
into EtOAc (2 × 50 ml). The organic layer was dried over MgSO4, evaporated and the
organic residue purified over silica gel, eluting with hexane:EtOAc (80:20) to afford
231a as dark yellow oil (0.39 g, 38.1%).
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δH (CDCl3, 400 MHz) 1.38 (dd, 3H, 3JHH = 6.6, 2JCH = 4.7, CHCH3), 3.88 (br, 2H,
CH2Br), 4.52 (dqt, 1H, 5JHH = 1.8, 3JHH = 6.6, 1JCH = 148.7, CHCH3); δC (CDCl3, 100
MHz) 14.4 (CH2), 24.0 (1JCC = 40.3, CH3), 58.2 (CH), 79.1 (C≡CCH2), 90.1
(C≡CCHOH). νmax (neat): 3340, 2983, 2250, 1081 cm-1.
5.4.7 [4-13C]-4-(Triisopropylsilanoyloxy)-1-bromopent-2-yne 232a
The procedure described in 5.4.2 was repeated for 231a (0.39 g, 2.39 mmol) to afford
232a as colourless oil (0.74g, 96.7%).
δH (CDCl3, 400 MHz) 0.99-1.04 (m, 21H, 3 × CH(CH3)2), 1.36 (dd, 3H, 3JHH = 6.5,
2JCH = 4.5, CHCH3), 3.86 (dd, 2H, 3JCH = 6.5, 5JHH = 1.8, CH2Br), 4.56 (dqt, 1H, 5JHH
= 1.8, 3JHH = 6.5, 1JCH = 144.8, 13CH(OH)CH3); δC (CDCl3, 100 MHz) 12.2 (3 ×
CH(CH3)2), 14.6 (CH2Br), 17.9, 18.0 (3 × CH(CH3)2], 25.4 (d, 2JCC = 41.6,
CH(OH)CH3), 59.0 (13CH(OH)CH3), 78.1 (2JCC = 13.1, C≡CCH2), 89.7 (1JCC = 75.5,
C≡CCHOTIPS). νmax (neat): 2944, 2233, 1464, 1100, 1031, 760 cm-1.
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5.4.8 [5-13C]-Diethyl-5-(triisopropylsilanoyloxy)-hex-3-ynyl-phosphonate 233a
The procedure described in 5.4.3 was repeated for 232a (0.61g, 1.90 mmol) to afford
233a as a colourless oil (0.42 g, 56.9%).
δH (CDCl3, 300 MHz) 0.98-1.02 (m, 21H, 3 × CH(CH3)2), 1.26 (t, 6H, 3JHH = 7.1, 2 ×
CH2CH3), 1.33 (dd, 3H, 3JHH = 6.5, 2JCH = 4.5, CH(OH)CH3), 1.84-1.95 (m, 2H,
CH2P=O), 2.35-2.45 (m, 2H, CH2CH2C≡C), 3.96-4.09 (m, 4H, 2 × CH2CH3), 4.50
(dtq, 1H, 5JHH = 1.9, 3JHH = 6.5, 1JCH = 144.5, 13CHCH3); δC (CDCl3, 75 MHz) 12.5
(3 × CH(CH3)2), 16.8 (d, 3JCP = 6.0, 2 × CH3CH2OP=O), 18.3, 18.4 (3 × CH(CH3)2),
25.8 (d, 1JCP = 140.7, CH2CH2P=O), 26.1 (d, 1JCP = 41.1, CH3CH(OH)), 31.3
(CH2CH2P=O), 59.4 (13CH(HO)CH3), 62.1 (d, 2JCP = 6.5, 2 × POCH2CH3); δP
(CDCl3, 121.5 MHz) 30.2-30.8 (m). νmax (neat): 2946, 1719, 1221, 1108, 1027 cm-1.
5.4.9 [5-13C]-Diethyl-5-(triisopropylsilanoyloxy)-3,4-dioxohexyl-phosphonate
234a
The procedure described in 5.4.3 was repeated for 233a (0.25g, 0.65 mmol) to afford
234a as a bright yellow oil (0.18 g, 64.6%).
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δH (CDCl3, 300 MHz) 0.95-1.01 (m, 21H, 3 × CH(CH3)2), 1.25 (t, 6H, 3JHH = 7.1, 2 ×
CH2CH3), 1.34 (dd, 3H, 3JHH = 6.4, 2JCH = 4.3, CHCH3), 1.90-2.00 (m, 2H, CH2P=O),
2.88-3.09 (m, 2H, CH2CH2C=O), 3.99-4.09 (m, 4H, 2 × CH2CH3), 4.95 (dq, 1H, 3JHH
= 6.9, 1JCH = 144.5, 13CH(OH)CH3); δC (CDCl3, 75 MHz) 12.6 (3 × CH(CH3)2), 16.8
(d, 3JCP = 6.1, 2 × CH3CH2P=O), 18.2, 18.3 (3 × CH(CH3)2), 19.1 (d, 1JCP = 146.2,
CH2P=O), 20.5 (d, 1JCP = 38.9, CH3CH(OH)), 31.7 (d, 2JCP = 3.3,CH2CH2P=O), 62.2
(d, 2JCP = 6.5, 2 × POCH2CH3), 70.3 (13CH(HO)CH3); δP (CDCl3, 121.5 MHz) 30.0-
30.6 (m). νmax (neat): 2945, 1720, 1212, 1105, 1025 cm-1. HRMS (ES+): Calcd. For
12C1813C1H39O6PSiNa [M+Na]+: 446.2185, found: 446.2192.
5.4.10 Deprotection of [5-13C]-diethyl-5-(triisopropylsilanoyloxy)-3,4-dioxohexyl-
phosphonate 228a
The same procedure described in 5.4.5 was repeated for 234a (28 mg, 0.7 mmol) to
obtain crude 228a. Only the isotopically enriched signals are reported in the 13C-
NMR. δC (D2O, 75 MHz) 207.5, 207.0 (C=O), 72.6 69.7 (CH(OH)); δP (D2O, 121.5
MHz) 30.9-31.7 (br, m).
This product was dissolved in D2O (3 ml) and the solution was basicified to pH 3.5
with 0.2 M NaOH. After removal of solvents, the 1H, 13C and 31P NMR spectra were
then recorded. The process was repeated at pH 7.0, 10.5, and 12.5.
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pH 3.5: δC (D2O, 100 MHz) 207.9 (C=O), 96.3 (C(OH)2), 70.1 (CH(OH)); δP (D2O,
121.5 MHz) 25.1-26.1 (br, m). m/z (ES-): 156.94 (100%).
pH 7.0: δC (D2O, 100 MHz) 208.3, 182.3 (C=O), 70.2, 69.1 (CH(OH)); δP (D2O,
121.5 MHz) 24.5-25.6 (br, m), 26.1-27.0 (br, m). m/z (ES+): 275.97 [M+3Na]
(100%). m/z (ES-): 156.96 (100%)
pH 10.5: δC (D2O, 100 MHz) 182.2 (C=O), 67.0 (CH(OH)); δP (D2O, 121.5 MHz)
21.7-22.0 (br, m), 22.5-23.0 (br, m), 23.2-23.7 (br, m). m/z (ES+): 275.94 [M+3Na]
(100%). m/z (ES-): 181.98 (100%)
pH 12.5: δC (D2O, 100 MHz) 182.3 (C=O), 69.1 (CH(OH)); δP (D2O, 121.5 MHz)
22.7-23.1 (br, m), 23.4-23.7 (br, m). m/z (ES+): 275.95 [M+3Na] (100%). m/z (ES-):
156.98 (100%).
5.5 Biochemical experiments
5.5.1 Bioassay for Chapter 2
Bioassays were carried out by Dr. Darwin W Reed, Plant Biotechnology Institute, 110
Gymnasium Place, Saskatoon, SK, Canada, S7N OW9.
5.5.1.1 Preparation of yeast microsomes
Yeast microsomes were prepared according to Katavic et al.16 and the microsomal
membrane pellet was re-suspended in storage buffer containing 100 mM potassium
phosphate buffer, pH 7.5, 1 mM EDTA, 20% (v/v) glycerol. Protein concentration
was determined by Bradford assay (Bio-Rad, Hercules, CA).
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5.5.1.2 GC/MS analysis
GC/MS analysis of the alkaloids was accomplished using an Agilent 5973 Mass
Selective Detector coupled to an Agilent 6890N Gas Chromatograph equipped with a
30 m X 0.25 mm DB-5MS column with 0.25 m film thickness (J&W Scientific).
The chromatograph conditions were a split injection (20:1) using a helium flow of 0.4
ml/min, an initial temperature of 175°C for 1 min, followed by a temperature ramp at
5°C/min to 300°C. The mass selective detector was run under standard EI+ conditions
(70 eV) scanning an effective mass range of 40 to 700 amu at 2.26 scan/s.
5.5.1.3 CYP80F1 enzyme assays with fluorolittorines
The complete reaction mixture (200 µl) contained 264 µg microsomal protein, 100
mM potassium phosphate buffer, pH 7.4, 3 mM NADPH, and 865 mM alkaloid
substrate. Reactions were initiated by the addition of substrate and carried out at
30OC for 10 mins with gentle shaking. Reactions were stopped by adding 800 µl of
100 mM sodium carbonate buffer (pH 10.8) containing 1 μg of internal standard 
(scopolamine, Sigma, Oakville, ON) to bring the final pH to 8.5. The reaction mixture
was immediately applied to an Extrelut QE column (EM Science, Gibbstown, NJ).
After 5 min, the alkaloids were eluted with 12 ml of DCM and the solvent was
removed under a nitrogen stream. For GC/MS analysis the residue was dissolved in
20 µl of BSA/pyridine (1:1).
Hyoscyamine aldehydes were monitored at m/z 359 (M+ of O-TMS derivative of
enol) and 3’-hydroxylittorines were monitored at m/z 449 (M+ of (O-TMS)2
derivative). Fluorohyoscyamine aldehydes were monitored at m/z 377 ((M+ of O-
TMS derivative of enol)) and fluoro-3'-hydroxylittorines were monitored at m/z 467
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(M+ of (O-TMS)2 derivative). Internal standard quantitation was done by comparison
of SIM (single ion monitoring) integrations (m/z 124) on peaks identified as products
using the integrated area of m/z 138 of scopolamine as 1 µg (a correction factor of 1.0
was used).
5.5.1.4 CYP80F1 enzyme assays for isotope effect experiments
The complete reaction mixture (200 µl) contained 64 µg microsomal protein, 100 mM
potassium phosphate buffer, pH 7.4, 3 mM NADPH, and 0.87 mM alkaloid substrate.
Reactions were initiated by the addition of NADPH and carried out at 30OC for 15
minutes with gentle shaking. Reactions were stopped by adding 800 ul of 100 mM
sodium carbonate buffer  (pH 10.8) containing 2.5 μg of internal standard 
(scopolamine) to bring the final pH to 8.5 and then the reaction mixture was
immediately applied to an Extrelut QE column (EM Science, Gibbstown, NJ). After 5
min, the alkaloids were eluted with 12 ml of dichloromethane and the solvent was
removed under a nitrogen stream. For GC/MS analysis the residue was dissolved in
25 µl of BSA/pyridine (1:1).
For competitive isotope effect experiments, a 1:1 mixture of [2',2'-d2]- and [do]- (S)-
littorines was used. Substrates were monitored at m/z 363 and 361 and products at m/z
179 (d0) and 180 (d1). The m/z = 180 was corrected by subtraction of the m/z 179 + 1
isotope peak. Competitive istotope effect were calculated using KIE (kH/kD) = ( d0
product / d1 product ) / ( d0 substrate / d2 substrate ).
For non-competitive isotope effect experiments with (S)-littorine the same ions were
monitored with no need for natural isotopic abundance correction of m/z 180. For
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noncompetitive experiments on the oxidation/rearrangement of (R)-littorine,
production of the hyoscyamine aldehyde was determined by comparing integrated
signals for m/z 124 and m/z 138 (scopolamine internal standard and correction factor
1.0).
5.5.2 Bioassay for Chapter 3
The enzyme assays were carried out by Dr. Stuart M. Cross, at the University of St
Andrews.17
5.5.3 Bioassay for Chapter 4
The enzyme assays were carried out by Dr. Denis Tritsch, Université Louis
Pasteur/Centre National de la Recherche Scientifique, Institut de Chimie de
Strasbourg, LC3-UMR 7177, 67070 Strasbourg cedex, France.
His-Tagged DXR from E. coli was purified as described in Kuntz et al.18 Assays were
performed in a 50 mM triethanolamine buffer pH 7.7 containing 3 mM MgCl2, 2 mM
dithiothreitol (triethanolamine was preferred over Tris buffer, which is able to react
with α-dicarbonyl compounds) at 37 °C. The final volume was 500 µL. The
compound (35.5 mg) was dissolved in 0.7 mL H2O (concentration 200 mM).
DXR (2 µL, stock concentration 2.7 µg/µL) was first preincubated with NADPH
(0.25 mM final concentration) and 228a at 37 °C for 2 min. The enzymatic reaction
was then initiated by addition of DXP (0.5 mM final concentration). The reaction was
followed at 340 nm with a Uvikon 933 spectrometer. The concentrations of inhibitor
varied from 10 to 800 µM and no decrease of the enzymatic rate was observed.
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Compound did not inhibit DXR. 228a (400 µM) was also incubated with NADPH and
DXR. No decrease of the absorbance at 340 nm was detected. It is not substrate of the
enzyme.
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Appendix I
Crystallographic data for (S,S)-147
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Table 1. Crystal data and structure refinement for (S,S)-147.
Identification code pndh6
Empirical formula C17 H18 F N O2
Formula weight 287.32
Temperature 93(2) K
Wavelength 0.71073 Å
Crystal system Monoclinic
Space group P2(1)
Unit cell dimensions a = 5.531(2) Å = 90°.
b = 22.228(9) Å = 101.881(5)°.
c = 12.362(5) Å  = 90°.
Volume 1487.1(10) Å3
Z 4
Density (calculated) 1.283 Mg/m3
Absorption coefficient 0.092 mm-1
F(000) 608
Crystal size 0.2000 x 0.0300 x 0.0100 mm3
Theta range for data collection 1.68 to 25.32°.
Index ranges -6<=h<=6, -26<=k<=26, -14<=l<=14
Reflections collected 14791
Independent reflections 5369 [R(int) = 0.0389]
Completeness to theta = 25.00° 99.5 %
Absorption correction Multiscan
Max. and min. transmission 1.0000 and 0.8638
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 5369 / 5 / 397
Goodness-of-fit on F2 1.045
Final R indices [I>2sigma(I)] R1 = 0.0566, wR2 = 0.1439
R indices (all data) R1 = 0.0649, wR2 = 0.1515
Absolute structure parameter -0.2(9)
Extinction coefficient 0.010(4)
Largest diff. peak and hole 1.455 and -0.355 e.Å-3
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Crystallographic data for (R,S)-149
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Table 1. Crystal data and structure refinement for (R,S)-149.
Identification code pndh5
Empirical formula C17 H18 F N O2
Formula weight 287.32
Temperature 93(2) K
Wavelength 0.71073 Å
Crystal system Orthorhombic
Space group P2(1)2(1)2(1)
Unit cell dimensions a = 8.9265(8) Å = 90°.
b = 9.0292(8) Å = 90°.
c = 19.3276(18) Å  = 90°.
Volume 1557.8(2) Å3
Z 4
Density (calculated) 1.225 Mg/m3
Absorption coefficient 0.088 mm-1
F(000) 608
Crystal size 0.200 x 0.200 x 0.030 mm3
Theta range for data collection 2.49 to 25.35°.
Index ranges -10<=h<=7, -10<=k<=10, -22<=l<=22
Reflections collected 12750
Independent reflections 2746 [R(int) = 0.0280]
Completeness to theta = 25.00° 97.6 %
Absorption correction Multiscan
Max. and min. transmission 1.0000 and 0.9539
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 2746 / 2 / 199
Goodness-of-fit on F2 1.083
Final R indices [I>2sigma(I)] R1 = 0.0261, wR2 = 0.0626
R indices (all data) R1 = 0.0271, wR2 = 0.0633
Absolute structure parameter -0.2(6)
Largest diff. peak and hole 0.138 and -0.133 e.Å-3
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Crystallographic data for (R,S)-148a
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Table 1. Crystal data and structure refinement for (R,S)-148a.
Identification code pndh2
Empirical formula C19 H20 F N O3
Formula weight 329.36
Temperature 93(2) K
Wavelength 0.71073 Å
Crystal system Orthorhombic
Space group P2(1)2(1)2(1)
Unit cell dimensions a = 9.2837(10) Å = 90°.
b = 12.9755(15) Å = 90°.
c = 14.5401(17) Å  = 90°.
Volume 1751.5(3) Å3
Z 4
Density (calculated) 1.249 Mg/m3
Absorption coefficient 0.091 mm-1
F(000) 696
Crystal size 0.1000 x 0.0500 x 0.0500 mm3
Theta range for data collection 2.60 to 25.34°.
Index ranges -10<=h<=9, -12<=k<=15, -17<=l<=17
Reflections collected 11629
Independent reflections 3099 [R(int) = 0.0459]
Completeness to theta = 25.00° 97.7 %
Absorption correction Multiscan
Max. and min. transmission 1.0000 and 0.9740
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 3099 / 1 / 224
Goodness-of-fit on F2 1.016
Final R indices [I>2sigma(I)] R1 = 0.0431, wR2 = 0.0814
R indices (all data) R1 = 0.0564, wR2 = 0.0875
Absolute structure parameter 0.8(10)
Extinction coefficient 0.0150(15)
Largest diff. peak and hole 0.182 and -0.184 e.Å-3
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Crystallographic data for 174a
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Table 1. Crystal data and structure refinement for 174a.
Identification code pndh7
Empirical formula C12 H25 F N O6 P
Formula weight 329.30
Temperature 93(2) K
Wavelength 0.71073 Å
Crystal system Triclinic
Space group P1
Unit cell dimensions a = 5.6457(14) Å = 85.28(2)°.
b = 11.273(4) Å = 81.582(18)°.
c = 12.867(4) Å  = 76.950(18)°.
Volume 788.2(4) Å3
Z 2
Density (calculated) 1.388 Mg/m3
Absorption coefficient 0.211 mm-1
F(000) 352
Crystal size 0.1500 x 0.1500 x 0.0100 mm3
Theta range for data collection 1.86 to 25.35°.
Index ranges -6<=h<=6, -13<=k<=12, -15<=l<=15
Reflections collected 6205
Independent reflections 4337 [R(int) = 0.0519]
Completeness to theta = 25.00° 99.3 %
Absorption correction Multiscan
Max. and min. transmission 1.0000 and 0.9734
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 4337 / 15 / 429
Goodness-of-fit on F2 1.032
Final R indices [I>2sigma(I)] R1 = 0.0530, wR2 = 0.1401
R indices (all data) R1 = 0.0552, wR2 = 0.1467
Absolute structure parameter -0.03(13)
Extinction coefficient 0.058(7)
Largest diff. peak and hole 0.428 and -0.394 e.Å-3
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“Tropic acid biosynthesis: Mechanistic insights into the P-450 mediated
isomerisation of littorine to hyoscyamine in Hyoscyamus niger”
Pitak Nasomjai, Darwin W Reed, David Tozer, Michael Peach, Alex M. Z. Slawin,
Patrick S Covello and David O’Hagan, ChemBioChem, 2009, 10, 2382-2393.
“Synthesis of phosphonate and phostone analogues of ribose-1-phosphates”
Pitak Nasomjai, David O’Hagan, and Alexandra M Z Slawin, Beilstein J Org Chem.,
2009; 5.
Conferences attended
 238th ACS National Meeting & Exposition, Washington DC (USA), Aug
2009. Poster presentation
 Organic Chemistry Final Year PhD Symposium, St Andrews (UK), June,
2009. Oral Presentation
 38th RSC Scottish Organic Division Meeting, Aberdeen (UK), Dec 2008.
Poster presentation
 8th RSC Fluorine Group Meeting, Henderson Hall, Newcastle University
(UK), Sep 2008. Oral presentation
 RSC Drugs from Natural Products IV, New Hall, Cambridge, Apr 2008.
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 RSC Bio-Organic Group Meeting: Biosynthesis in Unexpected Places, Firbush
(UK), Sep 2007.
 6th Annual RSC Fluorine Subject Group Meeting, Hulme Hall, University of
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